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Abstract 
 
 Toll like receptor (TLR) signalling is central in controlling innate immune 
responses, with dysregulation of TLR pathways associated in both autoimmune and 
inflammatory diseases.  Numerous reports suggest that cannabinoids, known to exhibit 
general immunosuppressive properties, have potential therapeutic value in the treatment 
of inflammatory conditions.  In relation to multiple sclerosis (M.S.), cannabinoids 
palliate M.S. patient symptoms and the severity of clinical signs associated with 
experimental autoimmune encephalomyelitis (EAE), an animal model of M.S.  
However, the precise molecular mechanism for these effects is not understood.  While 
the synthetic cannabinoid R(+)WIN55,212-2 exerts established anti-inflammatory 
effects in vitro and in vivo, the role of cannabinoid compounds in modulating TLR 
signalling events is unknown.  Here, using a variety of cell model systems, evidence is 
provided that R(+)WIN55,212-2, in the presence of the TLR3 ligand, Poly(I:C), targets 
interferon regulatory factor 3 (IRF3), a transcription factor essential for regulating type I 
interferon (IFN) expression.  These findings also demonstrate that protective effects of 
R(+)WIN55,212-2 in EAE mice exist, as evidenced by reduced clinical scores, 
demyelination and inflammation.  Furthermore, the anti-inflammatory effects of 
R(+)WIN55,212-2 in this model are IFN- dependent.  In addition to blunting pro-
inflammatory signaling induced by Poly(I:C) in PBMCs from both healthy donors and 
M.S. patients, R(+)WIN55,212-2 robustly enhanced IFN- production in these cells, an 
event restricted to M.S. patients.   
 This study also highlights the anti-inflammatory potential of R(+)WIN55,212-2 
by virtue of its inhibitory effects on the NFB pathway.  R(+)WIN55,212-2 can inhibit 
TLR3/4-induced activation of NFB.  This likely makes a major contribution to the 
inhibitory effects of R(+)WIN55,212-2 on pro-inflammatory gene expression.  Indeed, 
it is also demonstrated that R(+)WIN55,212-2 blunts TLR3/4 induction of TNF-.  The 
regulatory effects of R(+)WIN55,212-2 on TLR3/TLR4-induced activation of IRF3, 
IFN- and NFκB are independent of the cannabinoid receptors and evidenced is 
presented suggesting a potential role for peroxisome proliferator activated receptors in 
mediating the regulatory effects R(+)WIN55,212-2.   
 Overall these findings highlight that R(+)WIN55,212-2, by targeting IRF3 and 
IFN- downstream of TLR3 stimulation, may exert anti-inflammatory properties and 
vii 
 
provide evidence that cannabinoid administration may offer therapeutic potential in the 
treatment of M.S. 
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Chapter 1 
 
 
 
General Introduction 
 
 1 
1.1 The mammalian immune system 
 
As mammals are continually at risk from the pathogenic influences of a highly 
diverse range of microorganisms in the environment, this has resulted in the evolution of an 
extremely effective and efficient mammalian immune system.  The mammalian immune 
system is typically characterised by its ability to distinguish between the self and non-self 
recognition of various pathogenic molecules and can be divided into two interactive 
systems: the innate immune system and the adaptive immune system.  The phylogenetically 
older innate immune system surfaced approximately one billion years ago, while the 
adaptive immune system appeared around 450 million years ago with the emergence of the 
gnathostomes or jawed vertebrates (Andersson and Matsunaga, 1996).   
The innate immune system represents the hosts‟ first line of defense against a wide 
array of pathogens and does not require prior exposure to foreign antigens in order to be 
triggered.  Its antigen-nonspecific defense mechanism is fast acting and short lived.  
Elements of the innate immune system include anatomical barriers e.g. skin and mucosal 
membranes, cellular components e.g. macrophages, neutrophils, dendritic cells (DCs), 
natural killer (NK) cells, resident central nervous system (CNS) microglia and perivascular 
macrophages and soluble proteins e.g. complement.  Its ability to recognise such a broad 
spectrum of microorganisms is accomplished by a set of germline-encoded pathogen 
recognition receptors (PRRs) which detect conserved microbial sequence patterns or 
products of microbial metabolism known as pathogen-associated molecular patterns 
(PAMPs) (Janeway and Medzhitov, 2002).  The initial stimulation of PPRs by microbial 
targets culminates in the subsequent induction and control of the adaptive immune system. 
The adaptive immune system, also known as the acquired immune system, is found 
only in vertebrates.  This system is involved in the elimination of pathogens during the late 
phase of infection and is both specific and customised for each pathogen.  The adaptive 
immune system is mediated by the activation of lymphocytes e.g. T (Thymus) cells and B 
(Bursa) cells. Lymphocytes express a diverse range of recombinant receptors which are 
randomly generated by somatic gene rearrangement.  Lymphocyte activation in the 
adaptive immune system is governed by the type of immune response e.g. a cell-mediated 
immune response is responsible for T cell activation while a humoral immune response 
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chiefly involves B cells and is responsible for triggering clonal selection (Burgio and 
Ugazio, 1975).   
In recent years, PPRs e.g. toll like receptors (TLRs) have been subject to intensive 
characterisation as key recognition receptors of the innate immune system.  TLR 
stimulation by microbial components can result in the maturation of DCs, where DCs 
function in the presentation of pathogen-derived antigens to naïve T cells.  This 
presentation subsequently triggers the activation of the adaptive immune system and 
therefore highlights the important role TLRs play in linking innate and adaptive immunity. 
 
1.2 Pathogen and pathogen-associated molecular patterns 
 
Different PRRs react with specific PAMPs which determines the fate of specific 
signalling pathways (Janeway and Medzhitov, 2002).  PAMPs are identifiable microbial 
motifs that include lipids and nucleic acids.  PAMPs are not found in host cells, are highly 
conserved and essential for microbial viability.  PPRs can often form homodimers or 
heterodimers with each other thus allowing two separate PPRs to activate the same PAMP.  
Bacteria, viruses, fungi and protozoa all contain structures that can act as PAMPs (Fig 1.1) 
and hence elicit an innate immune response. 
 
1.3 Pathogen Recognition Receptors 
 
A number of PRRs have been identified, including receptors expressed on the cell 
surface, in intracellular compartments, or secreted into the blood stream and tissue fluids. 
These PRRs include members of nucleotide-binding oligomerization domain (NOD) 
proteins containing leucine-rich repeats (NLRs), retinoic acid-inducible gene (RIG-I)-like 
receptors (RLRs) and TLRs (Fig 1.2).  To date, TLRs have been the most intensively 
studied PRRs of the innate immune system. 
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1.3.1  Toll-Like Receptors 
 
The Toll protein was first discovered in Drosophila Melanogaster as a gene 
required for the establishment of dorso-ventral polarity in the developing embryo (Lohs-
Schardin et al., 1979).  Subsequently, it was shown to play a critical role in the antifungal 
immune response in flies against Aspergillus fumigatus (Lemaitre et al., 1996).  This 
finding prompted a search for orthologous receptors which led to the discovery of the 
human homolog of the Drosophila Toll (dToll), namely human Toll (Medzhitov et al., 
1997).  Human Toll has since been named TLR4.  Sequence alignment of human and 
Drosophila Toll proteins display a high degree of homology, with particular similarity 
between their cytoplasmic domains.  
TLRs are type I transmembrane proteins of the interleukin-1 receptor (IL-1R) 
family.  TLRs are horseshoe shape in structure and possess an extracellular N (amino) 
terminal domain, a multiple leucine-rich repeats (LRR) domain and a C (carboxyl) terminal 
cytoplasmic domain.  The LRR domain comprises 24 amino acids and functions in the 
recognition of PAMPs (West et al., 2006).  This is followed by a short single 
transmembrane region and finally a conserved C terminal cytoplasmic domain.  The C 
terminal domain is highly homologous among individual TLRs and also to the intracellular 
cytoplasmic domain of the IL-1R, therefore terming this domain Toll/IL-1R (TIR).  While 
the extracellular N terminal domain of TLR‟s consists of multiple LRR, the extracellular 
domain of IL-1R contains immunoglobulin (Ig)-like domains. 
Since 1997, 13 members of the mammalian TLR family have been identified, 12 of 
which are expressed in humans.  TLRs 1–9 are conserved among humans and mice, yet 
TLR10 is present only in humans and TLR11 is only functional in mice (West et al., 2006).  
TLRs are widely expressed in many cell types including B cells, certain subsets of T cells, 
nonhematopoietic epithelial and endothelial cells and hematopoietically derived sentinel 
cells, such as macrophages, neutrophils, and DCs (West et al., 2006).  DCs primarily have 
the highest expression of TLRs, however variations do exist among their different subsets, 
for example, between conventional DCs and plasmacytoid DCs (pDCs).   
TLRs can be divided into subfamilies based on their sequence similarity, subcellular 
localisation, and the nature of the recognised PAMP.  While certain TLRs (TLR 1, 2, 4, 5, 
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and 6) are expressed on the cell surface, other TLRs (TLR 3, 7, 8 and 9) are found almost 
exclusively in intracellular components such as endosomes (Akira et al., 2006).  Despite the 
conservation among their extracellular domain, different TLRs can recognise structurally 
unrelated ligands, enabling this family of receptors to detect microorganisms ranging from 
bacteria and protozoans, to fungi and viruses (Fig 1.1).  
At the cell surface most TLRs appear to function as homodimers.  However certain 
TLRs can form heterodimers.  It is speculated that before ligand binding, TLR dimers are 
pre-assembled in a low-affinity complex (O'Neill and Bowie, 2007).  Upon ligand binding, 
a conformational change occurs, which brings the two TIR domains into close proximity, 
thus creating a platform for adaptor recruitment and subsequent signalling induction. 
 
1.3.1.1   TLR1, TLR2 and TLR6 
 
Bacteria are generally classified as either Gram-positive or Gram-negative based on 
their staining characteristics (Manafi and Kneifel, 1990).  Lipoproteins and lipopeptides are 
abundant on the outer membrane of bacteria and are potent stimuli for certain TLRs.  
TLR1, TLR2 and TLR6 are all expressed on the plasma membrane (West et al., 2006).  
TLR1 can form homodimeric complexes and interact with the bacterial PAMP; triacylated 
lipoproteins.  TLR1 can also form heterodimers with TLR2 and also interact with 
triacylated lipoproteins including the 19 kDa mycobacterial lipoprotein, meningococcal 
lipoproteins (Wyllie et al., 2000) and the synthetic lipoprotein structure PAM3CSK4 
(Takeuchi et al., 2001).  Homodimerisation of TLR2 generates specificity to various 
ligands including lipoproteins and cell wall components including peptidoglycan (PG) and 
lipoteichoic acid (LTA) which are present in both gram positive and gram negative bacteria 
(Akira et al., 2006).  In accordance with the above, TLR2 deficient mice were found to be 
highly susceptible to infection by Gram-positive bacteria such as Staphylococcus aureus 
(Takeuchi et al., 2000).  The interaction of PG with cluster of differentiation 14 (CD14), an 
LRR-containing glycosylphosphatidylinositol (GPI)-linked molecule, not only causes 
TLR2 activation but several groups have postulated that CD14 also acts to transfer PG to 
TLR2 for subsequent signalling (Sellati et al., 1998, Vasselon et al., 2004).   
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While triacylated lipoproteins are preferentially recognised by the TLR1/TLR2 
complex, diacylated lipoproteins including mycoplasma lipoproteins (MALPs) are 
recognised by the TLR2/TLR6 complex (Takeuchi et al., 2002).  This discrimination 
between TLR complexes is associated with cysteine residues present in lipoproteins i.e. all 
lipoproteins contain a lipolyated cysteine at their N terminus which is responsible for 
bacterial-associated immunostimulatory activity (Akira, 2003).  PAM3CSK4 contains a 
triacylated cysteine residue at its N terminus while the cysteine residue present in MALP-2 
is diacylated.  Takeuchi and colleagues established that TLR6 deficient mice failed to 
produce tumour necrosis factor alpha (TNF-α) in response to diacylated lipoprotein 
stimulation but displayed a normal response to triacylated lipoproteins (Takeuchi et al., 
2002).  Furthermore, TLR1 knockout mice had impaired TNF-α production to triacylated 
lipoproteins but not to diacylated lipoproteins.  In parallel, CD36 is involved in the 
recognition of diacylated lipoproteins by TLR2/TLR6 heterodimers (Hoebe et al., 2005).   
Zymosan, a mixture of cell membrane components from Saccharomyces cerevisiae 
can also induce signalling through interaction with the TLR2/TLR6 complex (Kataoka et 
al., 2002).  In addition, a C-type lectin; Dectin-1 can collaborate with the TLR2/TLR6 
complex to mediate independent but cooperative signalling in response to zymosan.  
Lipopolysaccharide (LPS) has also been proposed to act as a TLR2 ligand, however this 
erroneous conclusion was later shown to be caused by contamination of „pure‟ LPS with 
traces of biologically active lipopeptides (Hirschfeld et al., 2000).  
In comparison to other TLRs, TLR2 appears to respond to the largest repertoire of 
PAMPs.  This is believed to be, in part, due to its ability to form heterodimeric complexes 
with other TLRs.  Previous crystallographic analyses of the TIR domain of human TLR1, 
TLR2 and TLR10 revealed that the TIR domain of each TLR is composed of five β-strands 
alternated with five α-helices connected by eight loops (Xu et al., 2000).  Moreover, this 
domain contains three highly conserved motifs.  One such conserved motif is the BB-loop 
which is situated between the second β-strand and second α-helix.  This loop is key for 
TLR signalling, as single residue substitutions abolish its ability to recognise PAMPs 
without changing the overall structure of the TIR domain (Xu et al., 2000).  
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1.3.1.2 TLR3 
 
TLR3 is composed of twenty-three LRRs and recognises the viral PAMP; double-
stranded RNA (dsRNA) which is the form of genetic information carried by many viruses 
(West et al., 2006).  TLR3 also binds to polyriboinosinic:polyribocytidylic acid (Poly(I:C)), 
a synthetic version of dsRNA. TLR3 is found mainly in endosomal compartments.  This 
strategic location enables TLR3 to recognise nucleic acids released by viruses that are 
internalised for delivery to the endosome (Barton and Kagan, 2009).   
Much of the TLR3 protein surface is covered with carbohydrate sugar molecules, 
where one face is glycosylation free, suggesting that this is where TLR3 may bind to its 
respective PAMP (Choe et al., 2005).  This surface also contains two distinct patches that 
are rich in positively-charged residues, which may be a possible binding site for negatively 
charged dsRNA.  
TLR3 expression is rapidly and dramatically upregulated via ligand binding 
interaction and culminates in the activation of interferon (IFN) regulatory factor- (IRF)-3 
and late phase nuclear factor κ B (NFκB) activation.  TLR3 is expressed in DCs, in a 
variety of epithelial cells, including airway, uterine, corneal and intestinal epithelial cells, 
which function as efficient barriers to infection (Akira et al., 2006).  Furthermore, TLR3 is 
strongly expressed in the brain, specifically in astrocytes and glioblastoma cell lines which 
highlights its potential involvement in multiple sclerosis (M.S.) (Bsibsi et al., 2006).  
Excessive TLR3 activation has also been associated with a number of other inflammatory 
diseases including lupus nephritis and West Nile virus-driven CNS inflammation (Wang et 
al., 2004). 
Recent studies have reported on two cytoplasmic PRRs that recognise dsRNA 
independently of TLR3; RIG-I and (melanoma-differentiation-associated gene 5) MDA5.  
RIG-I and MDA5 are abundantly expressed in multiple cell types (Andrejeva et al., 2004, 
Yoneyama et al., 2004) and overcome the pathogen-detection limitations posed on TLRs 
confined to the endosomes by surveying the cytoplasm for viral particles.   
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1.3.1.3 TLR4 
 
TLR4 was the first mammalian TLR to be discovered in 1997 (Medzhitov et al., 
1997).  TLR4 is expressed in cells including monocytes/macrophages, myeloid DCs 
(mDCs), mast cells and the intestinal epithelium (Sallusto and Lanzavecchia, 2002).  TLR4 
recognises a diverse range of structurally unrelated PAMPs including LPS, the plant 
diterpene paclitaxel, the fusion protein from respiratory syncytial virus (RSV), fibronectin, 
and heat-shock proteins (HSP) e.g. HSP60 (Akira et al., 2006).   
LPS is the most thoroughly studied TLR4 ligand.  LPS, also known as endotoxin, is 
a glycolipid component of the outer membranes of Gram-negative bacteria.  However, LPS 
has also been found in one species of Gram-positive bacteria; Listeria monocytogenes 
(Oppenheim et al., 1981).  LPS is composed of a core oligosaccharide with polysaccharide 
lipid portion and a Lipid A part.  Lipid A is responsible for most of the pathogenic 
phenomena associated with LPS and it is therefore unsurprising that it proves to be the 
portion of LPS recognised by TLR4 (Akira et al., 2006).  Lipid A is a unique and 
distinctive phosphoglycolipid, the structure of which is highly conserved among species 
(Tsubery et al., 2002).  However, variations in Lipid A can arise from the degree of 
phosphorylation, the presence of phosphate substituents, and the number and position of the 
acyl groups.   
Prior to TLR4 ligand stimulation, LPS leaves gram-negative bacteria and associates 
with the LPS-binding protein (LBP) (Schumann et al., 1994).  LBP is an acutephase protein 
present in the bloodstream.  Upon association with LBP, the LPS/LBP complex is delivered 
to CD14, where CD14 serves as a receptor for the LPS/LBP complex.  As CD14 has no 
intracellular signalling domain, CD14 therefore associates with TLR4 and myeloid 
differentiation protein 2 (MD-2), a small accessory protein.  MD-2 belongs to the MD-2 
related lipid-recognition family and is found associated with the extracellular domain of 
TLR4 on the cell surface (Shimazu et al., 1999).  The importance of MD-2 in TLR4 ligand 
recognition has previously been demonstrated (Schromm et al., 2001).  In Chinese hamster 
ovary (CHO) cells with mutant MD-2, TLR4 signalling is abolished, whereas, wild-type 
MD-2 cells are capable of restoring LPS-induced signalling to normal.   
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Although it is widely accepted that LPS is the dominant ligand for TLR4, variations 
do exist in the structure of LPS that can have both a drastic and negative impact on TLR4-
induced signalling.  For instance, Yersina pestis, the cause of the plague, augments TLR4 
signalling when grown at 25°C (Montminy et al., 2006).  However, at 37°C, the bacterium 
changes its hexa-acylated LPS into a tetra-acylated form which acts as a TLR4 antagonist 
and prevents the transcription of various pro-inflammatory cytokines.  Similarly in 
Escherichia coli (E. coli) LPS, the best known example of a potent agonist for TLR4, the 
tetra-acylated lipid A precursor of E. coli LPS, lipid IVa, exhibits potent antagonist activity 
to E. coli LPS in human monocytes (Golenbock et al., 1991).  Furthermore, the penta-
acylated form of E. coli LPS that is derived from a mutant E. coli strain can efficiently 
antagonise the ability of hexa-acylated E. coli LPS to activate human endothelial cells 
(Somerville et al., 1996).  While LPS variations can negatively impact on TLR4 signalling, 
their ability to behave as LPS antagonists has received significant attention as potential 
therapeutic agents.  For example, the synthetic penta-acylated lipid A-like compound, 
E5531, is an antagonist for LPS-dependent cell activation which has been considered as a 
potential therapeutic agent for bacterial induced septic shock (Christ et al., 1995, Kawata et 
al., 1999). 
In addition to its bacterial recognition ability, TLR4 has also been reported to 
recognise viral and fungal pathogens.  TLR4 is implicated in the recognition of Candida 
albicans (Netea et al., 2004), pertussis toxin from Bordetella pertussis (Kerfoot et al., 
2004) and mannan, a fungal constituent of Saccharomyces cerevisiae.  As aforementioned, 
TLR4 recognises the fusion protein from RSV.  In TLR4 knockout mice, RSV can persist 
for longer periods in the lungs in comparison to wild type mice (Kurt-Jones et al., 2000).  
The envelope glycoprotein of mouse mammary tumor virus (MMTV) can also activate B 
cells through TLR4 stimulation (Rassa et al., 2002).  Taxol, an anti-tumour agent purified 
from the bark of the pacific yew, is capable of mimicking the effects of LPS signalling in 
mice but not in humans (Kawasaki et al., 2001).   
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1.3.1.4 TLR5 
 
Flagellin is a protein component of gram negative bacterial flagella; the mobility 
apparatus used by many pathogenic microorganisms and constitutes as the main ligand for 
TLR5 (Hayashi et al., 2001).  The structure of flagellin is highly conserved.  Recent 
analysis of the crystal structure of a Salmonella flagellin revealed that the flagellin domains 
are composed of N- and C-terminal α-helix chains (D0), central α-helix chains (D1), and a 
hypervariable central region with β-sheets (D2 and D3) (Yonekura et al., 2003).  TLR5 
recognises the highly conserved central D1 domain in flagellin that is essential for 
protofilament assembly and bacterial mobility (Hayashi et al., 2001).  More specifically, 
flagellin appears to bind directly to TLR5 at residues 386–407 of the extracellular domain 
(ED), as TLR5-ED knockouts lacking this domain are unable to interact with flagellin 
(Mizel et al., 2003).   
Previous analysis of flagellin from various species has revealed that Campylobacter 
jejuni and Helicobacter pylori flagellin each fail to activate TLR5 (Andersen-Nissen et al., 
2005).  Likewise, the hypervariable D2 and D3 domain of flagellins from E. coli and 
Salmonella species is not required for TLR5 signalling (Smith et al., 2003).  Smith and 
colleagues also demonstrated that monomers of flagellin induce TLR5 signalling whereas 
filamentous flagella do not.   
TLR5 is expressed on a number of immune cells including monocytes, DCs, T cells 
and NK cells.  TLR5 expression is also found in epithelial cells which provide the receptor 
with the best strategy to respond to flagellated bacteria i.e. TLR5 is expressed on the 
basolateral side of the intestinal epithelium and can thereby only sense flagellin once the 
bacteria have crossed the epithelium (Akira, 2003).  
 
1.3.1.5 TLR7 and TLR8 
 
TLR7 and TLR8 are highly homologous and are located on the X chromosome 
(Wang et al., 2006).  While both TLR7 and TLR8 are expressed in mice, many reports 
suggest that mouse TLR8 appears to be non-functional (Zhu et al., 2008, Chi and Flavell, 
2008).  However, a recent study demonstrates that TLR8 deficient DC‟s over express TLR7 
 10 
and induce greater NFκB activation upon stimulation with the synthetic antiviral 
imidazoquinoline compound; R848 (Demaria et al., 2010).  Both TLR7/8 are also 
expressed in the endosomal or phagosomal compartments of cells including monocytes and 
neutraphils and recognise guanosine or uridine-rich single stranded RNA (ssRNA) from 
viruses such as influenza, Sendai and Coxsackie B.  TLR7/8 also recognise Imiquimod, an 
additional synthetic antiviral imidazoquinoline compound (Jurk et al., 2002) which is 
consistent with reports where TLR7 knockout mice fail to induce inflammatory cytokines 
and type I IFN in response to Imiquimod (Hemmi et al., 2002).   
Viral ssRNA is rich in the nucleosides; uridine or guanosine.  Since these 
nucleosides are not specific to viruses, TLR7 does not distinguish between self or viral 
RNA.  Instead, it triggers an inflammatory response to any ssRNA encountered in the 
endosome (Diebold et al., 2006). Host nucleic acids are not usually found in endosomal 
compartments but can trigger TLR signalling.  For example, inefficient removal of 
apoptotic debris may result in host nucleic acids being available to activate TLRs and 
therefore break self-tolerance, thus leading to autoimmunity (Leadbetter et al., 2002, 
Midwood et al., 2009).  Systemic lupus erythematosus (SLE), a systemic autoimmune 
disease, is characterised by the production of autoantibodies directed against self nuclear 
antigens such as chromatin or small nuclear ribonuceoproteins (snRNPs) (Rahman and 
Eisenberg, 2006, Somarelli et al., 2011).  B cells normally produce autoantibodies in 
response to engagement with self-antigens when activated by T helper cells (Linterman and 
Vinuesa, 2010).  However, a recent study has demonstrated the ability of B cells to produce 
autoantibodies independently of T helper cells (Herlands et al., 2008).  The activation, 
expansion, and differentiation of AM14 B lymphocytes depended on the TLR7/9 activation 
of MyD88, as mice deficient in either TLR displayed partial defects in B lymphocyte 
development.  TLR7 and TLR9 signalling pathways can also result in the transcription of 
IFN-α via IRF7.  An increase in IFN-α has been associated in the pathology of SLE (Plotz, 
2003, Liu et al., 2011).  
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1.3.1.6 TLR9 
 
Bacterial genomic DNA, which contains unmethylated 2‟-deoxyribocytidine-
phosphate-guanosine (CpG) motifs, has potent immunostimulatory activity.  Mutation 
studies have reported that a single nucleotide mutation or methylation of a cytosine residue 
within a CpG motif, results in the loss of the immunostimulatory property of bacterial DNA 
(Krieg et al., 1995).  Mammalian DNA differs from that of bacterial DNA in that it contains 
relatively few CpG motifs and is highly methylated.  TLR9 recognises bacterial DNA 
containing unmethylated CpG motifs, as TLR9-deficient mice are unresponsive to CpG 
DNA ligand stimulation (Hemmi et al., 2000).   
TLR9 is believed to be localised in the endoplasmic reticulum and is recruited to 
late endosomes or lysosomes upon recognition of its respective ligand (Leifer et al., 2004).  
This endosomal restriction of TLR9 is critical for discriminating between self and non-self 
DNA because host DNA, unlike microbial DNA, do not usually enter the endosomal 
compartments.  Activation of TLR9 also requires acidification of endosomes and 
lysosomes, as agents that block endosomal acidification completely abrogate CpG-induced 
signalling (Häcker et al., 1998).   
Studies have demonstrated that TLR5 and TLR9 co-operate in their signalling 
events (Merlo et al., 2007).  Likewise, human TLR8 can dimerise with both TLR7 and 
TLR9 (Wang et al., 2006).  Wang and colleagues also demonstrated that TLR9 can interact 
with TLR7 and antagonise its signalling.  Overall, the interactions within this family subset 
reveal their complexity of TLR signalling networks.  To date, pDCs are the only immune 
cells to selectively express TLR7 and TLR9 (Bekeredjian-Ding et al., 2005). 
 
1.3.1.7 TLR10 and TLR11 
 
TLR10 was first identified in 2001 and was shown to be expressed in lymphoid 
tissues e.g. spleen, lymph nodes, thymus and tonsil (Chuang and Ulevitch, 2001).  In 
addition, the transcription factor forkhead box P3 (FOXP3) has been shown to regulate the 
expression of TLR10 in human T regulatory (Tregs) cells (Bell et al., 2007).  TLR10 
contains 811 amino acid residues and is most closely related to TLR1 and TLR6 in regard 
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to the overall amino acid identity (Chuang and Ulevitch, 2001).  TLR10 appears to be only 
functional in humans and is absent in rodents which has limited the discovery of its specific 
ligand.  However, TLR10 is thought to have the ability to not only homodimerise but also 
to form heterodimers with TLR1 and TLR2 (Hasan et al., 2005).  This suggests that 
lipoproteins may be possible targets for TLR10 stimulation e.g. PAM3CSK4 (Govindaraj et 
al., 2010).  As previously mentioned, crystallographic analyses of the TIR domain of 
human TLR10 has revealed that it is composed of five β-strands alternated with five α-
helices connected by eight loops (Xu et al., 2000). 
TLR11 was initially identified in mice (Zhang et al., 2004) and is similar in 
structure to TLR5.  It is abundantly expressed in the bladder and kidneys and recognises 
components of uropathogenic bacteria as TLR11-deficient mice were found to be 
susceptible to infections caused by these bacteria (Zhang et al., 2004).  However, the exact 
nature of these ligands has yet to be identified.  Human TLR11 is non-functional due to the 
presence of a premature stop codon in the gene and may explain why humans are 
predisposed to urinary tract infections.  Mouse TLR11 can recognise a class of prolin-like 
molecules expressed by protozoans such as Toxoplasma gondii (Plattner et al., 2008).  
TLR11 ligand interaction with protozoans induces the transcription of IL-12, which may be 
mediated by NFκB, as this transcription factor is activated in a dose-dependent manner by 
mouse TLR11 in response to Toxoplasma gondii (Yarovinsky et al., 2005).  
 
1.3.1.8 TLR12 and TLR13 
 
Minor information is available on the ligand recognition by and cellular expression 
of TLR12 and TLR13.  However, a previous study has reported on the detection of each 
TLR in macrophages and in liver, kidney and bladder epithelial cells (Tabeta et al., 2004) 
which is consistent with the potential role of TLR12 in preventing infection of internal 
organs of the urogenital system.  Murine TLR12 and TLR13 are expressed in the brain 
(Mishra et al., 2008) where this expression is upregulated in response murine 
neurocysticercosis infection.  Mishra and colleagues also demonstrated the expression of 
TLR13 in ependymal cells, endothelial cells of pial blood vessels and astrocytes.   
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1.4 The IL-1 Receptor 
The IL-1 receptor (IL-1R) was first described in 1988 (Sims et al., 1988), but it was 
not until several years later that the IL-1R accessory protein (IL-1RAcP) was characterised 
as the signal transducing subunit for the IL-1R complex (Fig 1.3).  The IL-1R was the first 
mammalian protein shown to have homology to the Toll protein (Gay and Keith, 1991) and 
belong to the TIR superfamily (Martin and Wesche, 2002).  Numerous studies have 
reported on the role of IL-1 in inflammation, in the pathogenesis of various inflammatory 
disorders and as a crucial cytokine in mediating the link between the innate and adaptive 
immune responses (Rothwell and Luheshi, 2000, O'Neill, 2008).   
The IL-1 family (IL-1F) comprises of 11 members including IL-1α, IL-1β, IL-1 
receptor antagonist (IL-1Ra) and IL-18 (Taylor et al., 2002).  Each member is highly 
conserved.  Aside from IL-18 and IL-33, all genes encoding the IL-1F members are 
clustered on human chromosome 2.  With the recent characterisation of newly cloned IL-1F 
members, it is now proposed that each member be assigned an individual interleukin 
designation (Dinarello et al., 2010).  Previously, the IL-1F members were renamed e.g. IL-
6 (IL-1F6), IL-7 (IL-1F7) etc, where IL-1α, IL-1β and IL-1RA were renamed IL-1F1, IL-
1F2 and IL-1F3, respectively (Sims et al., 2001, Dunn et al., 2001).  Dinarello and 
colleagues now propose that IL-1F6, IL-1F8, and IL-1F9 be designated IL-36α, IL-36β and 
IL-36γ, respectively, due to the fact that each member signals through the same receptor 
complex and initiates similar signalling cascades.  IL-1F7 is to be renamed IL-37 and its 
various splice forms (Smith et al., 2000) be designated IL-37a, IL-37b etc.   
IL-1 is produced by a wide variety of cell types including immune cells, endothelial 
cells and astrocytes, and functions as a ubiquitous mediator of inflammation due to the 
widespread expression of the IL-1R (Dinarello, 1991).  As previously stated, the IL-1R 
contains extracellular Ig-like domains responsible for ligand binding and a TIR domain in 
its cytoplasmic portion which interacts with other TIR-domain containing proteins.  Upon 
ligand binding to the IL-1R, recruitment of the IL‑1RAcP occurs and forms a 
heterodimeric complex with IL-1R. Formation of the receptor heterodimer induces 
signalling as the juxtaposition of the two TIR domains enables the recruitment of the 
adaptor protein, myeloid differentiation factor 88 (MyD88) via its TIR domain.  The 
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ensuing phosphorylation cascade typically follows that of the MyD88-dependent pathway 
which is discussed below and culminates in the activation of transcription factors including 
NFκB and activator protein-1 (AP-1) (O'Neill, 2008). 
 
1.5 TLR signal transduction 
 
TLRs mediate a vital part of the induction of the innate immune system.  Ligand 
binding to respective TLRs leads to their conformational change and facilitates the 
interaction of their cytoplasmic TIR domains with downstream TIR domain-containing 
adaptors proteins.  There are five such adaptor proteins characterised to date; MyD88, 
MyD88 adaptor-like (Mal) also known as TIR-associated protein (TIRAP), TIR domain-
containing adaptor inducing IFN-β (TRIF) also known as TIR-domain-containing molecule 
1 (TICAM-1), TRIF-related adaptor molecule (TRAM) also known as TICAM-2 and sterile 
α- and armadillo-motif-containing protein (SARM) (O'Neill et al., 2003).  Selective use of 
the adaptor molecules partly explains the differential signalling responses that are observed 
in response to TLR ligand stimulation (Fig 1.3).  Furthermore, these responses occur 
through two distinct signalling pathways, broadly characterised as MyD88-dependent or 
MyD88-independent. 
 
1.5.1  TIR domain-containing adaptor proteins 
 
The TIR domain is present in all TLRs, the IL-1 receptor family and in the five 
intracellular TLR adaptor proteins as mentioned above.  The TIR domain is typically 
composed of 135–160 residues, with sequence conservation ranging from 20 to 30% across 
the five adaptor proteins (Ohnishi et al., 2009).  Within the TIR domain, three conserved, 
highly homologous boxes are crucial for signalling (Akira and Takeda, 2004).  While the 
hydrophobic core residues are conserved, the surface exposed residues vary greatly 
between each TIR domain.  Indeed, MyD88, Mal, TRIF and TRAM were all uncovered by 
groups searching the human genome for TIR domain-containing proteins.  The interest in 
these proteins derives from the intrigue of how different TLRs can induce individual gene 
expression profiles. 
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1.5.1.1 MyD88 
 
MyD88 transduces signals for all TLRs, except TLR3.  It is also a key mediator for 
the IL-1 and IL-18 receptors (Adachi et al., 1998, Janssens and Beyaert, 2002).  MyD88 
was isolated as a myeloid differentiation response gene that was induced when M1 
myeloleukaemic cells were differentiated into macrophages upon IL-6 stimulation (Lord et 
al., 1990).  MyD88 is 296 amino acids in length and contains two domains.  It has a 
modular structure, comprising of a C terminal TIR domain, through which it interacts with 
the TIR domain of TLRs, and an N terminal death domain (DD), which facilitates its 
interaction with other DD-containing proteins.  These domains are separated by a small 
intermediate domain (ID) (Janssens et al., 2002).   
Previous analysis of the MyD88 TIR domain revealed a mutation in an isoleucine 
residue at position 179, which abolished MyD88-mediated NFκB activation (Jiang et al., 
2006).  This is called the Poc site after the mutant phenotype Pococurante, and 
demonstrates the importance of MyD88 in NFκB signalling.  Recently, three functional 
surface sites (Sites I–III) of the MyD88 TIR domain that are important for the LPS-induced 
activation of the TLR4 signalling pathway have been identified (Ohnishi et al., 2009).  Sites 
II and III serve as binding sites for the TIR domain of Mal.  Site I is unlikely to be involved 
with Mal or TLRs and therefore is hypothesised to serve as a binding site for a yet 
unidentified MyD88 binding protein or specific membrane protein.  The TLR2 TIR domain 
has been demonstrated to directly interact with MyD88, while the TIR domain of the 
closely related TLR1 and TLR6 failed to mimic this interaction with MyD88 (Brown et al., 
2006).  TLR5 and TLR10, like TLR4, can also interact with MyD88 (Hasan et al., 2005). 
 
1.5.1.2 Mal  
 
Mal, also named TIRAP, was the second TIR domain-containing adaptor to be 
identified in 2001 by two independent groups (Fitzgerald et al., 2001, Horng et al., 2001).  
Mal is 256 amino acids long and contains many domains and phosphorylation sites.  At its 
N terminus is a phosphatidylinositol 4,5-bisphosphate (PIP)-2-binding domain (Kagan and 
Medzhitov, 2006) which functions to recruit Mal specifically to PIP2-rich regions in the 
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plasma membrane.  This is followed by the TIR domain and a TNF receptor associated 
factor (TRAF)-6-binding domain. There are two separate phosphorylation sites for Bruton‟s 
tyrosine kinase present on Mal (Watters et al., 2007).  Mal also contains a single-nucleotide 
polymorphism (SNP) representing a serine (Ser) to leucine (Leu) mutation located at 
position 180 and this has been linked to several diseases including tuberculosis and malaria 
(Sheedy and O'Neill, 2007).  At the C terminus is an aspartic acid (Asp) residue which is 
cleaved by caspase-1, therefore indicating the novel ability of Mal to interact with caspase-
1 (Miggin et al., 2007). 
TLR1, TLR2, TLR4 and TLR6 are expressed in the plasma membrane.  Since PIP-2 
is enriched here, Mal may mediate the signalling events induced by ligand activation of 
these TLRs.  Studies utilising Mal-deficient mice revealed that it lies on the MyD88-
dependent pathway and functions as a bridging adaptor for MyD88 by recruiting it to the 
cytoplasmic domain of TLR4 and TLR2 (Horng et al., 2002).  The importance of Mal in 
TLR2 signalling is emphasised in studies where NFκB and p38 activation is abolished in 
Mal-deficient cells in response to TLR2 ligands (Yamamoto et al., 2002).  However, Mal is 
not utilised by TLR5 or the IL-1R, which are also found on the plasma membrane as Mal-
deficient mice show normal signalling in response to these receptors. 
Studies also hypothesised that Mal may be the elusive adaptor for the MyD88-
independent pathway.  However, it was soon discovered that this was not the case as 
MyD88 and Mal double knockout mice display a similar phenotype to single knockouts of 
each, revealing that these two adaptors could not compensate for one another (Yamamoto et 
al., 2002).  Furthermore, IRF3 transcriptional activation and subsequent IFN-β induction 
remained intact in double knockout mice, thus excluding a role for Mal in the MyD88-
independent pathway.   
In relation to both TLR2 and TLR4 signalling events, it is well recognised that Mal 
acts as a bridging adaptor for MyD88, helping to recruit MyD88 to the plasma membrane 
via its PIP-2 domain.  In TLR2 signalling, the TIR domain of MyD88 specifically interacts 
with the TIR domain of TLR2 and activates NFκB and the mitogen-activated protein 
(MAP) kinases via a phosphorylation cascade.  Interestingly, a recent study has confirmed 
that the TIR domain of MyD88 does not exclusively interact with TLR4 TIR domain 
(Ohnishi et al., 2009) and instead Mal may interact directly with TLR4 TIR domain and 
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recruit MyD88 to the complex, where it can activate downstream signalling components 
required to bring about the TLR4-induced response.  Ohnishi and colleagues also revealed 
that the distal location of the Mal binding sites on the MyD88 TIR surface suggests that the 
TIR domain of MyD88 simultaneously interacts with two Mal TIR molecules, which may 
provide a highly efficient scaffold for signal transduction.  The importance of the PIP-2 
binding domain in TLR4 activation has also been revealed as blocking this localisation 
abolishes TLR4-MyD88-dependent signalling (Sheedy and O'Neill, 2007). 
Mal may function as more than a bridging adaptor.  Mal contains a TRAF6 binding 
domain and unlike MyD88, can interact directly with TRAF6 in response to TLR2 and 
TLR4 stimulation (Verstak et al., 2009).  Moreover, a Mal mutant lacking the TRAF6-
binding motif fails to initiate the proinflammatory response to TLR2 and TLR4 ligand 
activation.   
Mal also contains two separate phosphorylation sites for Bruton‟s tyrosine kinase. 
Interestingly, these phosphorylation sites allow the suppressor of cytokine signalling 1 
(SOCS-1) protein to bind to Mal via its Src homology (SH)2 domain and orchestrate its 
degradation by mediating the ubiquitation of Mal and subsequent degradation by the 26S 
proteasome (Mansell et al., 2006).  Furthermore, SOCS-1-deficient cells are particularly 
sensitive to LPS as Mal is not targeted for degradation (Kinjyo et al., 2002, Nakagawa et 
al., 2002).   
 
1.5.1.3 TRIF 
 
Previous analysis of MyD88- and Mal-deficient cells, which lead to late phase 
NFκB activation following TLR4 and TLR3 ligand activation (Yamamoto et al., 2003a), 
suggested the possible presence of additional adaptor proteins.  Searches of the human 
genome for TIR domain-containing proteins unveiled the TIR adaptor; TRIF, also known 
as TICAM-1.  Yeast two-hybrid screens performed on TLR3, also identified the TRIF 
molecule, which was of particular interest because no known adaptor for TLR3 had been 
identified prior to this discovery (Oshiumi et al., 2003a).  Overexpression studies revealed 
that TRIF induces the IFN-β promoter while in TRIF-deficient macrophages, cytokine 
production was decreased in response to TLR4 signalling but normal for TLR2, TLR7 and 
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TLR9 (Yamamoto et al., 2003a).  Furthermore, LPS induction of NFκB was completely 
abolished in MyD88 and TRIF double knockouts macrophages (Hirotani et al., 2005).  
TRIF is the longest adaptor protein characterised to date and is composed of 712 
amino acids (Han et al., 2004).  TRIF contains three TRAF6-binding sites in its N terminal 
domain, a TIR domain and a receptor-interacting protein (RIP) homotypic interaction motif 
(RHIM) in its C terminal domain. Upon ligand activation of TLR3 (and also TLR4), a 
MyD88-independent signalling response is induced to regulate IRF3 and late phase NFB 
transcriptional activity.  This signalling response occurs via interaction with TRIF.  In 
relation to type I IFN induction, TRIF interacts with TLR3 through its TIR domain while 
its N terminal domain forms a complex with TRAF family-member-associated NFκB 
activator (TANK) binding kinase 1 (TBK1) and inhibitor of NFκB (IκB) kinase (IKK)ε 
(Fitzgerald et al., 2003).  This leads to direct phosphorylation of IRF3 at C-terminal serine 
residues which culminates in nuclear translocation of IRF3 and increased transcription of 
type I interferons. 
TLR4 appears to utilise both the MyD88-dependent and MyD88-independent 
pathways to induce the activation of NFκB (Kawai et al., 1999).  As aforementioned, TRIF 
contains three TRAF6-binding sites in its N terminal region.  Mutations of these sites 
results in the partial loss of TRIF induction of NFκB including the failure to associate with 
TRAF6, implying that TRIF directly binds to TRAF6 to mediate NFκB activation.  
However, the TRAF6-binding motif mutants remain capable of activating the IFN-β 
promoter (Jiang et al., 2004) as TLR3 signalling via activation of TRIF is not affected by 
TRAF6 deletion in macrophages (Häcker et al., 2000).   
A recent study has elaborated on the TRAF6 binding sites where TRAF1, 2 and 6 
are capable of interacting with the N-terminus of TRIF (Sasai et al., 2010).  While a single 
mutation in the TRAF2-binding motif of TRIF only marginally affects TRIF induction of 
the IFN-β promoter, mutations in both the TRAF2- and TRAF6-binding sites of TRIF 
abrogate the TRIF signalling pathway.  Furthermore, mutations in the TRAF2 and TRAF6-
binding domains of TRIF reduce N terminal polyubiquitination of the adaptor molecule as 
TRAF2 and TRAF6 both function as E3 ligases to mediate the K63 ubiquitination of TRIF.  
TRAF1 is also capable of directly interacting with TRIF via binding to the TRIF TIR 
domain.  However, overexpression of TRAF1 negatively regulates the TRIF pathway and 
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the TRIF mediated activation of NFκB, IFN-stimulated response element (ISRE) and the 
IFN-β promoter.  Numerous groups have also reported on TRIFs recruitment of TRAF3 in 
the activation of IRF3 and subsequent IFN-β activation (Hacker, Redecke et al. 2006; 
Colonna 2007).   
The RHIM motif present in the C terminal domain of TRIF is responsible for 
direction association with RIP1 and RIP3.  In RIP1-deficient mice embryonic fibroblasts, 
NFκB activation is normal in response to LPS induction but is lost in response to Poly(I:C) 
stimulation (Meylan et al., 2004), therefore suggesting that TLR3 and TLR4 utilise TRIF in 
a dissimilar manner.  RIP3 can also bind to the RHIM motif and acts as an inhibitor of 
TRIF-RIP1 signalling. 
TRIFs direct binding with RIP1 can also induce apoptosis via recruitment of Fas-
associated death domain (FADD) by DD interactions and subsequent caspase-8 activation 
(Han et al., 2004).  The ability to elicit TRIF-dependent apoptosis may be due to its role as 
protector against viruses in the TLR3 pathway as TRIF is targeted for immune evasion by 
the vaccinia virus protein, A46R (Stack et al., 2005) and also by the hepatitis C virus 
protease, NS3-4A (Li et al., 2005).  While TRIF is a positive regulator of TLR3 induced 
signalling, TRIF has shown to play an inhibitory role in TLR5 elicited responses by 
inducing proteolytic degradation of TLR5 (Choi et al., 2010). 
 
1.5.1.4 TRAM 
 
TRAM /TICAM-2 was also initially discovered by the use of bioinformatics, on the 
basis that TRAM possessed strong homology to the TIR domain of TRIF (Yamamoto et al., 
2003b).  While Mal functions as a bridging adaptor by recruiting MyD88 to TLR2 and 
TLR4, TRAM also functions as a bridging adaptor by recruiting TRIF to TLR4 to mediate 
the activation of the MyD88-independent pathway (Oshiumi et al., 2003b).  However, 
TLR3 does not require TRAM for IFN-β production (Yamamoto et al., 2003b).  
TRAM is the smallest adaptor protein at 235 amino acids long (Yamamoto et al., 
2003b).  It contains a putative myristoylation site at its N terminus followed by serine at 
position 16 which is phosphorylated by protein kinase Cε (PKCε) and a TIR domain in its 
C terminus. 
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Analogous to Mal, TRAM is also targeted to the plasma membrane, albeit in a 
diverse manner.  Studies have demonstrated that a mutation in the N-terminal 
myristoylation site causes the dissociation of TRAM from the plasma membrane (Sheedy 
and O'Neill, 2007) and relocates TRAM to the cytoplasm where this mutant is unable to 
restore LPS-induced signalling in macrophages deficient in wild-type TRAM (Rowe et al., 
2006), indicating that this site serves to target TRAM to the plasma membrane.  The 
membrane localisation of TRAM may serve to recruit TRIF to the membrane as the only 
known function attributed to TRAM is that of a bridging adaptor between TLR4 and TRIF.  
Small interfering RNA (siRNA) and dominant negative studies also reveal that although 
TLR3 and TLR4 both utilise TRIF, TLR4 requires initial binding to TRAM before 
recruiting TRIF (Fitzgerald et al., 2003).  TLR4 activation of IRF3 and subsequent 
induction of the type I interferons is dependent on TRAM.  
TRAM is also subject to regulation by phosphorylation.  After LPS stimulation, 
TRAM leaves the membrane and this is dependent on PKCε-mediated phosphorylation of 
TRAM on Ser16 (McGettrick et al., 2006).  This phosphorylation event is necessary for 
TRAM signalling as a mutant containing a substituted alanine for Ser16; TRAM S16A, 
abolished the ability of the adaptor protein to activate IRF3 or NFκB.  
 
1.5.1.5 SARM 
 
SARM was first discovered in 2001 as an ortholog of the Drosophila melanogaster 
protein, CG7915, which is highly conserved in mice that contained sterile alpha and 
HEAT-Armadillo motifs (SAM and ARM motifs) (Mink et al., 2001).  SARM was also 
described to be a human orthologue of the Caenorhabditis elegans protein TIR-1, which is 
involved in the induction of the antifungal peptides; NLP-29 and NLP-31 and is required 
for antibacterial responses occurring upstream of PMK-1, the ortholog of human p38 
(Couillault et al., 2004, Liberati et al., 2004).  While the SARM ortholog of C. elegans has 
a positive function both in development and in immunity, the role of SARM in humans is 
quite different. 
SARM is 690 amino acids in length and is made up of several domains all located 
near the N terminus with two SAM motifs followed by the TIR domain (Watters et al., 
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2007).  SARM has been reported to be closely related to bacterial proteins with TIR 
domains (Zhang et al., 2011) but is functionally distinct from TIR domain containing 
adaptor proteins in that it fails to activate NFκB or IRF3 (Liberati et al., 2004) and 
negatively regulates TRIF-mediated signalling (Carty et al., 2006).  Although SARM fails 
to activate NFκB, LPS induced activation of TLR4 in primary human peripheral blood 
mononuclear cells (PBMC) strongly enhances endogenous SARM expression (Carty et al., 
2006) indicating a potential auto-regulatory feedback system.   
In resting cells, SARM and TRIF weakly associate (O'Neill, 2006).  However, upon 
ligand activation of TLR4 and possibly TLR3, the SARM and TRIF complex stabilises via 
interaction with the SAM motifs.  The TIR domains of SARM and TRIF possibly also 
interact by stabilising the SARM-TRIF complex and also by preventing TRIF interacting 
with other TIR domain containing adaptors, as a SARM construct lacking the TIR domain 
fails inhibit TRIF (Carty et al., 2006).  However, the exact mechanism by which SARM 
targets TRIF has yet to be discovered.  O‟Neill and colleagues speculate that because SAM 
domains are necessary for the interaction with TRIF, it is possible that other SAM domain 
containing proteins may be recruited to limit TRIF-mediated signalling (O'Neill et al., 
2003).  CrSARM, a functional SARM from the horseshoe crab, downregulates the TRIF-
dependent TLR signalling pathway culminating in the inhibition of NFκB, suggesting the 
conservation of SARM function from horseshoe crab to human (Belinda et al., 2008).  
While CrSARM targets TRIF-dependent signalling, it has no effect on MyD88 or TNF-α 
induced activation of NFκB (Belinda et al., 2008).  However, in contrast, amphioxus 
SARM (Branchiostoma belcheri tsingtauense SARM) can suppress TLR signalling by 
targeting amphioxus MyD88 and TRAF6 (Yuan et al., 2010).  
 
1.5.2  TLR signalling and activation of transcription factors 
 
TLR signalling pathways were intensively studied after the discovery of MyD88. 
The subsequent identification of additional TIR domain–containing adaptor proteins has 
demonstrated that individual TLRs selectively recruit distinct adaptor molecules, thus 
initiating various signalling transduction cascades.  This ultimately culminates in the 
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activation of various transcription factors including NFκB and the IRFs that, can act alone 
or in concert to regulate gene expression.  
 
1.5.2.1 NFκB 
 
As a central regulator of cell survival and a key mediator in the activation of various 
inflammatory signalling pathways, NFκB has been subject to intense research since its 
discovery over 20 years ago (Sen and Baltimore, 1986).  NFκB-binding sites, consisting of 
the consensus sequence GGGRNNYYCC (where R = purine, Y = pyrimidine, N = any 
base), have been identified in the promoter regions of genes encoding a plethora of 
cytokines, chemokines, adhesion molecules and including mediators of the adaptive 
immune response and proteins involved in antigen presentation (Phal, HL, 1999).  NFκB 
was first identified as a nuclear transcription-enhancing, DNA-binding complex governing 
the Ig light chain gene in mature B cells (Sen and Baltimore, 1986).  As NFκB binding sites 
were present in the promoters of genes that were not B cell specific, it became clear that 
NFκB was ubiquitously expressed and played a key role in regulating the expression of 
many inflammatory related genes.  Sen and Baltimore also demonstrated that in order to 
induce NFκB activation, an external stimulus for example LPS or phorbol ester treatment 
was required in certain cell types.   
NFκB is evolutionarily and structurally conserved and has representative members 
in a wide range of species.  Mammalian NFκB consists of five subunits; p100/52, 
p105/p50, p65 (RelA), c-Rel and RelB, which exist as homo- and heterodimers in the 
cytoplasm of resting cells, except for RelB which only forms heterodimers.  Each of the 
NFκB subunits contains a Rel homology domain (RHD) at its N terminus of roughly 300 
amino acids long.  The RHD facilitates dimerisation, DNA-binding, nuclear localisation, 
and cytoplasmic retention by members of the inhibitor of NFκB (IκB) family.  The 
dimerisation domain is located in the C terminal region of the RHD, whereas the N terminal 
part of the RHD contains the DNA-binding domain.  In contrast, the transcription activation 
domain (TAD), necessary for target gene expression, is present only in the C terminus of 
p65, c-Rel, and RelB subunits (Ghosh et al., 1998).   
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p50 and p52 are made from immature IκB precursors, p105 and p100 respectively.  
The partial proteolysis of p105 and p100 is mediated by the ubiquitin/proteasome pathway.  
Both p105 and p100 have long C terminal domains that contain multiple copies of ankyrin 
repeats which are degraded upon maturation to p50 and p52, respectively.  Ankyrin repeats 
can mediate the repressive function of p50 and p52 in transcription (Moynagh, 2005) by 
binding to the RHD of NFκB subunits thus masking its nuclear localisation sequence (NLS) 
and retaining NFκB in the cytoplasm.  As a result, these subunits are generally termed 
repressors of transcription, unless when they form heterodimers with p65, RelB and c-Rel 
which is evident in the noncanonical NFκB pathway (discussed below).  Mice deficient in 
certain NFκB subunits, p50, RelA, c-Rel or RelB are highly susceptible to microbial 
infections from Streptococcus pneumoniae and Toxoplasma gondii infections (Ghosh et al., 
1998, Sha et al., 1995, Caamano et al., 1999).  
NFκB subunits are sequestered in the cytoplasm in an inactive form and impeded 
from entering into the nucleus by virtue of their association with members IκB family, 
homologs of Drosophila Cactus (Quivy and Van Lint, 2004).  IκBs, which bind to NFκB, 
mask its NLS, thereby preventing nuclear uptake of the transcription factor.  Upon IL-1R or 
TLR ligand stimulation, downstream activation of the IKK signalosome occurs and results 
in the phosphorylation and subsequent traffic of the inhibitory IκBs to the 26S proteasome 
for degradation (Hacker and Karin, 2006).  This cytoplasmic “switch” liberates the NFκB 
complex from the cytoplasm and targets it for subsequent nuclear translocation and target 
gene transcription.  The IKK signalosome complex comprises of two catalytic subunits; 
IKKα, IKKβ and a regulatory subunit; NFκB essential modulator (NEMO) or IKKγ (Karin 
and Ben-Neriah, 2000).  Analysis of IKKβ and IKKα deficient cells has demonstrated that 
the IKKβ subunit performs a significant contribution to canonical NFκB activation more so 
than IKKα.  Furthermore, NEMO also appears to be essential for NFκB activation, as 
NEMO-deficient cells fail to activate NFκB in response to the ligand stimulation by IL-1β, 
TNF-α, and LPS (Israel, 2006).   
The IκBs consist of three main subunits, IκBα, -β and -ε.  Although these proteins 
retain NFκB in the cytoplasm, IκBα can be potently upregulated by NFκB and enter the 
nucleus and interfere with NFκB binding to DNA.  IκBα can then transport NFκB back to 
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the cytoplasm leading to the resequestration of NFκB thus forming an overall negative 
feedback loop (Hoffmann and Baltimore, 2006).   
NFκB is also targeted by stimulation of the IL-1R.  Together with stimulation of 
TLRs and TNF receptor (TNFR), these pathways comprise the canonical NFκB pathway 
and converge on the IKK complex.  In noncanonical NFκB activation, stimulation of a 
subset of TNFR superfamily members, including the B cell activating factor (BAFF) 
receptor, induces NFκB activation via activation of NFκB-inducing kinase (NIK) and the 
IKKα subunit.  The noncanonical pathway is particularly important in the regulation, 
survival and maturation of B cells (Pomerantz and Baltimore, 2002) as B cells deficient in 
NIK or IKKα display defects in their ability to mature or survive.  In resting cells, the 
BAFF receptor recruits TRAF3 and TRAF2 to the plasma membrane where interactions 
occur via their TRAF-binding motif (Morrison et al., 2005).  BAFF induces proteolysis of 
TRAF3, leading to stabilisation of NIK.  NIK is consequently ubiquitinated by an E3 
complex consisting of TRAF3, TRAF2, and cellular inhibitor of apoptosis proteins (cIAPs).  
This polyubiquitination targets NIK for degradation by the proteasome and therefore it fails 
to engage with IKKα and mediate the subsequent activation of NFκB.  However, in 
stimulated cells, the formation of the TRAF3-TRAF2-cIAP complex causes TRAF2 to 
catalyse the K63 polyubiquitination of cIAPs, which promotes the ability of cIAPs to 
catalyse K48 polyubiquitination of TRAF3 and target it for degradation by the proteasome.  
NIK then phosphorylates IKKα, which in turn phosphorylates the p100 subunit, leading to 
its ubiquitination by the SKp1-Cullin-F-box (SCF)-protein β-transducing repeat-containing 
protein (βTrCP) (SCF-βTrCP) complex and subsequent proteasomal processing to p52.  
p52 forms a complex with RelB where the active heterodimer translocates to the nucleus 
and induces gene expression.  In contrast, p105 undergoes constitutive cleavage to produce 
p50.  Proteasomal processing of p105 occurs cotranslationally and posttranslationally, and 
can result in the complete degradation or formation of p50.  
 
1.5.2.2 The interferon regulatory factors 
 
The initial discovery of „the interferon‟ inhibition of viral replication occurred in 
1954 (Nagano and Kojima, 1954) where wider recognition was attained by Isaacs and 
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Lindenmann who coined the word "interferon" in 1957 (Lindenmann et al., 1957).  Since 
the 1950s, a vast body of evidence has now accumulated to demonstrate the central 
involvement of the IRFs and their associated transcription of a diverse range of interferons 
in various phases of host defense, including antiviral and anticancer immune responses.  
The type I IFNs are a multigene family evolutionarily conserved in vertebrates and are 
expressed following exposure to a wide variety of infectious agents.  They are characteristic 
of an antiviral response and are so called because of their ability to interfere with virus 
replication (Samuel, 2001).  The type I IFNs are the most diverse of all the cytokine 
families.  IFNs and their receptors are a subset of the class 2 α-helical cytokines and 
comprise of multiple subtypes including IFN-α, -β and -γ.  Thirty type I IFN gene clusters 
have been found on the human chromosome 9p:13, while 24 type I IFN genes are clustered 
on chromosome 4p:13 (Hardy et al., 2004).  Many cell types induce type I IFN secretion; 
however, the main IFN-producing cells (IPCs) are DCs (primarily pDC‟s), macrophages 
and other haemopoietic cells (Taniguchi and Takaoka, 2001).  These cells constitutively 
produce low levels of IFN-α/β which renders the cells „ready-to-go‟ for the enhancement of 
cellular responses to external stimuli.   
Viral infection induces the transcription of multiple type I IFN genes, a response 
that is in part mediated by the activation of the IRFs.  The initially characterised members; 
IRF1 and IRF2 are now part of a growing family of transcriptional regulators that has 
expanded to nine members (Taniguchi et al., 2001).  Although IRF1, IRF3, IRF5, and IRF7 
function as positive-feedback regulators of type I IFN genes, only IRF3, IRF5 and IRF7 
play a crucial role in the expression of type I IFN genes (Tamura et al., 2008).   
Each IRF family member contains an N-terminal DNA-binding domain of 
approximately 120 amino acid residues and a C-terminal IRF association domain (IAD) 
(also known as the regulatory domain (RD)) that is responsible for signal transduction 
(Mamane et al., 1999, Taniguchi et al., 2001).  The well conserved DNA-binding domain 
forms a helix-turn-helix motif with a conserved tryptophan cluster and mediates specific 
binding to 5′-GAAA-3′  and 5′-AANNGAAA-3′ sequences termed ISRE, that are found in 
promoters of all genes activated by IRFs (Taniguchi et al., 2001).  The C terminal IAD 
domain also includes the cyclic AMP-response element binding protein (CREB)-binding 
protein (CBP)/p300 interaction surface, an autoinhibitory domain and various 
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phosphorylation sites.  Transient transfection assays utilising IRF3, IRF5 and IRF7 have 
revealed that the autoinhibitory domain can suppress the transcriptional activity of these 
transcription factors (Barnes et al., 2002), a mechanism that is more likely used in resting 
cells.  Autoinhibition in IRFs is released upon phosphorylation which induces 
conformational changes, dimerisation and nuclear translocation.  Only one autoinhibitory 
domain has been found in the N terminus of IRF5 and IRF7 (Marie, Smith et al. 2000; 
Barnes, Kellum et al. 2002) while two autoinhibitory domains have been identified in both 
the C and N terminus of IRF3 (Lin et al., 1999).  A NLS is also present in the N terminus of 
IRF3, IRF5 and IRF7, which functions in nuclear translocation and cell retention (Chen and 
Royer Jr, 2010).   
IRF3 and IRF7 are key regulators of type I IFN gene expression in response to viral 
infection.  IRF7 was first described to bind to and repress the Epstein Bar Virus (EBV) Qp 
promoter, which regulates expression of the EBV nuclear antigen 1 (EBNA1) (Zhang and 
Pagano, 1997).  Virus-mediated phosphorylation of IRF7 occurs on Ser483 and Ser484 
which induces a conformational change in the transcription factor (Yang et al., 2003).  This 
is critical for its dimerisation, nuclear accumulation, DNA-binding, and transcriptional 
transactivation.  Although clusters of serine residues located in the C terminal regulatory 
domain of IRF7 are putative targets of virus-activated kinases, the critical residues for 
phosphorylation-induced activation have yet to be established.  However, similar to IRF3, 
TBK1 and IKKε have been reported to phosphorylate and activate IRF7 (Sharma et al., 
2003).  While IRF3 phosphorylation prominently induces IFN-β, IRF7 has the ability to 
preferentially activate IFN-α (Noppert et al., 2007).  Virus-mediated phosphorylation of 
IRF3 is discussed in Chapter 5.   
Although IRF3 is constitutively and ubiquitously expressed in many cell types, 
IRF7 expression is dependent on the cell type and in general, expression is much lower than 
IRF3 (Izaguirre et al., 2003).  However, pDCs constitutively express IRF7; therefore 
activation of TLR7 and TLR9 in these cells rapidly induces the production of type I IFN via 
the MyD88-dependent pathway.  Furthermore, IRF3 mediated IFN-β and IFNα4 activation 
can subsequently signal via the type I IFN receptor (IFNAR) to activate the Janus activated 
kinase (JAK)–signal transducer and activator of transcription (JAK–STAT) pathway 
(Noppert et al., 2007).  This in turn activates the IFN-stimulated gene factor 3 (ISGF3) 
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transcriptional regulator, which induces IRF7 expression.  In a similar manner to IRF3, 
phosphorylated IRF7 translocates to the nucleus and binds to positive regulatory domain 
(PRD) on the IFN-α promoter.  Thus, the induction of type I IFN initiates a positive 
feedback loop, which enables cells to produce large amounts of IFN-α/β, ensuring the 
efficient production of type I IFN during viral infection.  
 
1.5.2.3 MyD88 dependent pathway 
 
The MyD88-dependent pathway (Fig 1.3) transduces signals for all TLRs, except 
TLR3.  MyD88 is also a key mediator for the IL-1 and IL-18 receptors (Adachi et al., 1998, 
Janssens and Beyaert, 2002).  Following ligand interaction with TLR1, TLR2, TLR4 and 
TLR6, activated Mal recruits MyD88 to the plasma membrane via its PIP-2 binding 
domain.  Whether MyD88 interacts directly with the TIR domain of TLR4 following 
recruitment to the plasma membrane is controversial, as a recent study suggests that the 
TIR domain of MyD88 does not exclusively interact with TLR4 TIR domain (Ohnishi et 
al., 2009).  However, in relation to the other TLRs (except TLR3), MyD88 interacts with 
the TIR domain of these TLRs via MyD88 C terminal domain.  MyD88 subsequently 
recruits the IL-1R–associated kinase (IRAK); IRAK4, IRAK1, and IRAK2 through 
homotypic interactions between their respective DDs (Ohnishi et al., 2009).  Once IRAK4 
binds to MyD88, it is initially activated, whereby it recruits and phosphorylates IRAK1 and 
IRAK2 in a sequential manner. IRAK1 then autophosphorylates, dissociates from the 
MyD88 complex and interacts with the E3 ligase, TRAF6.  TRAF6 catalyses the K63 
polyubiquitination on target proteins including itself and IRAK1.  This is in conjunction 
with the dimeric E2 ubiquitin conjugating enzymes Ubc13 and Uev1A.  The K63-linked 
polyubiquitin chains bind to the novel zinc finger–type ubiquitin-binding domain of TGF-
β-activated protein kinase (TAK-1) binding protein (TAB)-1 and -2 which leads to the 
activation of TAK1.  TRAF6, K63-linked polyubiquitin chains also bind to the ubiquitin-
binding domain of NEMO and they may also be responsible for the recruitment of TAK1 to 
the TAB1/2 complex (Kawai and Akira, 2010). As previously mentioned, NFκB subunits 
are sequestered in the cytoplasm in an inactive form and impeded from entering the nucleus 
by virtue of their association with members of the IκB family.  Once TAK1 is activated, it 
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interacts with the IKK signalsome complex and induces phosphorylation of IKKβ (Kawai 
and Akira, 2010).  IKKβ subsequently induces the phosphorylation of IκB where IκB 
becomes polyubiquitinylates and trafficked to the 26S proteasome for degradation (Hacker 
and Karin, 2006).  This cytoplasmic “switch” liberates the NFκB complex from the 
cytoplasm for subsequent nuclear translocation and target gene transcription.   
IRF7, which is constitutively expressed by pDCs, is also targeted by the MyD88 
dependent pathway.  Following the engagement of MyD88 with TLR7, TLR8 or TLR9, a 
multiprotein signalling complex involving IRAK4, TRAF6, TRAF3, IRAK1 and IKKα 
occurs.  IRF7 becomes phosphorylated by IRAK1 and/or IKKα, on its C terminus where it 
dissociates from this complex, dimerises and translocates into the nucleus to induce 
transcription of IFNα/β.  IRAK1 plays an important role in IRF7 activation.  Not only does 
the kinase phosphorylate IRF7, but IRAK1 deficient pDC‟s display defects in IRF7 
translocation and ensuing IFNα expression (Uematsu et al., 2005).  In relation to IRF3, 
NRDP1, a RING-containing E3 ligase has reported to positively regulate TBK1 activation 
of IRF3 (Wang et al., 2009).  NRDP1 directly targets and polyubiquitinated MyD88 and 
TBK1, leading to degradation of MyD88 but activation of TBK1.   
 
1.5.2.4 MyD88 independent pathway 
 
The MyD88 independent pathway (Fig 1.3) is a key inducer of IRF3.  As previously 
mentioned, TRIF is the sole adaptor protein utilised by TLR3 in response to IRF3 
activation.  Upon engagement with the TIR domain of TLR3, TRIF recruits a signalling 
complex involving TRAF3-TBK1-IKKε which target the N terminal domain of IRF3, 
ultimately resulting in the phosphorylation of the latter on its C terminal domain.  
Phosphorylated IRF3 dimerises and translocates to the nucleus where it associates with 
CBP/p300 on its hydrophobic surface and binds to the cognate-DNA PRD in the promoter 
region of IRF3 target genes, including type I IFN.   
TRIF is also involved in mediating MyD88 independent signalling events in the 
TLR4 pathway.  TRIF and TRAM act cooperatively in the activation of IRF3 and late 
phase induction of NFκB.  Upon TLR4 activation, TRAM is recruited to the plasma 
membrane and subsequently interacts with TRIF.  TRIF forms a multi-protein signalling 
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complex with TRAF6 and RIP1.  The interaction between TRIF and RIP1 occurs through 
the distinct RIP homotypic interaction motif which leads to the K63-linked 
polyubiquitination of RIP1. The adaptor TNFR1-associated death domain protein 
(TRADD) also binds RIP1 (Natoli and Austenaa, 2008).  Studies have revealed that 
TRADD-deficient cells show impaired RIP1 ubiquitination with concomitant loss of NFκB 
activation (Pobezinskaya et al., 2008), thus demonstrating the importance of the 
TRADD/RIP1 complex in NFκB activation.  The TRADD/RIP1 complex consequently 
leads to the activation of TAK1, which in turn activates the NFκB pathway.   
Whilst TLRs and the above signalling pathways play key protective roles in the 
innate immune system, their dysregulation can often lead to chronic inflammatory diseases. 
One such disease of particular relevance to the present thesis is M.S.   
 
1.6  Multiple Sclerosis 
 
M.S. is a chronic, inflammatory, demyelinating disease of the CNS characterised by 
demyelinated plaques with relative axonal sparing and glial scar formation (Lassmann, 
1983).  The target of the chronic inflammatory response, predominantly by autoreactive T 
cells, is the myelin sheath.  The myelin sheath is a protective phosolipid covering that 
surrounds the axon of nerves and facilities the rapid and effective transmission of nerve 
impulses.  There are over 350,000 people in Europe with M.S.(Pozzilli et al., 2002), with 
approximately 2.5 million patients worldwide (Baker and Tickle-Degnen, 2001). 
Although the earliest suggestive description of M.S. dates back to the late fourteenth 
century, it was not until 1868 that the condition was recognised as a distinct disease by 
French neurologist, Jean-Martin Charcot (Murray, 2009).
 
  In drawings from brain autopsies 
in suspected M.S. patients, Charcot described the characteristic scars or “plaques” of M.S., 
thus naming the disease; sclerose en plaques.  
While the aetiology of M.S. remains unknown, data gathered from extensive studies 
on experimental autoimmune encephalomyelitis (EAE), an animal model of M.S., suggest 
that it is an immune-mediated disease consisting primarily of autoreactive CD4
+
 T cells, 
where also a small number of autoreactive B cells (Harp et al., 2008), plasma cells, and 
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extensive macrophage/glial activation act cooperatively in the destructive process of 
demyelination.   
The major focus on the role of the adaptive immune system in autoimmune disease 
has increased our understanding in the pathogenesis of M.S.  In the peripheral immune 
system, antigen presenting cells (APC) e.g. DCs, B cells and macrophages present myelin 
specific antigens to autoreactive CD4
+
 T cells via major histocompatibility complex (MHC) 
class II-T cell receptor (TCR) interactions.  MHC is a highly polymorphic gene region 
found in most vertebrates which function in the defence against viral infection.  In humans, 
MHC is also called human leukocyte antigen (HLA) and is located on chromosome 6p21.  
Due to the nature of multiple variants at this locus, MHC is one of the most extensively 
studied regions in the human genome and in its role in autoimmune disease.  
The upregulation of various adhesion molecules specifically intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) also facilitate the 
interaction between APCs and T cells.  This cellular interaction is crucial in determining T 
cell differentiation into either Th cells (Th1, Th2 and Th17 cells) (Ivanov et al., 2007, 
Mendoza and Pardo, 2010) or Treg cells (natural Tregs and induced Tr1 cells) (Gilliet and 
Liu, 2002, McClymont et al., 2011) depending on the cytokines produced.  For example, 
IL-12 induces a Th1 cell response while IL-23 induces a Th17 cell response (O'Brien et al., 
2008).  Transforming growth factor-β (TGF-β) and IL-6 can also act in concert to induce 
the polarization of Th17 cells.  Th1 and Th17 are the proposed pathogenic cells in M.S. 
(Lovett-Racke et al., 2011)  In the peripheral immune system, these cells reside and along 
with macrophages, cross the blood brain barrier (BBB) and interact with resident CNS 
APCs.  This leads to the reactivation of the IFN-γ secreting Th1 cells (Bettelli et al., 2004) 
and IL-17 producing Th17 cells ((Bettelli et al., 2008)) within the CNS.  Th1 and Th17 act 
in concert with other cytokines including TNF-α to activate resident CNS cells which target 
myelin specific antigens including myelin oligodendrocyte glycoprotein (MOG), 
proteolipid protein (PLP) and myelin basic protein (MBP).  This attack on myelin antigens 
results in demyelination, axonal loss and subsequent neurological disability (Sospedra and 
Martin, 2005). 
Recent studies have suggested that the innate immune system also plays an 
important function in the initiation and progression of M.S. (Weiner, 2008, Gandhi et al., 
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2010).  Cytokines secreted from innate immune cells including microglial, mast and NK 
cells, not only function in T cell differentiation but the cells can also cross the BBB and 
mediate the direct cytotoxicity against myelin or oligodendrocytes thus resulting in 
demyelination.   
Epidemiological data implicates both genetic and environmental factors in the 
aetiology of M.S., with various factors interacting with one another.  Due to the high 
polymorphic nature of the MHC and its viral deference mechanisms, it is not surprising that 
the MHC has been implicated in M.S.  The precise role of the various associated HLA 
alleles in particular the HLA class II antigens e.g. HLA-DP, -DM, -DOA, -DQ, -DOB and 
–DR is largely unresolved.  Nevertheless, the recent availability of dense SNP marker sets 
that span the HLA class II antigens in individuals reveals that each locus has several 
genetically determined alleles where many of these are associated with certain autoimmune 
diseases.  The association of the HLA-DR2 haplotype among M.S. patients was first noted 
around 1972 (Bertrams et al., 1974) and remains one of the most reproduced findings 
concerning MHC genetics.  The geographical spread of M.S. suggests a relationship 
between latitude and disease prevalence, where M.S. is predominately a disease of 
temperate latitudes and of the western hemisphere.  The low rate of M.S. in tropical 
climates may be due to a person‟s long-term exposure to sunlight, as vitamin D has 
previously demonstrated to be protective in M.S. patients (Munger et al., 2004). 
Any part of the brain is susceptible to demyelination during an M.S. immune 
mediated-attack.  Consequently, M.S. is associated with a broad range of symptoms, 
including muscular weakness, tremor, disturbances of coordination and motor function and 
visual complications.  Depending on the intensity of the inflammatory response and the 
subsequent severity of demyelination, M.S. patients suffer from relapses which determine a 
patient‟s progression through the four clinical types of M.S (Confavreux and Vukusic, 
2008).  The most frequent is relapsing-remitting M.S. (RR-M.S.) which affects around 80% 
of patients and is characterised by acute attacks (relapses) which can last from 24 hours to 
several days/weeks, followed by partial or full recovery (remission) occurring at variable 
intervals (Weiner, 2008).  Many patients with RR-M.S. may later progress to the second 
clinical stage, secondary progressive M.S. (SP-M.S.), where gradual worsening of the 
disease between relapses occurs with no real recovery.  The third form of M.S., primary-
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progressive M.S. (PP-M.S.), affects 10%-15% of patients, whereas the fourth and most rare 
form of M.S. is progressive-relapsing M.S. (PR-M.S.).  In PR-M.S., gradual worsening of 
symptoms is observed from the onset of disease, with superimposed relapses and 
remissions.   
M.S. diagnosis is based on the confirmation of neurological deficits, the 
development of the clinical course and the use magnetic resonance imaging (MRI), a 
powerful tool which scans the brain and spine to detect the presence of plaques caused by 
M.S.  Depending on the instance of diagnosis and with currently available treatments, many 
M.S. patients remain in stage one or two for the majority of their life.   
 
1.6.1 Current Multiple Sclerosis Therapeutics 
 
The start of the therapeutic era in M.S. was heralded by the introduction of 
recombinant IFN-β in the USA, the first therapy proven effective in altering the natural 
course of RR-M.S. and SP-M.S. patients (Jacobs et al., 1996).  To date, there are three 
formulations of beta-interferon disease-modifying drugs (DMD); intramuscular IFNβ-1a 
(Avonex
®), subcutaneous IFNβ-1a (Rebif®) and subcutaneous IFNβ-1b (Betaseron or 
Betaferon).  Each DMD differs in method of production, chemical structure, method of 
injection and dosage.  Recently a Novartis branded version of IFNβ-1b, Extavia, has been 
approved by FDA for treatment of M.S.  However, there are no published studies on the 
efficacy of this new brand.  
IFN-β is widely recognised for its ability to interfere with viral infection.  In the 
1980‟s, studies profiling the inflammatory response in the cerebrospinal fluid (CSF) of 
M.S. patients determined that the antibody response observed was due to viral infection 
(Tourtellotte et al., 1984).  Although no causative virus was identified, it was accepted that 
endogenous lymphocyte IFN production was deficient in M.S. patients (Neighbour et al., 
1981).  This lead to the idea that exogenously delivered IFN may correct this deficit.  While 
it was unsure which IFN may be an attractive agent in M.S. clinical trials, further studies 
revealed that IFN-γ induced exacerbations in M.S. patients which correlated with an 
increase in NK cell activity (Panitch et al., 1987).  However since this finding, numerous 
studies now provide evidence suggesting both detrimental and protective effects of IFN-γ in 
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M.S. and EAE (Furlan et al., 2001, Petereit et al., 2000, Franciotta et al., 2003). IFN-α has 
also been investigated as a possible therapeutic in M.S.  While the cytokine may reduce 
relapse rate, it is not as significant as IFN-β (Jacobs and Johnson, 1994).  Furthermore, the 
reduction in relapse rate is temporary and restricted to the period of IFN-α administration 
(Durelli et al., 1996).  As a result of the comparative interferon studies, IFN-β was targeted 
and clinically assessed.   
Although the precise mechanisms by which IFN-β exerts its therapeutic effects in 
M.S. remain unresolved, various studies have published on its immunomodulatory effects.  
Generally, IFN-β inhibits the proliferation of T cells and reduces the production of 
proinflammatory cytokines including IFN-γ, thus shifting the cytokine response from an 
inflammatory Th1 response to a anti-inflammatory Th2 type (Noronha et al., 1993).  IFN-β 
is also associated with the ability to enhance immunoglobulin class switching (Meyer, 
2009) and reduce leukocyte migration across the BBB (Stone et al., 1995), an effect that is 
likely dependent on the downregulation of adhesion molecules, chemokines and matrix 
metalloproteinases. 
Jacobs and colleagues were among the first to report on IFN-β (delivered 
intrathecally) reducing relapse rates in patients with active RR-M.S. (Jacobs et al., 1981).  
Clinical trials of systemically administered IFN-β followed and established the efficacy of 
this cytokine in reducing relapse rate and slowing disease progression.  The Expanded 
Disability Status Scale (EDSS) gauges the extent of a person‟s disability by measuring the 
level of neurologic impairment (Kurtzke, 1983).  EDSS scores range from 0 to 10 where 
higher scores indicate a more severe form of disability.  Most patients have an EDSS of 1-
6.  The time interval for development of disability varies with every patient.  This scale is 
frequently used to compare the effectiveness of currently available IFN-β treatments on 
patient relapse, where on average relapse rate is reduced by 30% (Bermel and Rudick, 
2007). 
Comparative analysis studies of the three currently approved IFN-β treatments 
report various dissimilarities among each.  Although Limmroth and collegeues showed 
similar effectiveness among the IFN-β products (Limmroth et al., 2007), others have 
demonstrated the superiority of Betaseron to Rebif and Rebif to Avonex in decreasing 
relapse rate and EDSS (Etemadifar et al., 2006).  Likewise, Rebif (Panitch et al., 2002) and 
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Betaseron (Khan et al., 2001) have also been shown to be more effective than Avonex.  
Each treatment also displays markedly different side effects.  Avonex is injected 
intramuscularly, where the agent is slowly released into the bloodstream.  As effective 
amounts of Avonex stay longer in the body, the injection does not have to be repeated as 
frequently at its counterpart agents.  Betaseron and Rebif are injected subcutaneously.  As 
both agents remain in the body for shorter periods, they are administered up to three times a 
week or every other day.  This frequent occurrence of injections causes patients to 
experience injection site reactions including discomfort, swelling and pain.  The incidence 
of flu-like symptoms occurs approximately 50% in patients taking Avonex and Rebif while 
is higher in patients (~75%) taking Betaseron (Bermel and Rudick, 2007).  Furthermore, 
universal side effects associated with all three treatments include muscle aches, spasms, 
fever, chills, headache, and back pain.  Avonex, Rebif and Betaseron are generally given to 
RR-M.S. and SP-M.S. patients.  Current randomised double or single blind placebo-
controlled trials in patients with PP-M.S. receiving IFN-β report no effect on the primary 
outcome measure of EDSS progression (Rojas et al., 2009, Leary et al., 2003).  However, 
the numbers of active lesions on brain MRI scans are significantly lower than placebo 
groups. 
Several other DMD are now available that specifically target RR-M.S. and SP-M.S.  
Administration of the synthetic polypeptide (that resembles myelin protein), glatiramer 
acetate (Copaxone®) is comparably effective as IFN-β given subcutaneously in RR-M.S. 
patients (O'Connor et al., 2009).  To date, no direct comparisons of Copaxone with IFN-β 
given intramuscularly have been undertaken.  The precise mechanism of action of 
Copaxone is not completely understood.  It is felt that the drug acts in the periphery by 
inducing Copaxone-specific T cells that secrete anti-inflammatory cytokines at the site of 
inflammation (Brandes, 2010).  Copaxone may shift the inflammatory response from a pro-
inflammatory Th1 type to an anti-inflammatory Th2 response, incorporating the induction 
of regulatory CD8+ and CD4+ CD25+ T-cells.  Furthermore, given its resemblance to 
myelin protein, Copaxone may also act as a sort of decoy, diverting an autoimmune 
response against myelin.  Interestingly, a recent pilot study demonstrated that M.S. patients 
receiving Copaxone experienced less spasticity than those taking IFN-β (Meca-Lallana et 
al., 2010).   
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Natalizumab (Tysabri®) is also licensed for treatment of RR-M.S.  Tysabri is an α4-
integrin antagonist.  Its proposed mechanism is the ability to interfere with leukocyte 
migration across the BBB by binding to the α4 subunit of α4β1-integrin and preventing 
leukocyte adhesion to VCAM-1 (Coyle, 2010).  While the efficacy of Tysabri among RR-
M.S. patients has been demonstrated (Polman et al., 2006), Tysabri is generally considered 
a second-line therapy for patients who are refractory to other treatments (Ransohoff, 2007). 
This is mainly due to cases of progressive multifocal leukoencephalopathy (PML).  PML is 
a rapidly progressive and often fatal human brain infection by the Jacob–Creutzfeldt (JC) 
virus which has been associated in M.S. patients taking Tysabri.   
Fingolimod is a novel oral treatment that has recently been submitted for FDA 
approval (Vasiliou, 2010).  Fingolimod is a synthetic analogue of the fungal sphingosine 1-
phosphate (S1P) receptor agonist myriocin.  Fingolimod is proposed to prevent lymphocyte 
egress from lymph nodes thus reducing lymphocyte infiltration into the CNS.  In a recent 
proof-of-concept study, daily use of oral fingolimod in patients with RR-M.S. showed a 
statistically significant benefit on time to first relapse, annual relapse rate and a reduction in 
enhancing lesions on MRI compared with placebo (Cohen et al., 2010).  In 2005, Canadian 
authorities approved the marketing of Sativex, an oromucosal spray containing a 
combination of two natural cannabis plant extracts for the treatment of neuropathic pain 
and spasticity associated with M.S.  In 2010, Sativex was licensed as a prescription only 
medicine in the U.K. (Kmietowicz, 2010).  While there is currently no approved disease 
modifying treatment for PP-M.S, natalizumab, IFN-β and fingolimod are currently under 
investigation. 
 
1.7 Cannabinoids 
 
 Cannabinoids are a group of lipid soluble chemical messengers derived from 
the cannabis plant.  The cannabis plant is one of the oldest plant-derived recreational and 
therapeutic drugs in human history and contains over 70 cannabinoid compounds.  
Cannabis has been exploited in the past in the treatment of migraine, convulsions, 
neuralgia, nausea, asthma and anorexia (Di Marzo et al., 1998, Russo, 1998).  The term 
“cannabinoid” incorporates the active components (phytocannabinoids) of the cannabis 
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plant including delta-9-tetrahydrocannabinol (δ-9-THC) and cannabinol, endogenous 
cannabinoids (endocannabinoids) e.g. anandamide and 2-Arachidonoylglycerol and 
synthetic cannabinoid ligands e.g. WIN55,212-2, HU-210 and JWH-133.  Cannabinoids 
elicit their immunosuppressive properties by activating the cannabinoid receptors (see 
Chapter 4).   
Cannabinoids can be further classified into two types, neutral cannabinoids and 
cannabinoid acids, based on whether they contain a carboxyl group or not (Taura et al., 
2007).  It is now known that in fresh cannabis plants the concentrations of neutral 
cannabinoids are much lower than those of cannabinoid acids. The isolation and synthesis 
of δ-9-THC in 1964 served to further our understanding of the molecular basis of action of 
this class of drug (Gaoni and Mechoulam, 1964).  In the δ-9-THC biosynthetic pathway, δ-
9-THC initially occurs as δ-9-tetrahydrocannabinolic acid (δ-9-THCA).  Initial precursors, 
geranyl diphosphate (GPP) and olivetolic acid, are condensed by the prenylase geranyl 
diphosphate: olivetolate geranyltransferase (Fellermeier and Zenk, 1998) to yield 
cannabigerolic acid (CBGA). CBGA is further oxido-cyclized into cannabidiolic acid 
(CBDA) by the enzyme; cannabidiolic acid synthase (Futoshi et al., 2007).  δ-9-THCA and 
cannabichromenic acid (CBCA) (Morimoto et al., 1999) are also further oxido-cyclized by 
the enzymes; δ-9-tetrahydrocannabinolic acid synthase and cannabichromenic acid 
synthase (Sirikantaramas et al., 2004), respectively.  Over time, or when heated, δ-9-THCA 
is decarboxylated to produce δ-9-THC. 
Arachidonylethanolamine, which is commonly known as anandamide (AEA), is an 
arachidonic acid derivative and was the first endocannabinoid to be discovered in porcine 
brain (Devane et al., 1992).  The endocannabinoid was termed "anandamide" based on 
"'ananda", the Sanskrit word for bliss.  AEA is a lipid neurotransmitter and has also been 
proposed to function as a neuromodulator (Di Marzo et al., 1999).  It acts as a retrograde 
messenger and exerts a modulatory effect on memory, cognition and pain perception 
(Wilson and Nicoll, 2002).  The generation of AEA in stimulated cells was first described 
in 1994 (Di Marzo et al., 1994).  AEA is not stored in cell vesicles, but rather is synthesised 
by neurons on demand from lipid precursors such as N-Arachidonoyl-
phosphatidylethanolamine (NAPE) and diacyglycerols (DAGs) (Rossi et al., 2010, Fowler 
et al., 2005) (Fig 1.4).  The synthesis of AEA is dependent on two distinct pathways; a 
 37 
calcium-dependent pathway and a G-protein coupled receptor (GPCR)-dependent pathway 
which control N-acyltransferase (NAT) activity; an enzyme responsible for the production 
of NArPE (Cadas et al., 1996).  A specific phospholipase D (NAPE-PLD) catalyses the 
release of AEA (Rossi et al., 2010).  The release of AEA is either by diffusion through the 
postsynaptic cell membrane or by transport out of the cell where AEA can gain access to 
cannabinoid receptors concentrated on the nerve terminals of either GABAergic 
interneuron‟s such as those found in the hippocampus, neocortex and amygdale or 
excitatory glutamergic axons located in the cerebellum (Alger, 2002).  AEA is subsequently 
taken up into the post- or pre-synaptic cells via the AEA-transporter where once within the 
cell, AEA is hydrolysed to arachidonic acid and ethanolamine by the integral membrane 
enzyme, fatty acid amide hydrolase (FAAH) (Di Marzo, 1998).  AEA has been detected in 
immune cells including DCs, macrophages and microglia (Felder et al., 1996).  The 
activation of certain types of these cells can causes a rapid and robust increase in AEA 
levels, thus further supporting a role for AEA in immune regulation (Maccarrone et al., 
2001). 
Until the early 1990s, all compounds known to display cannabimimetic properties 
were structurally related to δ-9-THC.  This situation changed when Sterling Winthrop 
researchers reported a new family of aminoalkylindoles possessing cannabimimetic 
properties that were structurally unrelated to δ-9-THC.  This discovery resulted from the 
development of structurally constrained analogs of pravadoline (Pacheco et al., 1991, Bell 
et al., 1991).  One such analog was WIN55,212-2 and it is now the most highly studied, 
commercially available compound of the series.  Although WIN55,212-2 is structurally 
diverse from δ-9-THC, it was found to exhibit a pharmacological profile similar to the 
phytocannabinoid.  The existence of chiral centres in classical cannabinoids such as δ-9-
THC and WIN55,212-2 has made it possible to develop enantiomers of this class of 
cannabinoids (Howlett et al., 2002).  These stereo-chemical changes have shown that the 
pharmacological activity of the (-) enantiomer is greater than that of the (+) enantiomer in 
terms of receptor affinity and potency at both cannabinoid receptor subtypes. 
Many reports suggest that cannabinoids, known to exhibit general 
immunosuppressive properties, have potential therapeutic value in the treatment of 
neuroinflammatory conditions (Ungerleider et al., 1987, Consroe et al., 1997).  Most of 
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these immunosuppressive properties occur by interfering with both humoral and cell-
mediated immunity (Correa et al., 2009) e.g. inhibition of T cell mitogenesis, IL-2 
production (Kaplan et al., 2003, Börner et al., 2009) with consequent inhibition of T cell, 
NK cell, and B cell proliferation..  Furthermore, cannabinoid inhibition of cell proliferation, 
induction of apoptosis and inhibition of bone-marrow-derived myeloid cell recruitment also 
play key roles to down-regulate the immune system (Guzmán et al., 2002, Wu et al., 2008).  
Cannabinoids have also been demonstrated to target various transcription factors involved 
in inflammation including NFκB (Downer et al., 2011) and CREB (Ofek et al., 2011).   
Cannabinoids elicit their effects via the cannabinoid receptors (CB1 and CB2) 
(Cencioni et al., 2010, Jean-Gilles et al., 2010).  Cannabinoid receptors are localized 
throughout the CNS (Walter and Stella, 2004) and on immune cells associated with 
neuroinflammation (Galiègue et al., 1995).  CB1 expression on neurons can suppress CNS 
inflammation (Maresz et al., 2007) while CB2 activation on immune cells has been shown 
to shift immune responses from a Th1 (IFN-γ, TNF-α, and IL-2 production) to a Th2 
phenotype (with production of IL-4 and IL-5) (Yuan et al., 2002).  Certain studies have also 
demonstrated the regulation of the cannabinoid receptor by cytokines (Halttunen and Mäki, 
1999, Gardner et al., 2002).  TGF-β regulates CB2 expression on lymphocytes (Gardner et 
al., 2002) while splenocytes cultures stimulated with anti-CD40 antibody show a increase 
in CB1 mRNA expression (Noe et al., 2000, Noe et al., 2002).  However, some 
cannabinoid-induced effects are mediated independently of the receptors (Mestre et al., 
2009, O'Sullivan and Kendall, 2009).  This is particularly relevant as cannabinoids 
therapeutically impact diseases associated with a dysregulation of the immune and nervous 
systems (Walter and Stella, 2004).  Indeed in EAE cannabinoids attenuate the development 
of disease (Lyman et al., 1989).  The role of CB1/2 in mediating these effects varies 
depending on the pharmacological profile of the cannabinoid (Palazuelos et al., 2008).  
Furthermore, much interest has also been generated by reports of the therapeutic effects of 
cannabis in alleviating the symptoms of M.S. (Consroe et al., 1997) where patients with 
spasticity claim relief from using the drug (Iversen, 2003).  The introduction of Sativex 
further demonstrates the therapeutic action of cannabinoids in M.S. (Kmietowicz, 2010).  In 
relation to R(+)WIN55,212-2, many groups have published on the protective effects of this 
drug in various animal models of M.S. (Hasseldam and Johansen, 2010, Arevalo-Martin et 
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al., 2003, Croxford and Miller, 2003, Baker et al., 2000).  As a result, this project hoped to 
define the molecular basis to its mechanism of therapeutic action. 
 
1.8 Specific aims of this project    
 
The specific objectives of this project were to: 
 
 Define the regulatory effects of WIN55,212-2 on TLR3 and TLR4 
signalling 
 
 Identify the pharmacological mechanism of the regulatory effects of 
WIN55,212-2 on TLR3 and TLR4 signalling 
 
 Define the molecular target for the action of WIN55,212-2 on TLR3 
signalling  
  
Fig. 1.1 TLR ligand specificities. 
TLRs recognise a diverse array of PAMPs from bacteria, viruses, protozoa, and fungi.  In 
the detection of bacteria, heterodimeric TLR2/1 bind triacyl lipopeptides, whereas TLR2/6 
dimers bind diacyl lipopeptides and lipoteichoic acid.  Homodimeric TLR2 binds 
peptidoglycan, atypical LPS, phenol-soluble modulin from Staphylococcus epidermidis, 
and porin proteins from Neisseria.  In addition, TLR4 binds LPS, TLR5 binds flagellin, and 
TLR9 binds bacterial CpG DNA. TLR11 detects an unidentified protein(s) from 
uropathogenic Escherichia coli.  Viral dsRNA, RSV F protein, ssRNA, and unmethylated 
CpG DNA are sensed by TLRs 3, 4, 7/8, and 9, respectively.  Finally, heterodimeric 
TLR2/6 binds fungal-derived zymosan and Trypanosoma cruzi GIPLs, whereas TLR11 
also senses a profilin-like protein from Toxoplasma gondii.  
(Adapted from West, A. P., A. A. Koblansky, et al. (2006). "Recognition and Signaling by 
Toll-Like Receptors." Annual Review of Cell and Developmental Biology 22(1): 409-437.)
  
Figure 1.2 TLRs, RLHs, and NLRs in renal cells.  
TLRs signal through the MyD88 and/or TIR domain-containing adaptor proteins.  The 
RLHs signal through mitochondrial IPS1 and NLRs interact with RICK/RIP2.  The 
respective ligands to these receptors are indicated in red; LPS, PG, LTA, LP and 3P-RNA. 
 
 
 
(Adapted from Anders, H. J. (2007). "Innate pathogen recognition in the kidney: Toll-like 
receptors, NOD-like receptors, and RIG-like helicases." Kidney Int 72(9): 1051-1056.) 
 
 
  
  
Fig. 1.3 The MyD88-dependent, -independent and interferon signaling pathways. 
TLR signalling consists of two main pathways that are governed by the principle TIR 
domain-containing adaptors, MyD88 and TRIF.  All TLRs, except TLR3, induce NFκB 
activation and subsequent production of pro-inflammatory cytokines via the MyD88-
dependent pathway.  IL-1 also signals through the MyD88-dependent pathway to activate 
NFκB.  In pDCs, TLR7, TLR8 and TLR9 induce IRF7 activation via the MyD88-
dependent pathway.  TRIF mediates TLR3 and TLR4 signalling to induce IRF3 and late 
phase NFκB activation, respectively, via the MyD88-independent pathway.  Type I IFN 
signalling is mediated by the IFNAR1 and IFNAR2 receptor components, which activate 
multiple STATs, particularly the ISGF3 transcriptional regulator.   
(P) = phosphorylation, (Ub) = ubiquitination. 
 
 
  
Fig. 1.4 Anandamide synthesis and degradation pathways.  
The anandamide biosynthetic enzymes NAT catalyses the transfer of arachidonic acid from 
phosphatidylcholine to phosphatidylethanolamine, synthesizing the precursor NAPE of 
anandamide. A specific phospholipase D (NAPE-PLD) catalyses the release of 
anandamide. An alternative parallel pathway involves hydrolysis of NAPE by 
phospholipase C (PLC), followed by dephosphorylation through a phosphatase. The 
catabolic enzymes FAAH is responsible for the degradation of AEA. An endocannabinoid 
transporter (ET) on cellular membrane seems to facilitate both endocannabinoid release and 
re-uptake.  
 
(Adapted from Rossi, S., G. Bernardi, et al. (2010). "The endocannabinoid system in the 
inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic 
lateral sclerosis." Experimental Neurology 224(1): 92-102. 
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2.1 Materials 
 
2.1.1  Reagents 
 
Reagent Supplier 
Agar Sigma 
Agarose         Promega 
Agarose, low melting point      Sigma 
Alexa488        Invitrogen 
Ampicillin        Sigma 
AMV Reverse Transcriptase                 Sigma  
Antibodies (monoclonal) against human- 
  β-Actin      Sigma 
  IRF3                                                                   Cell Signalling Tech. 
  IκBα       Santa Cruz 
  Phosho-IκBα/β     Cell Signaling Tech. 
Antibodies (polyclonal) against human- 
  Phospho-IRF3      Cell Signaling Tech. 
  IFN-β       Millipore 
  IRF3       Santa Cruz 
APS         Sigma 
Arachidonylethanolamide (Anandamide)    Sigma 
Biotinylated Molecular Weight Standards    Sigma 
Bovine serum albumin      Sigma 
Bromophenol blue        Sigma 
BX-795        Axon Medchem 
Chamber Slides       NUNC 
Chloroform        Sigma 
Chloroquine        Sigma 
Coelenterazine       Insight Biotech. 
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Cremophor El        Sigma 
DAPI         Sigma 
DEPC-treated water       Ambion 
DMEM        Invitrogen 
DMSO         Sigma 
DNA ladder (1Kb) & Loading dye (6X)    Promega 
dNTPs         Promega 
DTT         Sigma 
E.coli - TOP 10 competent cells     Invitrogen 
EDTA         Sigma 
Ethanol        Sigma 
Ethidium bromide       Sigma 
FBS         Invitrogen 
Fenofibrate        Sigma 
Glycerol        Sigma 
Glycine        Sigma 
Goat Serum        Vector Laboratories 
Gradient gel (4% - 20%)      Pierce 
GW6471        Sigma 
GW9662        Sigma 
Hydrogen Peroxide       Sigma 
HEPES        Sigma 
High speed plasmid midi kit      Qiagen 
High speed plasmid mini kit      Qiagen 
Human astrocytoma 1321N1    European Collection  
of Cell Cultures  
(ECACC) 
Human HEK 293 TLR3/TLR4 cell line(s)    Invivogen  
Hydrochloric acid       Merck 
IRDye 800CW Goat Anti-Rabbit     Licor Biosciences 
IRDye 680 Donkey Anti-Mouse     Licor Biosciences 
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IL-1β         R&D Systems 
Isopropanol         Sigma 
L-glutamine        Invitrogen 
Lipofectamine 2000       Invitrogen 
Lipopolysaccharide       Alexis 
Luciferase substrate       Promega 
Lymphoprep        Axis-Shield 
Magnesium Chloride       Sigma 
Nitrocellulose        Schleicher & Schuell 
2-6-β-Mercaptoethanol      Sigma 
Methanol        BDH 
Microlon 96-well plates      Greiner 
OptiMEM        Invitrogen 
Paraformaldehyde        Sigma 
PBS         Oxoid 
pcDNA 3.1/Zeo       Invitrogen 
pEGFP -N1        BD Biosciences 
Penicillin / Streptomycin / Glutamine    Invitrogen 
Pertussis Toxin       Sigma 
PMSF         Sigma 
Poly(I:C)        Sigma    
Ponceau         Sigma 
Prestained molecular weight marker (SeeBlue Plus)   Invitrogen 
Protease inhibitor mixture      Roche 
Protein A/G-agarose       Santa Cruz 
Random primers       Invitrogen 
Restriction enzymes       NewEnglandBiolabs 
Reverse Transcription System     Promega 
RNase Zap        Ambion 
RPMI                   Invitrogen 
R(+)WIN55,212-2       Sigma 
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SDS         Sigma 
Skim milk powder       Sigma 
Sodium chloride (NaCl)      Sigma 
Sodium hydroxide (NaOH)      Sigma 
Sodium orthovanadate (Na3VO4)     Sigma 
SR144528        National Institute of  
         Mental Health (NIMH)  
         Chemical Synthesis and 
         Drug Supply Program 
SR141716        NIMH  Chemical  
         Synthesis and  Drug  
         Supply Program 
Sulphuric acid        Sigma 
S(-)WIN55,212-2       Sigma 
Synthetic oligonucleotides      MWG Biotech 
Taq polymerase       Invitrogen 
T4 DNA ligase       Promega 
TEMED        Sigma 
TMB         Sigma 
Tissue culture ware       Greiner 
TK Renilla        Promega 
TNF-α (human) ELISA kit      R&D Systems 
Tri reagent        Sigma 
Tris-base        Sigma 
Tris-HCl        Sigma 
Triton-X        Sigma 
Trypsin/EDTA       Invitrogen 
Tryptone        DIFCO 
Tween-20        Sigma 
Whatmann paper       AGB  
Yeast extract        DIFCO 
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2.1.2 Gifts 
 
Cell lines: 
 Bone marrow derived macrophages (BMDMs) from wildtype and TRIF deficient 
mice - Dr. Kate Fitzgerald (The University of Massachusetts Medical School, 
Worcestor, Massachusetts 01605, USA) 
 U373 cell line – Dr. Sinead Miggin (Biology Department, NUI Maynooth, Ireland). 
 
Constructs: 
 TRIF, IRF-3/7 Gal4 reporter and IFN-β-luciferase reporter constructs – Dr. Kate 
Fitzgerald (The University of Massachusetts Medical School, Worcestor, 
Massachusetts 01605, USA). 
 pFR-luciferase Gal4 reporter construct, green fluorescent protein (GFP)-tagged 
IRF3 and enhanced GFP (EGFP) construct – Dr. Andrew Bowie (Trinity College 
Dublin, Ireland). 
 PRD II- and PRD I/III-luciferase reporter constructs - Dr. Sinead Miggin (Biology 
Department, NUI Maynooth, Ireland). 
 NFκB-luciferase reporter construct – Prof. Luke O’Neill (Trinity College Dublin, 
Ireland). 
 
Multiple Sclerosis Experiments: 
 
 EAE mice – Prof. Padraic Fallon (Institute of Molecular Medicine, Trinity College 
Dublin and St. James’s Hospital, Dublin 8, Ireland). 
 Multiple Sclerosis patients – Dr. Bruno Gran (Division of Clinical Neurology, 
University of Nottingham, Nottingham, United Kingdom). 
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2.1.3 Company Addresses 
 
AGB Scientific:    AGB Scientific, 
                        Dublin Industrial Estate, 
           Dublin 11.     
  
Alexis:     Enzo Life Sciences (UK) Ltd. 
      Palatine House, 
      Matford Court, 
      Exeter EX2 8NL, 
      United Kingdom. 
 
Ambion:     Ambion (Europe) Ltd. 
      Ermine Business Park, 
      Spitfire Close, 
      Huntingdon, Cambridgeshire, 
      PE29 6XY, 
      United Kingdom. 
 
Axis-Shield:     Axis-Shield PoC, 
      P.O.Box 6863 Rodelokka, 
      N-0504 Oslo, 
      Norway. 
 
Axon Medchem:    Axon Medchem BV. 
      Biotech Center UMCG, 
      Hanzeplein 1, 
      9713 GZ Groningen, 
      The Netherlands. 
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BD Biosciences:    BD Biosciences, 
      2350 Qume Drive, 
      San Jose, 
      CA 95131, 
      USA.  
       
Cell Signaling Tech:    Cell Signaling Technology, Inc., 
      3 Trask Lane, 
      Danvers, 
      MA 01923, 
      USA.  
 
DIFCO:     DIFCO Laboratories  
      Detroit, 
      Michigan, 
      USA. 
 
ECACC:     European Collection of Animal Cell Cultures, 
      Salisbury, 
      Wiltshire, 
      SP4 0JG, 
      United Kingdom. 
 
Greiner:     Greiner Bio-One Ltd., 
      Brunel Way, 
      Stroudwater Business Park, 
      Stonehouse, 
      Gloucestershire, 
      GL10 3SX, 
      United Kingdom. 
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Insight Biotechnology:    Insight Biotechnology Ltd., 
      Wembley, 
      Middlesex, 
      HA9 7YN, 
      United Kingdom. 
 
Invitrogen:     Invitrogen Ltd., 
      3 Fountain Drive, 
      Inchinnan Business Park, 
      Paisley, 
      United Kingdom. 
 
Invivogen:     Cayla- InvivoGen Europe 
      5 rue Jean Rodier 
      F-314000 Tououse, 
      France. 
 
Merck:     Merck Biosciences Ltd., 
      Boulevard Industrial Park, 
      Padge Road, 
      Beeston, 
      Nottingham NG9 2JR, 
      United Kingdom.     
 
Millipore:     Millipore, 
      290 Concord Road, 
      Billerica, 
      MA 01821, 
      USA. 
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MWG Biotech:    MWG Biotech AG, 
      Anzingerstr. 7a, 
      85560 Ebersberg, 
      Germany. 
 
NEB:      New England Biolabs (UK) Ltd., 
      73 Knowl Piece, 
      Wilbury Way, 
      Hitchin, 
      Hertfordshire, 
      United Kingdom. 
 
National Institute of Mental Health  
(NIMH):     NIMH Chemical Synthesis and  
      Drug Supply Program, 
      6001 Executive Boulevard, 
      Rockville, 
      MD 20852, 
      USA. 
 
NUNC:     Nalge Nunc International, 
      75 Panorama Creek Drive, 
      Rochester, 
      NY 14625-2385, 
      USA. 
 
Oxoid:     Oxoid Ltd. 
      Wade Road, 
      Basingstoke, 
      Hampshire RG24 8PW, 
      United Kingdom. 
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Pierce:     Perbio Science UK Ltd., 
      Unit 9, Atley Way, 
      North Nelson Industrial Estate 
      Cramlington,  
Northumberland NE231WA, 
      United Kingdom. 
 
Promega:     Promega US, 
      2800 Woods Hollow Road, 
      Madison WI 53711, 
      USA. 
 
Qiagen:     Qiagen House, 
      Fleming Way, 
      Crawley, 
      West Sussex, 
      RH10 9NQ, 
      United Kingdom.  
 
R & D:     R & D Systems Europe, 
      Bartone Lane, 
      Abington, 
      Oxon, 
      United Kingdom. 
 
Roche:     Roche Diagnostics GmbH, 
      Roche Applied Science, 
      Nonnenwald 2, 
      82372 Penzberg, 
      Germany. 
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Santa Cruz:     Santa Cruz Biotechnology Inc., 
      2161 Delaware Ave., 
      Santa Cruz, 
      CA 95060, 
      USA. 
 
Schleicher and Scheull:   Schleicher and Scheull Inc., 
      10 Optical Avenue, 
      Keene,  
      New Hampshire, 
      USA. 
 
Sigma:     Sigma-Aldrich Ireland Ltd., 
      Airton Road, 
      Tallaght, 
      Dublin 24, 
      Ireland. 
 
Vector Laboratories:   Vector Laboratories Inc., 
      Burlingame, 
      CA 94010, 
      USA. 
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2.2 Methods 
 
2.2.1 Mammalian cell culture 
 
2.2.1.1  Adherent cell lines. 
 
Human embryonic kidney (HEK) 293 cells stably transfected with the TLR3 or 
TLR4 receptors, human U373 astrocytoma cells stably transfected with CD14 (U373-
CD14), human 1321N1 astrocytoma and murine BMDM cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM), which was supplemented with 10% (v/v) 
foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin.  Cells were 
maintained in a 37ºC humidified atmosphere with 5% CO2.  Cells were passaged every 2 to 
3 days using 1% (w/v) Trypsin/ethylenediaminetetraacetic acid (EDTA) solution in 
phosphate-buffered saline (PBS).  The neomycin analog G418 (500 µg/ml) was used to 
select for the stably transfected TLR cell lines and maintenance of CD14 expression while 
gentamicin (50 µg/ml) was used to maintain the transfected oncogene in BMDM. 
 
2.2.1.2  Isolation of primary murine astrocytes. 
 
Mixed glia were prepared from the cortices of 1-day old Wistar rats.  For 
preparation of astrocytes, dissected cortices were chopped, added to Dulbecco’s modified 
Eagle’s medium (DMEM) triturated, passed through a sterile mesh filter (40µm) and 
centrifuged (2000 x g for 3 min at 20°C).  The pellet was resuspended in DMEM and plated 
onto T25 flasks.  Cells were maintained in a 37ºC humidified atmosphere with 5% CO2.  
On day 14, non-adherent cells (microglia) were isolated by mechanical shaking and 
removed. The adherent astrocytes were isolated by harvesting in 1% (w/v) 
trypsin/ethylenediaminetetraacetic acid (EDTA) solution in phosphate-buffered saline 
(PBS).  Cells were centrifuged (2000 x g for 5 min at 20°C) and the astrocyte-enriched 
pellet was resuspended in DMEM.  Astrocytes were plated (1x10
6
 cells/ml) in 12-well 
plates.  
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2.2.1.3  Isolation of human primary peripheral blood mononuclear 
 cells (PBMCs) 
 
Healthy donors and MS patients attending out-patient clinics at Queens Medical 
Centre University Hospital, University of Nottingham, UK, were recruited for this study. 
Written informed consent was obtained from each patient and the study received ethical 
approval from the Nottingham Research Ethics Committee.  Patients with relapsing-
remitting MS were clinically stable with an age ranging between 38-56 yrs (mean 48.4 ± 
8.3; n =3).  Patients were naïve to any disease modifying therapies including IFN-β, 
glatiramer acetate and natalizumab.  Healthy individuals were recruited from the University 
of Nottingham (mean age 31 ± 2.6; n = 3).  
Venous blood (30 ml) was obtained from each subject was collected into vacutainer 
tubes with 0.5% (w/v) EDTA.  Blood was diluted 1:1 with Hank’s Balanced Salt Solution 
(HBSS) medium containing 1% (v/v) FBS (which was heat inactivated for 30 min at 56
o
C 
to avoid complement activation).  Diluted blood (35 ml) was layered carefully onto 
Lymphoprep (15 ml) in 50 ml centrifuge tubes and centrifuged (400 x g for 25 min at 
20°C), allowing deceleration to occur without braking.  The cloudy layer sitting above the 
Lymphoprep contains the mononuclear cells and this was carefully collected with a Pasteur 
pipette and transferred to a new 50 ml centrifuge tube.  HBSS medium was added to top up 
volume to 25 ml.  Samples were centrifuged (400 x g for 10 min at 20°C).  The supernatant 
was decanted off once and the pellet was resuspended in ~1 ml of remaining medium.  
Samples were vortexed and again topped up to 25 ml with HBSS medium and centrifuged 
at (400 x g for 10 min at 20°C).  The supernatant was again decanted by tipping off once 
and the pellet was resuspended in ~10 ml RPMI 1640 containing 25 mM HEPES, 2mM L-
glutamine, 50 μg/ml streptomycin, 50 U/ml penicillin and 10% heat-inactivated FBS.  Cells 
were counted and seeded at 1x10
6
 cells/ml in 24-well plates (1 ml per well).  
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2.2.2 Transient transfection of mammalian adherent cells 
 
2.2.2.1  Transfection of cells for luciferase reporter assay and   
 ELISA 
 
HEK293 TLR3/TLR4 cells, human U373-CD14 and 1321N1 astrocytoma cells 
were seeded at 1.8x10
5 
cells/ml (200 μl DMEM/well) in 96-well plates and allowed to 
adhere for 24 h to approximately 80% confluency.  Cells were transfected using 
Lipofectamine 2000.  For each well to be transfected, 25 µl of OptiMEM was mixed with 
the DNA.  DNA mixes were made up for the appropriate luciferase construct as outlined in 
section 2.2.4.  Lipofectamine 2000 (0.4 μl) was diluited in OptiMEM (25 µl) per sample 
and the reaction was mixed gently and left at room temperature for 5 min.  After the 
incubation, the Lipofectamine/OptiMEM solution was added to the DNA/OptiMEM mix 
(total volume 50 µl per well to be transfected) and the combined reaction was mixed gently 
and incubated at room temperature for 20 min.  The transfection mixture was then added to 
each well and mixed gently by tapping the side of the plate.  Each sample was transfected 
in triplicate.  24 h after transfection, cells were pre-treated with various agents for 1 hour 
followed by TLR ligand or IL-1β stimulation for 6 h.  The supernatants were subsequently 
removed and stored at -20°C and then assayed for TNF-α production using sandwich 
enzyme-linked immunosorbent assay (ELISA), while cell lysates were generated and used 
to measure luciferase activity. 
 
2.2.3  Propagation of DNA 
 
2.2.3.1  Rapid transformation of competent E.coli cells 
 
Commercially available TOP 10 competent E.coli bacterial cells were used for 
propagation of plasmids of interest.  Plasmids (100 ng) were added to five times as much 
TOP10 cells, i.e. 1 μl of a 100 ng plasmid was added to 5 μl cells.  DNA was mixed gently 
with cells by pipetting gently up and down and allowed to incubate on ice for 30 min.  The 
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plasmids were allowed to enter the bacterial cells by heat shocking the mixture at 42
 o
C for 
45 seconds.  The cell membrane become permeable to allow easy entry of the plasmid and 
cooling on ice for 2 min makes the cell membrane once again impermeable.  The 
transformed cells were then incubated in 1 ml Luria Bertoni (LB) broth (1% (w/v) tryptone, 
0.5% (w/v) yeast extract, 85 mM NaCl) at 37
 o
C on a shaker at 220 rpm for 1 h.  Bacterial 
cells were centrifuged at 9000 rpm for 3 min and 850 μl supernatant was removed.  The 
pellet was resuspended in the remaining LB broth and plated out onto LB agar plates (LB 
broth with 1.5% (w/v) agar) containing ampicillin (50 μg/ml).  Plates were inverted and 
incubated overnight at 37
 o
C.  Plates were then stored at 4
 o
C. 
 
2.2.3.2  Small scale preparation of DNA from E. coli cells 
 
LB broth (2 ml) containing the relevant antibiotic (50 μg/ml) was inoculated with a 
single transformed E coli colony from an agar plate.  The culture was incubated overnight 
at 37
 o
C shaking at 220 rpm.  Small plasmid preparations were made using the Qiaprep 
Spin Miniprep kit from Qiagen Inc.  The bacterial cells were centrifuged at 9000 rpm for 3 
min and the supernatant was discarded and the plasmid DNA was extracted as outlined in 
the manufacturer’s handbook.  DNA was quantified using a Cary spectrophotometer. After 
diluting the DNA appropriately in Tris-EDTA (TE) buffer, pH 8.0, (10 mM Tris-HCl, 1 
mM EDTA) the absorbance of the solution was measured at 260 nm and 280 nm.  All 
samples used had an optical density (OD)260/OD280 ratio in the range of 1.7 to 1.9. Ratios 
below 1.7 or above 1.9 indicated RNA or protein contamination, respectively. The 
concentration was calculated using the formula: 
 
  µg/ml DNA = 50 µg/ml/OD260 x (OD260 measured) x (dilution factor).  
 
2.2.3.3   Large scale preparation of DNA from E. coli cells 
 
A starter culture of LB broth (2 ml) containing the relevant antibiotic (50 μg/ml) 
was inoculated with a single transformed E.coli colony and incubated at 37
o
C with shaking 
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at 220 rpm for 6-8 h. This was then added to a larger volume of LB broth (100 ml) 
containing the relevant antibiotic and incubated at 37
o
C overnight shaking at 220 rpm.  
Large plasmid preparations were made using the Qiagen high speed plasmid midi kit from 
Qiagen.  The bacterial cells were centrifuged at 3000 rpm for 40 min and the supernatant 
was discarded and the plasmid DNA was extracted as outlined in the manufacturer’s 
handbook.  DNA was quantified as outlined in Section 2.2.3.2. 
 
2.2.4  Luciferase assays 
 
HEK293 TLR3, TLR4 cells and U373-CD14 and 1321N1 astrocytoma cells were 
all seeded at 1.8 x 10
5
 cells/ml in 96-well plates (200 µl DMEM/well) and grown for 24 h.  
All transfections were performed using Lipofectamine 2000 transfection reagents (as 
described in sections 2.2.2.1).  Details of the constructs transfected are given below.  24 h 
post-transfection, cells were pre-treated with various agents for 1 hour followed by TLR 
ligand or IL-1β stimulation for 6 h.  The medium was then removed from the cells and 
reporter lysis buffer (100 µl, Promega) was added to each well using a multi-channel 
pipette.  The plate was then wrapped in aluminium foil and placed on a rocker for 30 min at 
room temperature before being placed at -80
o
C for a minimum of 1 h.  After thawing at 
room temperature, aliquots (40 µl) of each were assayed for firefly luciferase activity using 
firefly luciferase substrate (40 µl, Promega), while Renilla luciferase activity was assayed 
using coelenterazine (0.1 µg/ml in PBS).  Luminescence was monitored with a Glomax 
microplate luminometer (Promega). 
 
2.2.4.1 NFκB assay 
 
To measure activation of the NF-κB pathway, cells were transfected with NFκB -
regulated firefly luciferase reporter plasmid (80 ng) and constitutively expressed Renilla-
luciferase reporter construct phRL-TK (40 ng).  The total amount of DNA was maintained 
at 240 ng using pcDNA3.1. 
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2.2.4.2 IFN-β assay 
 
The activation of the IFN-β promoter was assessed by transfecting the cells with an 
IFN-β promoter-regulated luciferase construct (80 ng), or PRD-II-regulated-luciferase 
construct (80ng) or PRD-I/III-regulated-luciferase construct (80ng), phRL-TK (20 ng) and 
varying amounts of expression constructs (detailed in figure legends).  The total amount of 
DNA was maintained at 240 ng using pcDNA3.1. 
 
2.2.4.3 IRF3 assay 
 
To measure the activation of IRF3, cells were transfected with pFR-Luc (60 ng), the 
trans-activator plasmid pFA-IRF3 (IRF3 fused downstream of the yeast Gal4 DNA binding 
domain, 30 ng), phRL-TK (20 ng) and varying amounts of expression constructs (detailed 
in figure legends).  The total amount of DNA was maintained at 270 ng using pcDNA3.1. 
 
2.2.4.4 IRF7 assay 
 
To measure the activation of IRF7, cells were transfected with pFR-Luc (60 ng), the 
trans-activator plasmid pFA-IRF7 (IRF7 fused downstream of the yeast Gal4 DNA binding 
domain, 25 ng), phRL-TK (40 ng) and varying amounts of expression constructs (detailed 
in figure legends). The total amount of DNA was maintained at 270 ng using pcDNA3.1. 
 
2.2.5  Enzyme-linked immunosorbent assay (ELISA) 
 
U373-CD14 astrocytoma cells, BMDM were seeded in 12-well plates at a density of 
1x10
5 
cells/ml.  Primary astrocytes were seeded in 12-well plates at a density of 1x10
6 
cells/ml and human PBMCs were seeded in 24-well plates at a density of (1 x 10
6
 
cells/ml)..  Cells were grown for 24 h to approximately 80% confluency.  Next day, cells 
were stimulated with TLR ligands for 24 h (3 h for PBMCs) and pre-treatment with various 
agents for 1 hr, supernatants were collected from each well and stored at -20
o
C until 
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analysis of TNF-α using Human TNF-α ELISA kits.  96-well NUNC “Maxisorb” plates 
were coated with mouse anti-human TNF-α capture antibody and were incubated overnight 
at room temperature.  Plates were washed three times with wash buffer (PBS with 0.05% 
(v/v) Tween-20) and dried.  Plates were blocked for 1 hour with PBS containing 1% (w/v) 
bovine serum albumin (BSA) and 5% sucrose (w/v).  Plates were again washed three times 
and dried.  Samples or standards (100 μl) diluted in reagent diluent (0.1% (w/v) BSA, 0.5% 
(v/v) Tween in 10 mM Tris–HCl, pH 7.5 containing 150 mM NaCl in Tris-buffer saline 
(TBS) were added to each well.  TNF-α standard concentrations were between 0 and 2000 
pg/ml.  Plates were incubated with samples or standards for 2 h and then the series of 
washes was repeated.  Detection antibody (100 μl) (biotinylated goat anti-human antibody) 
for human TNF-α diluted in reagent diluent was added to each well (20 ng/ml).  Again 
plates were incubated for 2 h and washed. Streptavidin-horseradish peroxidase (HRP) 
conjugate (100 μl) was added to each well.  The plates were incubated in the dark for 20 
min and then the wash step was repeated.  3, 3’, 5, 5’-TeTRAMethylbenzidine liquid 
substrate (TMB, 1.25 mM/L) (100 μl) solution was added to each well and again plates 
were incubated in the dark for no longer than 20 min.  1N sulphuric acid (H2SO4) (50 μl) 
was used to stop the reaction and the OD was measured for each well at 450 nm and 590 
nm using a ELx800
TM
 microplate reader with Gen5 Data Analysis Software.  The 
concentrations of TNF-α in each sample were extrapolated from a standard curve that 
related the OD of each standard amount to the known concentration. Standard samples were 
assayed in duplicate to generate the standard curve, while all samples were assayed in 
triplicate.  
 
2.2.6 Western blot analysis 
 
BMDM were seeded at a density of 1x10
5
 cells/ml in 6-well plates.  Cells were 
grown for 24 h to approximately 80% confluency.  Next day, cells were stimulated with 
TLR ligands for 1 h-3 h and pre-treatment with various agents for 1 hr.  Cells were then 
washed in ice-cold PBS before being lysed on ice for 10 min in 150 µl lysis buffer (20mM 
HEPES, pH 7.4 containing 10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1 mM 
dithiothreitol, 0.1mM phenylmethylsulfonyl fluoride, pepstatin A (5 µg/ml), leupeptin (2 
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µg/ml), and aprotinin (2 µg/ml)).  Cell lysates were centrifuged at 13,000g for 15 min at 
4°C.  The supernatant was mixed with SDS-PAGE sample buffer (0.125 Tris-HCl pH 6.8, 
20% (v/v) glycerol, 4% (w/v) SDS, 1.4 M β-mercaptoethanol and 0.0025% (w/v) 
bromophenol blue).   
For in vivo experiments, samples of spinal cord were homogenised in lysis buffer 
and the resulting lysate was centrifuged (16000 x g for 15 min at 40°C).  Supernatants were 
then further centrifuged (10000 x g for 1h at 40°C) and the supernatant (cytosolic fraction) 
added to sample buffer.  All samples in sample buffer were boiled for 5-10 min and 
separated on SDS-PAGE gels.  
 
2.2.6.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was conducted according to the method of Laemmli (Laemmli, 1970), 
as modified by Studier (Studier, 1973).  Samples and appropriate prestained (26.6-180 kDa) 
protein markers were loaded into separate wells.  Electrophoresis was performed at 80 V 
through a 5% SDS polyacrylamide stacking gel and then through a 10% SDS 
polyacrylamide resolving gel at 100 V for 1.5-3 h, depending on the size of the proteins 
being electrophoresed. 
 
2.2.6.2 Immunoblotting 
 
Following separation by electrophoresis, the proteins were transferred 
electrophoretically to nitrocellulose membranes in a Hoefer TE 70 Semiphor semi-dry 
transfer unit at 80 mA for 2 h using Whatmann and nitrocellulose pre-soaked in cold 
transfer buffer (25 mM Tris Base, 0.2 M glycine and 20% (v/v) methanol for 10 min.  
Following transfer, non-specific binding was blocked by incubating the nitrocellulose 
membranes at room temperature for 2 h (or overnight) in TBS (20 mM Tris-HCl pH 7.5, 
containing 0.05% (v/v) Tween 20 and 0.5 M NaCl) containing 5% (w/v) skimmed milk 
powder.  The membranes were then washed 3 times for 10 min each in TBS prior to 
incubation at 4
°
C overnight with the primary antibodies diluted in TBS containing 2.5% 
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(w/v) skimmed milk powder.  The membranes were subsequently subjected to 5 x 10 min 
washes in TBS prior to incubation with secondary antibody (1:5000 dilution) specific for 
the primary antibody in question (anti-rabbit or anti-mouse) in Odyssey Blocking Buffer 
(Licor, Bioscience) for 1 h in the dark at room temperature.  The membranes were then 
washed a further 5 times for 10 min each in TBS in the dark.  The immunoreactive bands 
were detected using Odyssey Infrared Imaging System from Licor Bioscience, according to 
the instructions of the manufacturer.  Membranes were stripped and incubated with β-actin 
antibody, overnight at 4°C.  Molecular weight markers were used to calculate molecular 
weights of proteins represented by immunoreactive bands.  Densitometry was performed 
using ImageJ software, and values were normalized for protein loading relative to levels of 
total IRF3.   
 
1
o 
antibody   Dilution   2
o 
antibody* 
β-actin    1:1000    mouse 
IRF3        1:1000    rabbit 
Phospho-IRF3   1:750    rabbit 
IκBα    1:200    mouse 
Phosho-IκBα/β  1:1000    mouse 
 
* All secondary antibodies were used at a dilution of 1:5000.   
 
2.2.7 Isolation of RNA and cDNA synthesis 
 
2.2.7.1 Isolation of total RNA from HEK293, U373-CD14 
astrocytoma, BMDM cell, PBMCs and primary astrocytes 
 
In order to minimise RNA degradation, a number of precautions were taken 
throughout the following procedures.  All water and salt based solutions were treated with 
diethylpyrocarbonate (DEPC) (0.2% v/v) and then autoclaved.  All plastic ware was 
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certified RNase-free.  Before commencing, equipment was wiped with “RNase Zap” an 
RNase decontamination solution.  Gloves were worn at all times and changed regularly.  
 To investigate the regulatory effects of various agents on TLR-induced activation of 
IFN-β, BMDM and primary astrocytes were seeded at 1x105 cells/ml in 6-well plates (3 ml 
DMEM/well).  PBMCs were seeded at 1x10
6
 cells/ml in 12-well plates.  To investigate the 
expression of cannabinoid receptors, HEK293 TLR3/TLR4 cells and U373-CD14 
astrocytoma cells and BMDM cells were seeded at 1x10
5 
cells/ml in 12-well plates (1 ml 
DMEM/well).   
 Total RNA was extracted from all cells as follows: after aspirating off the medium, 
Tri reagent was added (1 ml per well) and the plate was placed on a shaker at room 
temperature for 5 min.  Following transfer to eppendorf tubes, insoluble material was 
removed by centrifugation (12000 x g for 10 min at 4°C).  The supernatant was then moved 
to fresh eppendorf tubes and incubated at room temperature for 5 min.  Chloroform was 
next added (0.2 ml).  Samples were covered tightly and shaken vigorously for 15 s. This 
was followed by further incubation at room temperature for 15 min.  Centrifugation at 
12,000 x g for 15 min at 4
o
C caused separation of the homogenate into an upper aqueous 
phase and lower organic phase.  The aqueous phase containing RNA was transferred to 
fresh eppendorf tubes, taking care to avoid contamination with the lower organic layer. 
RNA was precipitated by adding isopropanol (0.5 ml per 1 ml of Tri reagent initially used) 
and maintaining samples at room temperature for 10 min.  The precipitate was pelleted by 
centrifugation at 12,000 x g for 8 min at room temperature.  The supernatant was discarded 
and the RNA pellet washed by vortexing with 70% ethanol (1 ml per 1 ml of Tri reagent 
initially used).  The previous centrifugation step was repeated to collect the washed RNA 
pellet.  Ethanol was then removed and the pellet was allowed to air-dry for up to 5 min. 
Care was taken not to allow the pellet to dry completely.  RNA was dissolved in 30 µl 
RNAse-free water by passing the solution through a pipette several times.  The amount of 
isolated RNA was quantified by measuring the absorbance at wavelengths of 260 nm and 
280 nm on a spectrophotometer, where an absorbance of 1 unit at 260 nm is ~ 40 μg/ml. 
Pure RNA preparation have an OD260/OD280 ration of 1.6-1.8.  Extracted RNA was stored at 
-80
o
C. 
 
61 
 
2.2.7.2 Synthesis of first strand cDNA from messenger RNA 
(mRNA) 
 
1 µg of RNA was placed in nuclease-free microcentrifuge tubes and incubated for 
10 min at 70
o
C. The mixture was then chilled on ice and centrifuged briefly. The following 
components were then added: 
 
Avian myeloblastosis virus reverse transcriptase (AMV RT) (15 U/µl) 0.75 µl 
dNTPs (10 mM)        2 µl 
10X AMV Buffer        2 µl 
MgCl2 (25 mM)        4 µl 
RNasin (40 U/µl)        0.5 µl 
Random Primers (0.5 μg/μl)       1 µl 
Nuclease-Free Water        to 20 μl 
 
The reaction mixture was incubated for 10 min at RT allowing the primers to anneal to the 
RNA. Next, The reaction was incubated at 42°C for 2 h.  AMV RT was then deactivated by 
heating to 95
o
C for 5 min followed by cooling to 0-5
o
C for 5 min.  Generated cDNA was 
stored at 4
o
C for short-term storage or -20
o
C for long-term storage. 
 
2.2.7.3 PCR analysis of specific cDNA expression 
 
Total RNA was isolated from HEK293 TLR3/TLR4 cells, U373-CD14 astrocytoma 
cells seeded at 1x10
5 
cells/ml in 12-well plates (1 ml DMEM/well) and BMDM seeded at 1 
x 10
5 
cells/ml in 6-well plates (3 ml DMEM/well) using the Tri Reagent (Sigma) as per 
manufacturer’s instructions.  First strand cDNA synthesis was carried out using Superscript 
II reverse transcriptase and random oligonucleotide
 
primers and PCR amplification was 
performed using TaqDNA polymerase
 
and primers to selectively amplify regions of the 
human/mouse cannabinoid (CB) CB1 and CB2 receptors and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNAs.   
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The sequences of the forward and reverse oligonucleotide
 
primers were as follows:  
 
NAME PRIMER SEQUENCE 
human CB1  
(a 500-bp fragment)  
 
For: 
5’- GAGACAACCCCCAGCTAGTCCCAGCAGACC-3’ 
Rev: 
5’-TGGGCCTGGTGACAATCCTCTTATAGGCC-3’ 
Human CB2  
(a 400-bp fragment)   
For: 
5’-CTTCTGGCCCTGCTAAGTGCCCTGGAGAACG-3’ 
Rev: 
5’-CAGCAAGTCCATCCCATGAGGGGCAGCTAGG-3’ 
Mouse CB1  
(a 400-bp fragment)   
For: 
5’-GTCACCAGTGTGCTGTTGCT-3’ 
Rev: 
5’-TGTCTCAGGTCCTTGCTCCT-3’ 
Mouse CB2  
(a 374bp fragment) 
For: 
5’-TGCTGCTCATATGCTGGTTC-3’ 
Rev: 
5’-CTTCTGACTCGGGCTGTTTC-3’ 
 
Human GAPDH  
(a 450-bp fragment) 
 
For: 
5’-ACCACAGTCCATGCCATC-3’ 
Rev: 
5’-TCCACCACCCTGTTGCTG-3’ 
Mouse GAPDH  
(a 450-bp fragment) 
For: 
5’-GCACAGTCAAGGCCGAGAAT-3’ 
Rev: 
5’-GCCTTCTCCATGGTGGTGAA-3’ 
 
Amplification parameters were as follows: step 1: 35 cycles
 
at 94 °C for 1 min, at 
55 °C for 1 min and at 72 °C
 
for 1 min; step 2: at 72 °C for 10 min.  The PCR products
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were subjected to electrophoresis on a 1% TAE agarose gel, containing
 5 μg/ml ethidium 
bromide. 
 
2.2.7.4.  Agarose gel electrophoresis 
 
Agarose gels were prepared by suspending agarose (0.8-1% (w/v)) in TAE (0.484% 
(w/v) Tris base, 0.1% (v/v) glacial acetic acid, 0.2 M EDTA).  This was heated in a 
microwave until the agarose had completely dissolved, and was then cooled to less than 
50
o
C. Ethidium bromide (5 µg/ml) was added and the agarose poured into the gel tray.  
Following solidification, agarose gels were covered and electrophoresed in TAE (1X).  
Samples were mixed with loading dye (0.017% (w/v) xylene cyanol, 0.017% (w/v) 
bromophenol blue and 5% (w/v) glycerol).  Samples were run simultaneously with 
molecular size markers, with the range of ladder chosen to suit the particular sample size.  
The voltage at which gels were run depended on the particular application.  Nucleic acids 
were visualised under UV light (254 nm) and images acquired using the Syngene G box gel 
documentation system (Frederick, MD, USA). 
 
2.2.7.5 Quantitative RT-PCR (QRT-PCR) of BMDM and primary 
mouse astrocytes 
 
BMDM and primary astrocytes were seeded at a density of 1x10
5 
cells/ml in 12-well 
plates and 6-well plates respectively.  PBMCs were seeded at a density of 1x106 cells/ml in 
12-well plates.  Cells were pre-treated with various agents for 1 h prior to TLR ligand 
exposure for 16 h (PBMCs for 3 h).  RNA was extracted from cells using Tri Reagent™ 
(Invitrogen) and cDNA generated from normalized RNA using Superscript II reverse 
transcriptase. cDNA (1 μg) was amplified in the presence of SYBR® Green PCR 
mastermix.  
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Primers used were as follows:  
 
NAME PRIMER SEQUENCE 
Mouse IFN-β For: 
5’-GGAGATGACGGAGAAGATGC-3’ 
Rev: 
5’-CCCAGTGCTGGAGAAATTGT-3’ 
Human IFN-β For: 
5’-GACCAACAAGTGTCTCCTCCAAA-3’ 
Rev: 
5’-CTCCTCAGGGATGTCAAAGTTCA-3’ 
Mouse PPARα For: 
5’-AAGTGACTTCGCTATCCAGG-3’ 
Rev: 
5’-TAGGGGACCTTCCAAACATA-3’ 
Mouse PPARγ For: 
5’- GCGGAGATCTCCAGTGATATC -3’ 
Rev: 
5’- TCAGCGACTGGGACTTTTCT -3’ 
 
Mouse GAPDH For: 
5’-AGGTCATCCCAGAGCTGAACG-3’ 
Rev: 
5’-ACCCTGTTGCTGTAGCCGTA-3’ 
Human HPRT For: 
5’-TTGCTGACCTGCTGGATTAC-3’ 
Rev: 
5’-TCTCCACCAATTACTTTTATGTCC-3’ 
 
Accumulation of gene-specific PCR products was measured continuously by means 
of fluorescence detection over 40 cycles.  Samples were run in duplicate as follows: 10 min 
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at 95
o
C and for each cycle, 10 seconds at 95
o
C, 10 seconds at 55
o
C and 1 min at 72
o
C. 
Gene expression was calculated relative to the endogenous control and analysis was 
performed using the 2
-ΔΔCT
 method.  
 
2.2.8 Confocal Microscopy 
 
For characterisation of endogenous IRF3, primary astrocytes were seeded at a 
density of 1x10
5
 cells/ml in 4-well chamber slides and grown for 24 h.  Cells were pre-
treated with various agents for 1 h prior to TLR ligand exposure for 1 h.  Cells were fixed 
in 4% PFA, permeabilised with 0.2% Triton X-100 in PBS for 10 min at room temperature 
and blocked with 10% goat serum for 2 h.  Cells were treated overnight at 4°C with 
primary antibody.  Cells were washed and incubated with secondary antibody DAPI (1.5 
μg/ml) in PBS, washed, and mounted (Vectashield; Vector Laboratories).   
HEK293 TLR3 cells were seeded at a density of 1.5x10
5
 cells/ml in 4 well chamber 
slides for 24 h and transfected using Lipofectamine 2000 with an expression construct 
encoding GFP-tagged IRF3 (800 ng).  Control slides were transfected with EGFP construct 
(800ng).  Cells were pre-treated with various agents for 1 h prior to TLR ligand exposure 
for 1 h.  Cells were fixed in 4% PFA, incubated with DAPI (1.5 μg/ml) in PBS for 30 min, 
washed, and mounted.  All samples were viewed using an Olympus FluoView FV1000 
confocal laser scanning microscope equipped with the appropriate filter sets. Acquired 
images were analysed using the Olympus FV-10 ASW imaging software. Negative control 
experiments were performed by replacing the primary antibody with isotype controls and 
using equal gain settings during acquisition and analysis. 
 
2.2.9 Induction and assessment of EAE. 
 
EAE was induced in mice as described (Smith et al., 2005).  Female SJL/J mice (8 
weeks old) were injected subcutaneously at 2 sites, with 2 injections (100 μl) of emulsified 
Freund’s complete adjuvant containing 100 μg of Myelin proteolipid protein amino acid, 
139-151 (PLP139-151) and 200 μg Mycobacterium tuberculosis H37Ra followed 2 hours later 
66 
 
with 200ng Pertussis toxin injected intraperitoneally.  The preparation and immunisation of 
the synthetic cannabinoid R(+)WIN55,212-2 was modified from previous studies (Croxford 
and Miller, 2003).  R(+)WIN55,212-2 was prepared in Cremophor El and PBS (20:80) and 
administered (20 mg/Kg) intraperitoneally on days 0, 1, 2, 3, 4 and 5. Rabbit anti-mouse 
IFN-β polyclonal antibody was administered intraperitoneally (2 x 103 Neutralizing Units) 
on days 3 and 5 after PLP immunisation. Control mice received Cremophor:PBS (20:80) as 
vehicle.  Data are from 4-8 mice per group.  To ensure objective clinical scoring, all mice 
had electronic data chips placed subcutaneously prior to experiment and were subsequently 
tracked by barcode reader (AVID, UK).  An investigator blinded to the treatment of the 
mice scored all animals by barcode number, to determine the mean clinical score as 
follows: 0, normal; 1, limp tail or hind limb weakness; 2, limp tail and hind limb weakness, 
3, partial hind limb paralysis; 4, complete hind limb paralysis, and 5, moribund. 
 
2.2.10  Histology 
 
Spinal cords were dissected and fixed in 10% formaldehyde saline.  Spinal cords 
were sectioned and stained with haematoxylin and eosin for inflammatory scoring (Wraith 
et al., 2009).  Inflammatory scores were as follows: 0, no inflammatory cells; 1, a few 
scattered inflammatory cells; 2, perivacular cuffing; 3, perivascular cuffing with extensions 
into adjacent parenchyma, or parenchymal infiltration without obvious cuffing. 
Demyelination was assessed on Luxol fast blue-stained spinal cord sections and scored as 
follows: 0, no evident demyelination; 1, decreased myelination with no foci; 2, obvious 
demyelination with evident foci; 3: severe demyelination. An investigator blinded to the 
treatment groups scored all stained sections, with slides labelled by mouse barcode number. 
 
2.2.11  Statistical Analysis 
 
 Data is expressed as mean + standard error of the mean (S.E.M.), and the results 
represent three independent experiments (nine independent experiments for primary 
cultures).  Statistical comparisons of different treatments were done by a one-way analysis 
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of variance using a post hoc Student’s Newman-Keuls test.  Differences with a p value less 
than 0.05 were considered statistically significant.   
 
 
 
 
  
 
 
 
 
 
 
 
 
Chapter 3 
 
 
 
Defining the regulatory effects of WIN55,212-2 on 
TLR3 and TLR4 signalling 
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3.1 Introduction 
 
TLRs and their adaptor molecules are essential regulators of the mammalian 
immune system and although have been studied for over a decade, their complexity 
continues to intrigue researchers.  Since the discovery of the first mammalian TLR, 
TLR4, (Medzhitov et al., 1997) much work has been carried out in characterising these 
receptors and their central role in the innate and adaptive immune response.  TLR 
recognition of diverse microorganisms and initiation of complex signalling pathways 
culminates in the induction of various transcription factors including NFκB, IRFs, AP-1 
and CREB.  However, dysregulation of the same pathways can result in the onset of 
various inflammatory and autoimmune diseases. 
TLRs play a significant role in modulating M.S. (Hansen et al., 2006).  Much of 
our insight has emerged from the use of the EAE model.  Studies have confirmed that 
TLR expression is strongly increased within the CNS during EAE (Prinz et al., 2006).  
The absence of TLR4 exacerbates EAE and this clinical feature is associated with 
increased expression of IL-17, a potent inflammatory mediator of M.S. (Marta et al., 
2008).  Other studies have demonstrated how pertussis toxin (PTX) can facilitate 
leukocyte migration across the BBB by increasing its permeability, an effect that is 
mediated by activation of TLR4 (Kerfoot et al., 2004).  Studies have also reported on 
the presence of the TLR2 ligand, PG, in the CNS of M.S. primates (Visser et al., 2006).  
PG has been found to be able to act as an adjuvant to induce EAE (Visser et al., 2005).  
Similarly, TLR9 agonists can also mediate the development of EAE (Waldner et al., 
2004) as TLR9 deficient mice are partially resistant to the disease (Prinz et al., 2006) 
MyD88, an essential adaptor in the activation of NFκB, also functions in the 
induction and progression of EAE as MyD88 knockout mice are completely resistant to 
EAE and show no brain inflammation (Prinz et al., 2006).  This contrasts with the 
MyD88 independent pathway, the central pathway utilised by TLR3.  Poly(I:C)-induced 
activation of TLR3 and subsequent induction of IFN-β suppresses relapsing EAE (Touil 
et al., 2006).  In addition, IFN-β knockout (KO) mice are more susceptible to EAE and 
develop further extensive CNS inflammation and demyelination than wild-type mice 
(Teige et al., 2003).   
One of the most recently introduced treatments for M.S. patients is the use of 
recombinant IFN-β.  Transcriptional activation of the IFN-β gene is tightly regulated 
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and transcriptionally controlled by a limited number of transcription factors.  The 
assembly of the transcription enhancer complex referred to as the enhanceosome is a 
key requirement for IFN-β transcription.  Following TLR ligand stimulation, activated 
transcription factors e.g. NFκB and IRF3/7 translocate to the nucleus and bind to the 
PRD on the IFN-β promoter (Thanos and Maniatis, 1995).  This results in high levels of 
IFN-β expression.  While NFκB and IRF3 are expressed in multiple cell types, IRF7 
expression is mainly confined to pDCs and dependent on activation of the ISGF3 
transcriptional regulator (Taniguchi and Takaoka, 2002, Noppert et al., 2007). 
The above studies demonstrate there is increasing evidence supporting a role for 
TLRs in M.S.  Reports have also suggested that cannabinoids, known to exhibit general 
immunosuppressive properties, have potential therapeutic value in the treatment of 
neuroinflammatory conditions (Consroe et al., 1997).  Furthermore, much interest has 
also been generated by reports of the therapeutic effects of cannabis in alleviating the 
symptoms of M.S. (Consroe et al., 1997) where patients with spasticity claim relief 
from using the drug (Iversen, 2003).  In rats and guinea pigs, δ-9-THC suppressed both 
the histological and clinical manifestations of EAE (Lyman et al., 1989).  The 
introduction of Sativex (a combination of δ-9-THC and cannabidiol) further 
demonstrates the therapeutic action of cannabinoids in M.S.   
The advent of synthetic and endogenous cannabinoid compounds accompanied 
by the development of animal models of M.S. have enabled the pharmacology of 
cannabinoids to blossom and shed light on anecdotal reports of the medicinal value of 
cannabis.   
EAE is one of the most intensively studied animal models of M.S.  The origins 
of EAE date back to 1885 and arose from vaccination with rabies-infected rabbit spinal 
cord by Louis Pasteur (Baxter, 2007).  Nowadays, EAE can be induced in a number of 
species, including mice, rats, guinea pigs, rabbits and primates.  EAE may be induced 
via active immunisation with CNS tissue or myelin antigens in complete Freund’s 
adjuvant or by adoptive transfer whereby CD4
+
 T cells specifically reactive to myelin 
antigens that are transferred from affected animals to healthy recipients (Stromnes and 
Goverman, 2006).  It has been previously been reported that treatment with high 
concentrations of R(+)WIN55,212-2 in EAE rats significantly improves the clinical 
performance of the animals during relapse (Hasseldam and Johansen, 2010).  
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R(+)WIN55,212-2 treatment reduced T cell, microglia production and axonal 
degeneration where high doses resulted in reduced demyelination.   
Viral models of M.S. have also contributed in the understanding of the disease.  
Viral models are particularly relevant in the increasing evidence for viral mechanisms in 
the etiology of M.S. (Pohl, 2009).  Theiler’s murine encephalomyelitis virus (TMEV) is 
a picornavirus natural pathogen in mice.  Injection of TMEV in the CNS induces an 
immune-mediated demyelinating disease in susceptible mouse strains that resembles 
progressive M.S. (Dal Canto and Lipton, 1977).  An immune response directed against 
viral and myelin epitopes takes place in the CNS of TMEV-infected mice and this event 
is considered to be the cause of TMEV-induced demyelinating disease (TMEV-IDD).  
In TMEV-IDD mice, treatment with R(+)WIN55,212-2 was shown to reduce microglial 
activation, diminish MHC class-II antigen expression and decreased the number of 
CD4+ infiltrating T cells in the spinal cord (Arevalo-Martin et al., 2003).  
R(+)WIN55,212-2 treatment has also been demonstrated to suppress ICAM-1 and 
VCAM-1 activation in this model (Mestre et al., 2009).  Furthermore, intraperitoneal 
treatment of R(+)WIN55,212-2 at different time points in TMEV-IDD mice 
significantly inhibit the progression of clinical disease (Croxford and Miller, 2003).  In 
chronic relapsing experimental allergic encephalomyelitis (CREAE), an additional 
mouse model of M.S., R(+)WIN55,212-2 treatment quantitatively ameliorated both 
tremor and spasticity in diseased mice (Baker et al., 2000). 
R(+)WIN55,212-2 is anti-inflammatory in the brain by inhibiting leukocyte 
infiltration into the CNS (Arevalo-Martin et al., 2003).  Our laboratory has previously 
elaborated on this study in 1321N1 astrocytoma, a cell model of human astrocytes 
(Curran et al., 2005).  Astrocytes are resident CNS glial cells and play an important role 
in contributing to the pathogenesis of M.S.  They secrete factors required to maintain 
the BBB, and provide physical support through foot processes found on the abluminal 
surface of the vascular endothelium. Astrocytes are also immunocompetent cells, 
responding to and producing cytokines, and expressing adhesion molecules and 
chemokines upon appropriate stimulation (Aloisi et al., 1992, Dong and Benveniste, 
2001, Moynagh et al., 1994, Bourke and Moynagh, 1999).  Their ability to express 
MHC class I and class II molecules, (Wong et al., 1984) gives them the machinery to 
activate a range of T cells in particular encephalitogenic CD4+ Th1 cells, the main cell 
type to mediate demyelination.   
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Curran and colleagues demonstrated the inhibitory effects of R(+)WIN55,212-2 
on IL-1β-induced activation of NFκB (Curran et al., 2005).  This study also encouraged 
an examination of the downstream signalling components involved in the transcriptional 
activation of NFκB.  A number of molecules at various stages in the IL-1 signalling 
pathway were examined for their sensitivity to the inhibitory effects of 
R(+)WIN55,212-2.  In each case, overexpression of MyD88, TAK-1 and IKKβ caused 
robust induction of the NFκB-regulated reporter gene.  Treatment with 
R(+)WIN55,212-2 strongly inhibited the ability of each molecule to induce NFκB 
transcriptional activity.  However the molecular basis of R(+)WIN55,212-2 on TLR 
signalling was not examined.   
TLRs employ many of the same signalling components as the IL-1R  (Martin 
and Wesche, 2002).  As a result, it was deemed of interest to assess the regulatory 
effects of R(+)WIN55,212-2 on TLR activation of NFκB and other transcription factors.  
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3.2 Results 
 
3.2.1 R(+)WIN55,212-2 inhibits NFκB activation by TLR ligands. 
 
The initial focus of this study was to investigate if R(+)WIN55,212-2 regulated 
TLR-induced activation of NFκB.  Various cell lines engineered to individually express 
TLR3 and TLR4 were utilised.  TLR3 and TLR4 were selected as primary targets since 
they exert differential roles in the development of M.S. lesions (Racke and Drew, 2009, 
Bsibsi et al., 2006) and EAE inflammation (Hansen, Hussain et al. 2006).  Poly(I:C)-
induced activation of TLR3 and subsequent induction of IFN-β suppresses relapsing 
EAE (Touil et al., 2006) while PTX can facilitate leukocyte migration across the BBB 
by increasing its permeability, an effect that is mediated by activation of TLR4 (Kerfoot 
et al., 2004).  Furthermore, studies in Lewis rats indicated that a combination of LPS 
and the TLR9 agonist CpG ODN are required for the development of EAE, while in 
contrast Poly(I:C) does not induce disease (Wolf et al., 2007). 
R(+)WIN55,212-2 was first assessed for its regulatory effects on TLR-induced 
activation of NFκB.  HEK293 cells stably tranfected with TLR3 or TLR4, were treated 
with Poly(I:C) and LPS respectively.  The transcriptional activity of NFκB was 
measured by expression of a transfected NFκB-regulated reporter luciferase gene.   
LPS significantly enhanced the transcriptional activation of the NFκB-regulated 
reporter gene (Fig. 3.1A). Pre-treatment with various concentrations of 
R(+)WIN55,212-2 caused a dose-dependent inhibition of LPS-induced NFκB-regulated 
luciferase expression.  The WIN55,212-2 compound is available in two enantiomeric 
forms, R and S, with R being the active form (Herzberg et al., 1997).  In contrast to the 
R form, the inactive chiral form S(-)WIN55,212-2 failed to affect the ability of LPS to 
induce NFB activation (Fig. 3.1B), suggesting that a stereoselective mechanism 
underlies the inhibitory effects of R(+)WIN55,212-2.   
A similar experiment was also preformed in HEK293 TLR3 cells where 
R(+)WIN55,212-2 treatment caused a dose-dependent inhibition of Poly(I:C)-induced 
activation of NFκB (Fig. 3.1C) whereas its chiral form S(-)WIN55,212-2 was 
ineffective (Fig. 3.1D). 
 Owing to the importance of astrocytes in neuroinflammation, it was next of 
interest to explore the regulatory effects of R(+)WIN55,212-2 on NFκB in this cell type. 
72 
 
1321N1 and U373-CD14 astrocytoma cells were used as cell line models of human 
astrocytes.  Both astrocytoma cell lines failed to respond to LPS treatment but were 
strongly responsive to Poly(I:C) stimulation (Fig. 3.2).  Pre-exposure of the cells to 
R(+)WIN55,212-2 dose-dependently attenuated the Poly(I:C)-induced activation of 
NFκB in U373-CD14 astrocytoma (Fig. 3.2A) and 1321N1 astrocytoma (Fig. 3.2B) 
cells.   
 
3.2.2 R(+)WIN55,212-2 inhibits TNF-α expression by TLR ligands.   
 
TNF-α production is predominantly regulated by NFκB.  As a result, it was of 
interest to assess the regulatory effects of R(+)WIN55,212-2 in TLR-induced expression 
of TNF-α.   
Stimulation of U373-CD14 astrocytoma cells with either LPS or Poly(I:C) for 
24 hours induced a 10-fold increase in TNF-α expression and pre-treatment with 
R(+)WIN55,212-2 inhibited the induction of TNF-α in response to both TLR ligands 
(Fig. 3.3A and Fig. 3.3C).  Specificity for the WIN55,212-2 compound was also 
established as S(-)WIN55,212-2 failed to inhibit the activation of TNF-α expression in 
LPS (Fig. 3.3B) or Poly (I:C) treated cells (Fig. 3.3D).   
We next aimed to corroborate some of the above findings in primary cells.  
Primary mouse astrocytes were strongly responsive to LPS and Poly(I:C) stimulation 
(Fig. 3.4A and Fig. 3.4C) and showed significant TNF-α production after 24 hours of 
ligand treatment.  In both cases R(+)WIN55,212-2 dose-dependently inhibited the 
response (Fig. 3.4A and Fig. 3.4C).  Again, stereoselectivity for this effect was shown 
since S(-)WIN55,212-2 failed to affect TLR ligand induction of TNF-α expression (Fig. 
3.4B and Fig. 3.4D).   
R(+)WIN55,212-2 inhibits Poly(I:C) induction of TNF-α expression in a variety 
of human and animal cell models.  It was next examined if the inhibitory effects of 
R(+)WIN55,212-2 on TNF-α production were extended to cells from M.S. patients.  
PBMCs which endogenously express TLR3 and TLR4 (XIN-YI et al., 2007) were 
isolated from healthy and M.S. patient subjects.  PBMCs were responsive to Poly(I:C) 
and showed strong induction of TNF-α (Fig. 3.5A and Fig. 3.5B) expression.  In both 
patient groups, pre-treatment with R(+)WIN55,212-2 robustly downregulated Poly(I:C)-
induced activation of TNF-α expression (Fig. 3.5A and Fig. 3.5B).   
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3.2.3 R(+)WIN55,212-2 inhibits IRF7 activation by TLR ligands.   
 
The above studies demonstrate the regulatory effects of R(+)WIN55,212-2 on 
NFκB and its responsive gene.  Previous studies by our laboratory illustrated the 
inhibitory effects of R(+)WIN55,212-2 on MyD88 activation of NFκB (Curran et al., 
2005).  As MyD88 also activates the transcription factor IRF7, it was of significance to 
assess the effects of R(+)WIN55,212-2 on TLR-induced activation of IRF7.   
In luciferase assays, the trans-activator plasmid pFA-IRF7 (where IRF7 is fused 
downstream of the yeast Gal4 DNA binding domain) was transfected into HEK293 
TLR4 cells in conjunction with the Gal4-responsive pFR-luciferase construct.  Upon 
activation of IRF7, the trans-activation capacity of the IRF7-Gal4 fusion protein is 
induced.  This, in turn, induces the expression of luciferase from the Gal4-inducible 
promoter, pFR-Luc, which is used an index of IRF7 activity.  Following transfection, 
the cells were treated with LPS which resulted in significant induction of IRF7-
regulated reporter gene (Fig. 3.6A).  Pre-treatment of cells with R(+)WIN55,212-2 
dose-dependently and strongly attenuated LPS-induced IRF7 luciferase activity (Fig. 
3.6A).  Conversely, S(-)WIN55,212-2 exhibited no inhibition of LPS-induced activation 
of IRF7 (Fig. 3.6B).  
R(+)WIN55,212-2 was next assessed for its regulatory effects on Poly(I:C)-
induced activation of  IRF7.  Pre exposure of the cells to R(+)WIN55,212-2 inhibited 
Poly(I:C)-induced activation of IRF7 (Fig. 3.6C).  Again, specificity was confirmed 
since the S(-)WIN55,212-2 compound had no effect on Poly(I:C) induced activation  of 
IRF7 (Fig. 3.6D).   
A similar profile was also observed in U373-CD14 astrocytoma cells where pre-
exposure of the cells to R(+)WIN55,212-2 dose dependently attenuated LPS (Fig. 3.6E) 
and Poly(I:C)-induced (Fig. 3.6F) activation of IRF7.  
 
3.2.4 R(+)WIN55,212-2 differentially regulates IRF3 activation by TLR ligands.   
 
IRF3 is an additional transcription factor that is also activated by both TLR3 and 
TLR4 signalling events (Moynagh, 2005) which employs the signalling components 
TRIF and MyD88 respectively.  As MyD88 deficiency is protective in EAE (Prinz et 
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al., 2006), while TRIF deficiency exacerbates the disease (Guo et al., 2008), the 
sensitivity of MyD88-dependent and -independent signalling to R(+)WIN55,212-2 
exposure was further delineated.  HEK293 TLR3 and TLR4 cells were transfected with 
the trans-activator plasmid pFA-IRF3 (where IRF3 is fused downstream of the yeast 
Gal4 DNA binding domain) in conjunction with the Gal4-responsive pFR-luciferase 
construct and stimulated with Poly(I:C) and LPS respectively.  As illustrated in Fig. 
3.7A, exposure of HEK293 TLR4 cells to LPS enhanced IRF3 luciferase activity and 
this was abrogated by R(+)WIN55,212-2 in a dose-dependent manner.  Treatment of 
HEK293 TLR3 cells with Poly(I:C) enhanced IRF3 luciferase activity.  However, in 
contrast to LPS treatment, pre-treatment with R(+)WIN55,212-2 potentiated Poly(I:C)-
induced activation of IRF3 (Fig. 3.7B).  Pre exposure of the cells to S(-)WIN55,212-2 
failed to regulate Poly(I:C)-induced activation of IRF3 (Fig. 3.7C).  
Similar results were also obtained in U373-CD14 astrocytoma (Fig. 3.7D) and 
1321N1 astrocytoma cells (Fig. 3.7E), where R(+)WIN55,212-2 significantly 
augmented the Poly(I:C) induction of IRF3 in a dose-dependent manner. 
The above data demonstrates that R(+)WIN55,212-2 differentially regulates 
IRF3 activation by TLR ligand stimulation and this observation is consistent across a 
number of different cell types.  
 
3.2.5 R(+)WIN55,212-2 differentially regulates activation of the IFN-β promoter 
and induction of IFN-β mRNA by TLR ligands.   
 
IRF3, IRF7 and NFκB are important regulators of type I IFN expression, 
including IFN (Taniguchi et al., 2001).  As R(+)WIN55,212-2 exhibits diverse roles in 
the activation of these transcription factors, the functional consequences of 
R(+)WIN55,212-2 on TLR3/TLR4 activation of the IFN- promoter, and the induction 
of IFN- mRNA was next addressed. 
HEK293 TRL3 cells were transfected with the IFN-β promoter luciferase 
construct and subsequently stimulated with Poly(I:C).  This resulted in the Poly(I:C)-
induced activation of the IFN-β promoter and pre-treatment with R(+)WIN55,212-2 
significantly enhanced this response (Fig. 3.8A).  Similar effects were also apparent in 
U373-CD14 astrocytoma cells (Fig. 3.8B), albeit at higher concentrations.   
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The regulatory effects of R(+)WIN55,212-2 on the activation of the IFN-β 
promoter were further characterised by dissecting its regulation of specific regions of 
the promoter.  The PRDII region is recognised and regulated by NFκB while PRDI/III is 
recognised by IRF3/IRF7.  Transfection with the PRD-I/III-luciferase construct and 
subsequent stimulation with Poly(I:C) resulted in significant activation of the PRD-I/III 
promoter (Fig. 3.9A).  Pre-treatment with R(+)WIN55,212-2 inhibited this response 
(Fig. 3.9A).  This possibly indicates a preference towards the activation of the IFN-β 
promoter by IRF7.  Again, stereoselectivity for this effect was determined since S(-
)WIN55,212-2 failed to affect Poly(I:C)-induced activation of the PRD-I/III domain 
(Fig. 3.9B).  
A similar assay was also carried out in HEK293 TLR3 cells where the PRD-II-
luciferase construct was transfected and followed by Poly(I:C) treatment.  Pre-exposure 
of the cells to R(+)WIN55,212-2 inhibited the Poly(I:C) induction of the PRD-II (Fig. 
3.9C) which further supports our previous data on the negative regulatory effects of 
R(+)WIN55,21-2 on Poly(I:C) induced activation of NFκB. 
In order to further explore the mechanism underlying the regulatory effects of 
R(+)WIN55,212-2, transcriptional regulation of the IFN-β gene was probed as a 
potential target.  Real-time PCR was used to quantitate levels of mRNA encoding IFN-
β.  Bone marrow derived macrophages (BMDM), endogenously expressing TLR3 and 
TLR4 were employed.  Treatment of BMDM cells with LPS (Fig. 3.10A) or Poly(I:C) 
(Fig. 3.10C) enhanced the expression of IFN mRNA.  Pre-exposure of the cells to 
R(+)WIN55,212-2 reduced LPS (Fig. 3.10A), but enhanced Poly(I:C)-induced (Fig. 
3.10C) activation of IFN mRNA expression.  Surprisingly, S(-)WIN55,212-2 also 
inhibited the activation of IFN-β mRNA by LPS (Fig. 3.10B) and Poly(I:C) (Fig. 
3.10D) treatment.   
Primary rat astrocytes were next used as a more physiologically relevant model 
system to further investigate the regulatory effects of R(+)WIN55,212-2 on IFN-β 
mRNA expression.  Pre-exposure of the cells to R(+)WIN55,212-2 partially inhibited 
LPS induction of IFN-β mRNA, specifically at the 5µM and 50µM dose (Fig. 3.10E).  
In contrast, R(+)WIN55,212-2 treatment induced marginal augmentation of IFN-β 
mRNA expression following Poly(I:C) stimulation (Fig. 3.10F).  This effect was again 
observed in higher concentrations of the drug.   
76 
 
Overall, these results further emphasise the differential effects of 
R(+)WIN55,212-2 on TLR3 and TLR4 signalling pathways indicating that 
R(+)WIN55,212-2 acts as a positive regulator of Poly(I:C)-induced activation IRF3 and 
its associated IFN-β expression.   
Given that R(+)WIN55,212-2 can augment Poly(I:C)-induced activation of the 
IFN- promoter and IFN-β mRNA in a variety of human and animal cell models, it was 
next examined if R(+)WIN55,212-2 could modulate IFN- mRNA expression in cells 
from M.S. patients.  PBMCs isolated from healthy subjects were responsive to Poly(I:C) 
treatment, with a significant increase in IFN- mRNA expression, where pre-treatment 
with R(+)WIN55,212-2 ablated this response (Fig. 3.11A).  In contrast to healthy 
subjects, PBMCs isolated from M.S. subjects were unresponsive to Poly(I:C) and no 
IFN- mRNA expression was detected following Poly(I:C) treatment alone (Fig. 
3.11B).  Remarkably, PBMCs from M.S. subjects displayed exquisite sensitivity of 
exposure to R(+)WIN55,212-2, with treatment robustly inducing IFN- mRNA 
expression in the absence of Poly(I:C).  These findings are significant given that pDCs 
from M.S. patients produce lower levels of type I IFN (Stasiolek et al., 2006) and are 
weakly responsive to IFN-β-induced maturation (Kraus et al., 2008).  This suggests that 
any therapeutic potential for R(+)WIN55,212-2 would depend on its ability to augment 
IFN- in M.S. patients.  The differential sensitivity of cells from healthy and M.S. 
subjects to R(+)WIN55,212-2 appear to be specific for IFN-, since as previously 
shown, R(+)WIN55,212-2 blocks the Poly(I:C)-induced expression of TNF-α in 
PBMCs from both healthy (Fig. 3.5A) and M.S. (Fig. 3.5B) subjects.   
 
3.2.6 R(+)WIN55,212-2 manifests protective effects in EAE in an IFN-β-dependent 
manner.   
 
Given the therapeutic effects of IFN-β in the treatment of M.S. and the ability of 
R(+)WIN55,212-2 alone to augment IFN-β mRNA, it was intriguing to speculate that 
R(+)WIN55,212-2 may exert its therapeutic properties in M.S. animal models by 
inducing endogenous IFN-β.  A relapsing mouse model of EAE involving immunisation 
with the myelin antigen, PLP139-151 (PLP) was employed to address this hypothesis (Fig. 
3.12A).  PLP-immunised mice developed clinical symptoms of disease from day 5 post-
immunisation, with disease severity peaking on day 16 followed by a relapse on day 26 
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(Fig. 3.12B).  Mice treated with R(+)WIN55,212-2 (administered (20 mg/kg) showed 
delayed development of EAE and attenuated disease severity (Fig. 3.12B).  However, 
PLP-immunised mice treated with R(+)WIN55,212-2 and anti-IFN-β antibody (αIFN-β) 
were not protected (Fig. 3.12B).  
Scoring of histology sections confirmed R(+)WIN55,212-2 reduced lymphocytic 
infiltration (Fig. 3.13A and Fig. 3.13B) and demyelination of spinal cords (Fig. 3.13C).  
However, αIFN-β inhibited these protective effects (Fig. 3.13A, Fig. 3.13B and Fig. 
3.13C).  Animals that received αIFN-β antibody alone, displayed a similar degree of 
inflammation (Fig. 3.13B) and demyelination (Fig. 3.13C) compared to vehicle-treated 
mice.  The effects of R(+)WIN55,212-2 on astrogliosis/microglial activation in PLP-
immunised mice was also characterised.  R(+)WIN55,212-2 attenuated both GFAP 
mRNA (Fig. 3.13D) and CD11b mRNA (Fig. 3.13E) in EAE spinal cord, and this was 
reversed by αIFN-β.   
Finally, to characterise the anti-inflammatory effects of R(+)WIN55,212-2 at the 
molecular level, IκB proteins in spinal cords were analysed.  As mentioned in Chapter 
1, IκB proteins regulate NFκB by sequestering the transcription factor in the cytoplasm 
(Hacker and Karin, 2006) where NFκB activation is dependent on the phosphorylation 
and subsequent degradation of IκB.  R(+)WIN55,212-2 reduced IκBα phosphorylation 
and degradation associated with EAE, and these effects were reversed by αIFN-β (Fig. 
3.13F).  This provides strong evidence that IFN-β plays a role in the protective effects 
of R(+)WIN55,212-2 in EAE. 
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3.3 Discussion 
 
Although cannabis is illegal in many countries, it has been used for centuries as 
a therapeutic mediator for symptomatic relief in inflammatory and neuropathic 
disorders.  Anecdotal evidence suggests that M.S. patients who consume whole extracts 
of cannabis claim relief from pain and spasticity (Consroe et al., 1997).  Furthermore, 
similar results are also observed in M.S. patients administered with oral δ-9-THC 
(Pertwee, 2002).  However, it is only in recent years that cannabinoid pharmacology has 
become better understood. The regulatory effects of the aminoalkylindole 
R(+)WIN55,212-2 was targeted in this study due to its impressive therapeutic effects in 
ameliorating disease progression in animal models of M.S. (Croxford and Miller, 2003, 
Arevalo-Martin et al., 2003).  Furthermore, although R(+)WIN55,212-2 is structurally 
diverse from δ-9-THC, previous reports have identified the therapeutic value of 
R(+)WIN55,212-2 in attenuating EAE progression to a level that is comparable to the 
phytocannabinoid (Lyman et al., 1989).   
The previously observed inhibitory effects of R(+)WIN55,212-2 in adhesion 
molecule expression in a human astrocyte cell line (Curran et al., 2005), may play a 
central role in mediating the therapeutic effects of the drug.  Furthermore, adhesion 
molecules are expressed in elevated levels in astrocytes of acute M.S. lesions (Brosnan 
et al., 1995) and their expression is predominately mediated by IL-1β induced activation 
of NFκB.  TLRs employ many of the same signalling components as the IL-1 pathway 
and also induce NFκB activation.  As a result, the regulatory effects of 
R(+)WIN55,212-2 on TLR-induced activation of NFκB was deemed worthy of 
investigation .   
NFκB and IRF7 are of fundamental importance in the induction of pro-
inflammatory proteins, such as those encoding chemokines and cytokines, with MyD88 
functioning as a potent activator of the transcription factors.  Initial experiments using 
HEK293 cells and astrocytoma cells demonstrated that treatment with R(+)WIN55,212-
2 inhibits TLR4-induced activation of NFκB and IRF7.  Previous studies by our 
laboratory demonstrated that R(+)WIN55,212-2 strongly inhibits the ability of MyD88 
to induce activation of NFκB (Curran et al., 2005).  It is therefore suggested that 
R(+)WIN55,212-2 may target the TLR4 pathway downstream of MyD88, as both IRF7 
and NFκB are regulated by the adaptor protein.  Furthermore, R(+)WIN55,212-2 also 
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abolished TLR3 (MyD88-independent) activation of these transcription factors.  Such 
targeting of the NFB and IRF7 signalling pathways may provide major contributions 
to the inhibitory effects of R(+)WIN55,212-2 on pro-inflammatory gene expression.  
Indeed, this study also demonstrated that R(+)WIN55,212-2 blunts TLR3/4 induction of 
TNF- in a variety of human and murine cells.  Overall, the inhibitory effects attributed 
to R(+)WIN55,212-2 on inflammatory mediator production is comparable to other 
cannabinoid such as δ-9-THC (Puffenbarger et al., 2000), endocannabinoids 
(Facchinetti et al., 2003) and the synthetic cannabinoid ligand JWH-133 (Xu et al., 
2007). 
Interestingly, R(+)WIN55,212-2 exhibits contrasting effects on TLR3- and 
TLR4-induced activation of IRF3.  While the synthetic cannabinoid strongly inhibits 
TLR4-induced activation of IRF3, in response to TLR3 stimulation, R(+)WIN55,212-2 
profoundly augments IRF3 activation.  Similar to TLR3-induced activation of IRF3, 
R(+)WIN55,212-2 also upregulated Poly(I:C)-induced activation of the IFN-β promoter 
and IFN-β mRNA expression.  This effect was seen in astrocytoma cell lines and in 
both rodent and murine astrocytes.  It appears that IFN-β may be selectively targeted by 
R(+)WIN55,212-2 following TLR3 stimulation and subsequent IRF3 activation.  It is 
likely that R(+)WIN55,212-2 downregulation of LPS-induced activation of IFN-β 
mRNA expression is mediated via its inhibitory effects on NFκB and IRF3 in the same 
ligand response.  The observed inhibitory effects of R(+)WIN55,212-2 on LPS-induced 
activation of IRF3 and IFN-β is consistent with a recent report describing δ-9-THC and 
cannabidiol ability to inhibit LPS-induced expression of IFN-β (Kozela et al., 2010).  
Despite this, the disparity between the regulatory effects of R(+)WIN55,212-2 on TLR3 
and TLR4 activation of IRF3 and IFN-β is intriguing and highly novel.  It is also 
extremely complex when studied in patient populations.   
PBMCs from healthy donors responded to TLR3 stimulation by enhancing IFN-
β production.  Interestingly, this was absent in M.S. patient, suggesting that the TLR3 
signalling pathway may be desensitised, at least in respect to IFN-β induction.  Indeed, 
viral involvement in M.S. manifestation has been demonstrated (Pohl, 2009), and it is 
interesting to speculate that M.S. patients may be pre-sensitised to viral infection thus 
showing some form of TLR3 tolerance.  Intriguingly, the non-responsiveness of M.S. 
patient PBMCs to Poly(I:C) is only relevant in the context of IFN-β induction since 
Poly(I:C) shows comparable efficacy in inducing TNF-α in cells from both healthy 
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subjects and MS patients.  Therefore, any form of TLR3 tolerance that may exist, 
appears to be restricted to the pathway leading to IFN-β and this may explain why 
exogenous administration of IFN-β is effective in the treatment of M.S.  Remarkably, 
R(+)WIN55,212-2 alone induced the expression of IFN-β in PBMCs from M.S. 
patients.  Thus, whatever the basis underlying the refractory nature of M.S. cells to 
TLR3-induced IFN-β expression, R(+)WIN55,212-2 can bypass this blockage.  This 
argues strongly in favour of the therapeutic potential of R(+)WIN55,212-2 in M.S. and 
presents an additional novel therapeutic strategy to the current exogenous 
administration of IFN-β.  Furthermore, the induction of IFN-β by R(+)WIN55,212-2 in 
PBMCs from M.S. patients is strongly inhibited by Poly(I:C) treatment.  This suggests 
that stimulation of TLR3 in cells from M.S. patients generates a negative input on IFN-
β expression and is consistent with suggestions that viral infection can exacerbate 
disease.   
The non polar nature of R(+)WIN55,212-2 raised the possibility that it mediates 
its effects via non-specific membrane disruption.  However, the overall observed 
stereoselectivity of the response to the WIN55,212-2 enantiomers would seem to 
suggest receptor involvement.  In the majority of experiments the inactive S(-
)WIN55,212-2 enantiomer failed to affect TLR ligand activation of various transcription 
factors and their associated gene products.  This is consistent with the lack of effect of 
S(-)WIN55,212-2 in animal models (Croxford and Miller, 2003).  Furthermore, the 
concentrations of R(+)WIN55,212-2 used, are in line with those used in vitro 
(Facchinetti et al., 2003) and correlate well with the doses that are used to produce in 
vivo effects (Croxford and Miller, 2003). 
In summation, the present study highlights the importance of IFN-β production 
as a mechanism underlying the protective effects of R(+)WIN55,212-2 in EAE and 
preliminary data suggests that a similar phenomenon may exist in humans.  It is 
proposed that such effects are due to a combination of neuroprotection and dampening 
of inflammation. Whilst it is clear that the anti-inflammatory properties of 
R(+)WIN55,212-2 may be manifested directly by its inhibitory effects on NFκB, it is 
also apparent that in vivo anti-inflammatory effects of R(+)WIN55,212-2 are dependent 
on IFN-β and the immunomodulatory potential of the latter.  Such directly and 
indirectly acting mechanisms of R(+)WIN55,212-2 may combine to explain its strong 
anti-inflammatory propensity.   
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Understanding the pharmacology of R(+)WIN55,212-2 is crucial in elucidating 
its anti-inflammatory effects.  As a result, the involvement of the cannabinoid receptors 
in mediating the regulatory effects of R(+)WIN55,212-2 and the investigation of 
whether endocannabinoids mimic R(+)WIN55,212-2, forms the content of the next 
chapter.   
 
 
Chapter 3
FIGURES
A B
C D
Figure 3.1 R(+)WIN55,212-2 inhibits LPS and Poly(I:C)-induced activation of
NFκB in HEK293 TLR3/TLR4 cells.
HEK293 cells stably transfected with TLR4 or TLR3 were co-transfected with a NFκB-
regulated firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed Renilla
luciferase) (40 ng), and pcDNA3.1 (120 ng). Cells were allowed to recover overnight
and then pre-treated with or without various concentrations of R(+)WIN55,212-2 (A+C)
or S(-)WIN55,212-2 (B+D) for 1 h prior to stimulation in the presence or absence of LPS
(100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were generated and
assayed for firefly and Renilla (for normalizing transfection efficiency) luciferase. *P <
0.05, **P < 0.01 and ***P < 0.001 compared with vehicle-treated cells. +++P <0.001
compared with LPS or Poly(I:C)-treated cells. One way ANOVA effect of treatment (A)
F value (9, 20) = 3.710. P < 0.01 (B) F value (9, 20) = 10.45. P < 0.001 (C) F value (9,
20) = 56.92. P < 0.001 (D) F value (9, 20) = 22.02. P < 0.001. Results are mean +/-
S.E.M. of three independent experiments.
Figure 3.2 R(+)WIN55,212-2 inhibits Poly(I:C)-induced activation of NFκB in
astrocytoma cells.
U373-CD14 astrocytoma (A) and 1321N1 astrocytoma cells (B) were co-transfected
with a NFκB-regulated firefly luciferase reporter (80 ng), phRL-TK (constitutively
expressed Renilla luciferase) (40 ng), and pcDNA3.1 (120 ng). Cells were allowed to
recover overnight and then pre-treated with or without various concentrations of
R(+)WIN55,212-2 for 1 h prior to stimulation in the presence or absence of Poly(I:C)
(25μg/ml) for a further 6 h. Cell extracts were generated and assayed for firefly and
Renilla (for normalizing transfection efficiency) luciferase. **P < 0.01 and ***P <
0.001 compared with vehicle-treated cells. +P < 0.05 and ++P < 0.01 compared with
Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (9, 20) = 6.790. P < 0.001 (B) F
value (13, 28) = 8.995. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 3.3 R(+)WIN55,212-2 inhibits LPS and Poly(I:C) induction of TNF-α
expression in U373-CD14 astrocytoma cells.
U373-CD14 astrocytoma were pre-treated with or without various concentrations of
R(+)WIN55,212-2 (A+C) or S(-)WIN55,212-2 (B+D) for 1 h prior to stimulation in
the presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 24 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. ***P < 0.001
compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (13, 28) = 34.13. P < 0.001 (B) F
value (13, 28) = 94.90. P < 0.001 (C) F value (13, 28) = 30.22. P < 0.001 (D) F value
(13, 28) = 99.20. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 3.4 R(+)WIN55,212-2 inhibits LPS and Poly(I:C) induction of TNF-α
expression in primary mouse astrocytes.
Primary astrocyte cultures prepared from neonatal murine brains were pre-treated with
or without various concentrations of R(+)WIN55,212-2 (A+C) or S(-)WIN55,212-2
(B+D) for 1 h prior to stimulation in the presence or absence of LPS (100ng/ml) or
Poly(I:C) (25μg/ml) for a further 24 h. Supernatants were assayed for TNF-α levels
by sandwich ELISA. **P < 0.01 and ***P < 0.001 compared with vehicle-treated
cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with LPS or Poly(I:C)-
treated cells.
One way ANOVA effect of treatment (A) F value (19, 40) = 57.76. P < 0.001 (B) F
value (19, 40) = 8.564. P < 0.001 (C) F value (19, 40) = 15.62. P < 0.001 (D) F value
(19, 40) = 24.05. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
Figure 3.5 R(+)WIN55,212-2 inhibits Poly(I:C)-induced activation of TNF-α
expression in PBMCs.
PBMCs isolated from healthy subjects (A) and M.S. patients (B) were pre-treated with
or without various concentrations of R(+)WIN55,212-2 for 1 h prior to stimulation in
the presence or absence of Poly(I:C) (25μg/ml) for a further 3 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. ***P < 0.001
compared with vehicle-treated cells. +++P < 0.001 compared with Poly(I:C)-treated
cells. Results are mean +/- S.E.M. of three independent experiments.
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Figure 3.6 R(+)WIN55,212-2 inhibits LPS and Poly(I:C)-induced activation of
IRF7 in HEK293 TLR3/TLR4 and U373-CD14 astrocytoma cells .
HEK293 cells stably transfected with TLR4 (A+B) or TLR3 (C+D) and U373-CD14
astrocytoma cells (E+F) were co-transfected with the trans-activator plasmid pFA-
IRF-7 (25ng), pFR-Luc (60ng), phRL-TK (constitutively expressed Renilla luciferase)
(40ng) and pcDNA3.1 (145ng). Cells were allowed to recover overnight and then pre-
treated with or without various concentrations of R(+)WIN55,212-2 or S(-
)WIN55,212-2 for 1 h prior to stimulation in the presence or absence of LPS
(100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were generated and
assayed for firefly and Renilla (for normalizing transfection efficiency) luciferase.
***P < 0.001 compared with vehicle-treated cells. +P < 0.05 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (9, 20) = 24.10. P < 0.001 (B) F
value (9, 20) = 29.04. P < 0.001 (C) F value (9, 20) = 21.55. P < 0.001 (D) F value (9,
20) = 34.68. P < 0.001 (E) F value (13, 28) = 23.10. P < 0.001 (F) F value (13, 28) =
23.12. P < 0.001. Results are mean +/- S.E.M. of three independent experiments.
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Figure 3.7 R(+)WIN55,212-2 differentially regulates LPS and Poly(I:C)-induced
activation of IRF3 in HEK293 TLR3/TLR4 and astrocytoma cells .
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B+C), U373-CD14
astrocytoma cells (D) and 1321N1 astrocytoma cells (E) were were co-transfected with
the trans-activator plasmid pFA-IRF-3 (30ng) pFR-Luc (60ng), phRL-TK
(constitutively expressed Renilla luciferase) (40ng) and pcDNA3.1 (140ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of R(+)WIN55,212-2 or S(-)WIN55,212-2 for 1 h prior to stimulation
in the presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. *P < 0.05, **P < 0.01 and ***P < 0.001 compared
with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with
LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (9, 20) = 6.124. P < 0.001 (B) F
value (13, 28) = 27.17. P < 0.001 (C) F value (9, 20) = 11.94. P < 0.001 (D) F value
(13, 28) = 35.65. P < 0.001 (E) F value (13, 28) = 45.78. P < 0.001. Results are mean
+/- S.E.M. of three independent experiments.
Figure 3.8 R(+)WIN55,212-2 augments Poly(I:C)-induced activation of the IFN-β
promoter in HEK293 TLR3 and U373-CD14 astrocytoma cells .
HEK293 cells stably transfected with TLR3 (A) and U373-CD14 astrocytoma cells
(B) were co-transfected with IFN-β luciferase reporter plasmid (80ng), phRL-TK
(constitutively expressed Renilla luciferase) (40ng) and pcDNA3.1 (120 ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of R(+)WIN55,212-2 for 1 h prior to stimulation in the presence or
absence of Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were generated and
assayed for firefly and Renilla (for normalizing transfection efficiency) luciferase. *P
< 0.05 compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with Poly(I:C)-treated cells. One way ANOVA effect of treatment (A) F
value (19, 40) = 13.47. P < 0.001 (B) F value (13, 28) = 3.949. P < 0.01. Results are
mean +/- S.E.M. of three independent experiments.
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Figure 3.9 R(+)WIN55,212-2 inhibits Poly(I:C)-induced activation of PRDI/III
and PRDII on the IFN-β promoter in HEK293 TLR3 cells .
HEK293 cells stably transfected with TLR3 were co-transfected with the luciferase
reporter constructs, PRD-I/III-Luc (80ng) (A+B) or PRDII (80ng) (C), phRL-TK
(constitutively expressed Renilla luciferase) (40ng) and pcDNA3.1 (120 ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of R(+)WIN55,212-2 or S(+)WIN55,212-2 for 1 h prior to stimulation
in the presence or absence of Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. *P < 0.05 and ***P < 0.001 compared with vehicle-treated cells. +P <
0.05 and ++P < 0.01 compared with Poly(I:C)-treated cells. One way ANOVA effect
of treatment (A) F value (13, 28) = 20.42. P < 0.001 (B) F value (13, 28) = 9.101. P <
0.001 (C) F value (13, 28) = 19.05. P < 0.001. Results are mean +/- S.E.M. of three
independent experiments.
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Figure 3.10 R(+)WIN55,212-2 differentially regulates LPS and Poly(I:C)-induced
activation of IFN-β mRNA in BMDM cells and primary rat astrocytes .
BMDM cells (A-D) and primary astrocyte cultures prepared from neonatal rat brains
(E+F) were pre-treated with or without various concentrations of R(+)WIN55,212-2 or
S(-)WIN55,212-2 for 1 h prior to stimulation in the presence or absence of LPS
(100ng/ml) or Poly(I:C) (25μg/ml) for a further 16 h.
RNA extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. **P < 0.01 and ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05 and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (9, 20) = 10.59. P < 0.001 (B) F
value (13, 24) = 22.24. P < 0.001 (C) F value (9, 20) = 11.16. P < 0.001 (D) F value
(13, 24) = 18.22. P < 0.001 (E) F value (13, 28) = 9.488. P < 0.001 (F) F value (13,
28) = 14.27. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
Figure 3.11 R(+)WIN55,212-2 inhibits Poly(I:C)-induced activation of IFN-β
mRNA in PBMCs.
PBMCs isolated from healthy subjects (A) and M.S. patients (B) were pre-treated with
or without various concentrations of R(+)WIN55,212-2 for 1 h prior to stimulation in
the presence or absence of Poly(I:C) (25μg/ml) for a further 3 h.
RNA extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. *P < 0.05 compared with vehicle-treated cells. Results are mean
+/- S.E.M. of three independent experiments.
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Figure 3.12 R(+)WIN55,212-2 ameliorates the clinical symptoms of EAE in an
IFN-β-dependent manner.
Protocol for induction of EAE by PLP139-151 (PLP) immunisation (A). Mean clinical
Score (B). EAE was induced in female SJL/J mice (8 weeks old). R(+)WIN55,212-2
was administered (20 mg/Kg) intraperitoneally on days 0, 1, 2, 3, 4 and 5. Rabbit anti-
mouse IFN-β polyclonal antibody was administered intraperitoneally (2 x 103
Neutralizing Units) on days 3 and 5 after PLP immunisation. Control mice received
Cremophor:PBS (20:80) as vehicle.
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Figure 3.13 Characterising the effects of R(+)WIN55,212-2 treatment on the
development of EAE.
Representative images of Luxol fast blue-stained spinal cord sections from untreated
mice, PLP-treated, PLP+WIN-treated and PLP+WIN+antiIFN-β (αIFN-β)-treated
mice illustrating the extent of demyelination and lymphocytic inflammation (A). The
posterior funiculi of the spinal cord were observed under high power (right panels).
Images are representative of data from 4 to 8 animals per treatment group. Scale bars
are 200 and 50 m.
Quantification of (B) spinal cord inflammation and (C) extent of demyelination in
treated groups. Relative (D) GFAP mRNA and (E) CD11b mRNA detection in spinal
cord from vehicle treated, PLP-treated, PLP+WIN-treated and PLP+WIN+αIFN-β
treated mice. Phosphorylated Iκb-α, total Iκb-α and β-actin protein expression in
spinal cord cytosolic fractions from vehicle-treated, PLP-treated, PLP+WIN-treated
and PLP+WIN+αIFN-β-treated mice (F). *P < 0.05, **P < 0.01 and ***P < 0.001 for
differences between WIN-treated mice and other groups. All results are mean +/-
S.E.M..
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4.1 Introduction 
 
Cannabinoids (CBs) are defined as compounds that are either structurally similar 
to δ-9-THC, possess cannabimimetic properties and/or bind to specific CB receptors.  
For a long time the regulatory effects of cannabinoids were attributed to their 
nonspecific intercalation into the lipid bilayer of the cell membrane.  However, to date, 
five CB receptor subtypes have been identified; two cloned receptors (CB1 and CB2) 
(Munro et al., 1993, Matsuda et al., 1990), the orphan receptor (GPR55) (Baker et al., 
2006) and two as yet molecularly uncharacterised receptors (Hajos et al., 2001, Jarai et 
al., 1999).   
The CB1, CB2 and GPR55 receptors belong to the family of the ‘seven trans-
membrane spanning receptors’, namely the G-protein coupled receptors (GPCR) 
(Maccarrone, 2009).  The CB1 and CB2 receptors are single polypeptide receptors.  
Both possess an extracellular N-terminal domain, an intracellular C-terminal domain 
and seven transmembrane helices.  Indeed, the first evidence of a specific CB receptor 
came from the CB inhibition of cyclic adenosine 3’, 5’-monophosphate (cAMP) 
accumulation (Howlett et al., 1986).  This strongly indicated a GPCR-mediated 
mechanism, as GPCR activation leads to the negative regulation of adenylyl cyclase 
(AC) and subsequent inhibition of cAMP.   
The CB1 and CB2 receptors exhibit differential tissue expression patterns.  The 
CB1 receptor is widely distributed in several brain regions (Matsuda et al., 1990) with 
highest density in the cortex, hippocampus, basal ganglia and cerebellum, and mediates 
most of the neurobehavioral effects associated with cannabinoids.  CB1 receptor 
expression is sparse in areas of the brain stem, medulla, and thalamus (Pertwee, 1997) 
and may contribute to the general lack of life threatening effects associated with 
cannabis use.  Over the last few years, the CB1 receptor has been localised in peripheral 
tissues including testis, guinea pig small intestine, the mouse urinary bladder and vas 
deferens (Pertwee, 1997).  In EAE models, mice lacking the CB1 receptor develop more 
severe neuronal damage, thus supporting a role for the CB receptors in regulating 
inflammatory mediated neurodegeneration (Pryce et al., 2003).  Furthermore, CB1 
receptor expression by neurons is required for CB-mediated EAE suppression, while 
CB2 receptor knockdown exacerbates the inflammatory potential of autoreactive T cells 
in this model (Maresz et al., 2007).  Microglia have also been reported to constitutively 
express low levels of the CB1 receptor, but to upregulate the CB2 receptor upon 
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activation (Cabral and Marciano-Cabral, 2005).  The CB2 receptor is predominantly 
expressed in immune tissues such as the spleen and immunocompetent cells (Munro et 
al., 1993), with highest concentration in B cells, NK cells, mast cells and monocytes.  
This strategic location of the CB2 receptor in immunocompetent cells encourages the 
theory of cannabinoids exerting anti-inflammatory effects.  However, CB1 receptor 
mRNA and protein expression have also been found in B cells and certain subsets of T 
cells (Galiègue et al., 1995).  Therefore, the overall expression of CB receptors enables 
them to function as critical mediators in the regulation of the neuroimmune system.  
CB receptors have been cloned from numerous species including rat, mouse and 
human (Howlett et al., 2002).  The CB1 receptor exhibits approximately 98% amino 
acid sequence identity across species while the mouse CB2 receptor has an 82% 
sequence identity to the human CB2 receptor.  The lack of genetic variance across 
species suggests that the CB receptors may be evolutionarily conserved.  Distinction 
between the CB receptors is based on differences in their predicted amino acid 
sequence, signalling mechanisms and tissue distribution.  The CB1 and CB2 receptors 
exhibit approximately 48% amino acid sequence identity (Shire et al., 1996).  Both CB 
receptors primarily signal through the G proteins; G inhibitory (Gi) and G protein (Go).  
CB1 receptor activation of Gi leads to the negative regulation of AC and subsequent 
inhibition of cAMP, the activation of mitogen-activated protein kinase and the 
inhibition of certain voltage-gated calcium channels (Howlett, 2002).  Stimulation of 
CB2 receptors has similar consequences (Bouaboula et al., 1996).    
At submicromolar concentrations, the phytocannbinoid; δ-9-THC, binds to both 
the CB1 and CB2 receptors.  At CB1 receptors, it behaves as a partial agonist and 
exhibits higher efficacy at the CB1 receptor relative to the CB2 receptor (Bayewitch et 
al., 1995).  The synthetic aminoalkylindole; R(+)WIN55,212-2, displays high affinity 
and relative intrinsic activity at both the CB1 and CB2 receptors with a Ki range of 1.89-
123 nM and 0.28-39.3 nM, respectively (Howlett et al., 2002).  However, studies have 
demonstrated moderate selectivity of R(+)WIN55,212-2 in favour of the CB2 receptor 
(Bouaboula et al., 1997).  R(+)WIN55,212-2 mimics δ-9-THC by producing the full 
spectrum of pharmacological effects of δ-9-THC in vivo (Martin et al., 1991).  
However, the inactive enantiomer S(-)WIN55,212-2, lacks activity both in vivo and in 
vitro. 
The discovery of the CB receptors naturally led to the search for the 
endocannabinoid ligands e.g. AEA.  AEA was the first endogenous ligand of the CB 
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receptors to be discovered in porcine brain (Devane et al., 1992).  Subsequently, a 
further four arachidonic acid based natural ligands; 2-Arachidonoylglycerol 
(Mechoulam et al., 1995), 2-Arachidonylglyceryl ether (Hanuš et al., 2001), 
Virodhamine (Porter et al., 2002), and N-arachidonoyl-dopamine (NADA) (Huang et 
al., 2002) have been postulated to act as endocannabinoid ligands.  Signal transduction 
studies and ligand binding studies have suggested that AEA can act at both the CB1 and 
CB2 receptors, although it may be more efficacious at the CB1 receptor (Felder et al., 
1995).   
Studies on the regulatory effects of AEA and R(+)WIN55,212-2 on the two 
molecularly uncharacterised receptors have been reported.  R(+)WIN55,212-2 inhibits 
glutamate release in hippocampal pyramidal cells via a novel CB receptor (Hájos et al., 
2001).  Additionally, there have been indications that the vascular endothelium contains 
a novel CB receptor and AEA causes endothelium-dependent vasorelaxation in arteries 
from CB1/CB2 receptor knockout animals (Jarai et al., 1999).   
Similar to R(+)WIN55,212-2, AEA may also have potential in regulating the 
progression of M.S.  Increased levels of AEA have been reported in tissues from 
inflammatory lesions of M.S. patients (Eljaschewitsch et al., 2006).  AEA ameliorates 
spasticity in CREAE models (Baker et. al. 2001) and inhibits TNF-α production in 
astrocytes in TMEV infected mice (Molina-Holgado et al., 1997).  However, it has also 
been demonstrated that the expression of the enzyme involved in AEA degradation, 
namely FAAH, was upregulated in M.S. lesions, which indicates that the level of this 
endocannabinoid might be reduced in M.S. patients (Benito et al., 2007).   
The discovery of the CB receptors also led to the development of selective CB1 
and CB2 receptor antagonists, SR141716A and SR144528, respectively.  These 
compounds, termed diarylpyrazoles, readily prevent or reverse the effects mediated by 
the CB1 and CB2 receptors (Rinaldi-Carmona et al., 1994, Rinaldi-Carmona et al., 
1996).  Although both antagonists are selective for their respective receptor, they are not 
CB-specific.  As an example, SR141716A at concentrations of 10µM may block 
potassium channels and L-type voltage-operated calcium channels (White and Hiley, 
1998), thereby acting as an inverse agonist.  Interestingly, SR141716A is currently 
marketed in Europe under the name Acomplia
TM
 as a promising alternative therapy 
against cardiovascular and metabolic disease (André and Nicolas, 2009).  However use 
of this treatment can potentially contribute to disease pathogenesis in M.S. (van Oosten 
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et al., 2004) and therefore highlights the neuroprotective and immunosuppressive 
effects of CB agonism.   
Additional established CB1-selective antagonists include LY320135, AM251 
and AM281.  LY320135, developed by Eli Lilly, behaves as an inverse agonist where 
its CB1 affinity is less than that of SR141716A (Felder et al., 1998).  AM251 and 
AM281 are both structural analogues of SR141716A and bind more readily to the CB1 
receptor than the CB2 receptor (Lan et al., 1999a, Lan et al., 1999).  Studies utilising the 
CB receptor antagonists have demonstrated that AEA inhibits LPS induced NFκB and 
IL-8 activation in human gingival fibroblasts, an effect that was antagonised by AM251 
and SR144528 (Nakajima et al., 2006).  However, others have reported on AEA 
inhibition of NFκB in adenocarcinoma cells in a CB receptor-independent manner 
(Sancho et al., 2003).  Likewise, the inhibitory effects of R(+)WIN55,212-2 on NFκB 
activation (Curran et al., 2005) and adhesion molecule expression (Mestre et al., 2009, 
Curran et al., 2005) have also been demonstrated to be independent of the CB1 and CB2 
receptors.   
Various studies suggest that cannabinoids can also target the peroxisome 
proliferator activated receptors (PPAR) specifically the isoforms; PPARα and PPARγ 
(O'Sullivan and Kendall, 2009, Sun et al., 2007, Mestre et al., 2009).  Indeed, the first 
evidence of CB interaction with PPARs was demonstrated in 2002, where lipoxygenase 
metabolism of 2-Arachidonoylglycerol produced a metabolite that increased the 
transcriptional activity of PPARα (Kozak et al., 2002). 
PPARs belong to a family of nuclear receptors comprising three isoforms: α, β 
and γ.  PPARα was the first isoform to be identified (Issemann and Green, 1990) and 
was named mostly due its ability to increase hepatic peroxisome volume and density, or 
induce peroxisome proliferation in rodent liver (Lee et al., 1995).  PPARs contain an N-
terminal domain with a ligand-independent transcription activation function 1 (AF-1) 
domain, a DNA binding domain with two zinc fingers, a hinge region, and a C-terminal 
ligand binding domain (LBD) followed by a ligand-dependent transcription AF-2 
domain (Zoete et al., 2007).  While the AF-2 domain interacts directly with several 
transcriptional co-activator complexes including steroid receptor co-activator 1 (SRC1) 
and CBP/p300, the AF-1 domain is responsible for enhancing the interaction between 
AF-2 and co-activator complexes (Kilroy et al., 2009, Bugge et al., 2009). 
PPARs are ligand activated transcription factors.  In resting cells, PPARs are 
mainly localised in the nucleus and bound to various transcription co-repressors 
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including nuclear receptor co-repressor/silencing mediator for retinoid and thyroid 
hormone receptors (NCoR/SMRT) (Dowell et al., 1999).  NCoR/SMRT represses gene 
transcription through association with histone deacetylases.  However, upon PPAR 
ligand activation via its LBD, a conformational change occurs where PPARs 
heterodimerise with the retinoid X receptor (RXR) (Daynes and Jones, 2002).  Agonist 
induced activation of PPARs promotes co-repressor dissociation, co-activator 
association within the LBD and when complexed with RXR, PPARs bind to specific 
DNA response elements termed peroxisome proliferator response element (PPRE).  
PPRE have been found in the promoter regions of most PPAR regulated genes that are 
primarily involved in the regulation of metabolism and energy homeostasis, cell 
differentiation and inflammation (Sanderson and Kersten, 2010, Bishop-Bailey and 
Bystrom, 2009).  Each PPAR isoform is encoded by separate genes and differentially 
expressed in various tissues including liver, heart, muscle and adipose tissue (Peters et 
al., 2005).  All three PPAR isoforms are also expressed in the brain and peripheral 
nervous system (Moreno et al., 2004; Cimini et al., 2005).   
Ligands of PPARα include members of the fibrate family such as fenofibrate 
that is used clinically in the treatment of cardiovascular disease while PPARγ ligands 
include the thiazolidinediones (TZDs) which is used to treat type-2 diabetes (Baranova, 
2008).   
In relation to the TLR4 signalling pathway, fenofibrate has been demonstrated to 
inhibit the expression of various members of the IL-12 family of cytokines including 
IL-12, IL-23, and IL-27 in LPS stimulated microglia (Xu et al., 2007).  Xu and 
colleagues also confirmed the inhibitory effects of fenofibrate on mRNAs encoding 
TLR4, CD14 and MyD88, which all contribute to the activation of NFκB.  A recent 
study also provides evidence for the ability of fenofibrate to downregulate the nuclear 
translocation of p65 and to significantly inhibit the DNA binding of NFκB in a dose-
dependent manner (Zak et al., 2010), an effect that is distinct from R(+)WIN55,212-2 
mechanism on NFκB (Curran et al., 2005).  However, comparable to the synthetic 
cannabinoid (Arevalo-Martin et al., 2003), fenofibrate has also been reported to 
ameliorate the clinical signs of EAE by inhibiting CD4
+ 
T cells (Lovett-Racke et al., 
2004).   
The PPARγ ligand; 15d-PGJ2, a metabolite from the prostaglandin synthesis 
pathway (Forman et al., 1995), inhibits phorbol ester-induced nitric oxide, TNF-α, IL-1 
and IL-6 production by antagonising the transcriptional activity of AP-1 and NFκB in 
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cells of the monocyte/macrophage lineage (Jiang et al., 1998). Similar to 
R(+)WIN55,212-2 and fenofibrate, 15d-PGJ2 treatment also significantly reduces the 
severity of clinical signs associated with EAE (Diab et al., 2002). 
Selective PPAR antagonists are also available including MK886 and GW6471 
(PPARα), and GW9662 (PPARγ).  MK886 is an indole compound originally used to 
induce apoptosis and has now been shown to function as a non-competitive inhibitor of 
PPARα (Kehrer et al., 2001).  GW6471 functions by completely inhibiting GW409544-
induced activation of PPARα and induces a PPARα conformation that interacts 
efficiently with co-repressors (Xu et al., 2002).  GW409544, an L-tyrosine analog, is a 
potent and selective full agonist for PPARα.  The recruitment of co-repressors to 
PPARα is enhanced by GW6471.  The chemical structure of the PPARα antagonist is 
similar to that of GW409544 except that the carboxylate group of GW409544 has been 
modified into an amide group in GW6741 (Xu et al., 2002).  GW9662 is an irreversible 
PPARγ antagonist (Mestre et al., 2009). 
 Given the ability of cannabinoids to engage both CB- and non CB-receptors, this 
chapter aimed to characterise the pharmacology of the regulatory effects of 
R(+)WIN55,212-2 as described in the previous chapter.  In addition to defining the 
receptors that mediate R(+)WIN55,212-2 actions, the endocannabinoid, AEA and 
PPARα agonist, fenofibrate, were also assessed for their ability to mimic the regulatory 
effects of R(+)WIN55,212-2..    
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4.2 Results 
 
4.2.1 Regulatory effects of Anandamide on NFκB and IRF7 activation by TLR 
ligands.   
 
In the previous chapter, it was observed that R(+)WIN55,212-2 inhibits TLR3 
and TLR4 induced transcriptional activation of NFκB and IRF7.  As a result, it was next 
of interest to investigate the regulatory effects of AEA and to determine whether this 
endocannabinoid behaved in a similar manner to R(+)WIN55,212-2.   
The NFκB pathway was initially examined.  Treatment with LPS significantly 
enhanced the transcriptional activation of the NFκB-regulated reporter gene where pre-
treatment with various concentrations of AEA caused a dose-dependent inhibition of 
LPS-induced activation of NFκB (Fig. 4.1A) which is consistent with a previous study 
(Nakajima et al., 2006).  However, pre-exposure of HEK293 TLR3 cells to AEA failed 
to influence the Poly(I:C)-induced activation of NFκB (Fig. 4.1B).  This indicates that 
AEA differentially regulates NFκB activation by TLR ligand activation.    
The previously reported inhibitory effects of R(+)WIN55,212-2 on IL-1β-
induced activation of NFκB in 1321N1 astrocytoma cells (Curran et al., 2005) was next 
used as a cell model to investigate if AEA mimicked this effect.  Stimulation of 1321N1 
astrocytoma cells with IL-1β enhanced NFB activation (Fig. 4.1C) and AEA treatment 
attenuated this response.  The sensitivity of the TLR4 and IL-1 pathways to AEA 
suggests that the latter may target the MyD88 dependent pathway  
The regulatory effect of AEA on TLR ligand activation of IRF7 was next 
assessed.  LPS stimulation resulted in significant activation of IRF7 (Fig. 4.2A) where 
pre-treatment with AEA robustly and dose-dependently attenuated LPS-induced 
activation of IRF7.  AEA also significantly inhibited Poly(I:C)-induced activation of 
IRF7 (Fig. 4.2B). 
 
4.2.2 Anandamide inhibits TNF-α expression by TLR ligands.   
 
R(+)WIN55,212-2 significantly inhibits TNF-α expression by TLR ligand 
activation.  The regulatory effects of AEA on TNF-α production by TLR ligand 
activation was subsequently assessed in U373-CD14 astrocytoma cells.  Cells showed 
robust induction of TNF-α expression in response to LPS (Fig. 4.3A) and Poly(I:C) 
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(Fig. 4.3B) stimulation and the higher concentrations of AEA blunted TNF-α expression 
in response to both ligands. 
 
4.2.3 Anandamide differentially regulates IRF3 activation by TLR ligands.   
 
R(+)WIN55,212-2 differentially regulates IRF3 activation by TLR3 and TLR4 
ligand stimulation.  As a result, AEA was assessed for its regulatory function on IRF3 
activation by TLR ligands.  Exposure of HEK293 TLR4 cells to LPS enhanced IRF3 
luciferase activity, and this was abrogated by AEA in a dose-dependent manner (Fig. 
4.4A).  Treatment of HEK293 TLR3 cells with Poly(I:C) also enhanced IRF3 luciferase 
activity (Fig. 4.4B).  Whilst AEA showed a trend towards augmentation of Poly(I:C)-
induced activation of IRF3 (Fig 4.4B), unlike R(+)WIN55,212-2 treatment this failed to 
reach statistical significance.  
 
4.2.4 Anandamide differentially regulates activation of the IFN-β promoter and 
IFN-β mRNA by TLR ligands.   
 
Due to the therapeutic role of IFN-β in M.S. patients and the reported ability of 
AEA to act as a positive neuromodulator of the disease (Eljaschewitsch et al., 2006, 
Baker et al., 2003), it was of significance to assess the regulatory effects of AEA on the 
IFN-β promoter and IFN-β mRNA following TLR ligand activation.  HEK293 TRL3 
cells were transfected with the IFN-β luciferase reporter plasmid and subsequently 
stimulated with Poly(I:C).  This resulted in significant activation of the IFN-β promoter 
(Fig. 4.5A) and pre-treatment with AEA significantly and dose dependently enhanced 
the response. 
In an effort to delineate the mechanism underlying the regulatory actions of 
AEA, transcriptional regulation of the IFN-β gene by TLR ligand activation was probed 
as a potential target for AEA.  Real-time PCR was used to quantitate levels of mRNA 
encoding IFN-β.  LPS treatment enhanced the expression of IFN- mRNA in BMDM 
cells, and this was blocked by pre-treatment with AEA (Fig. 4.6A).  However, AEA 
treatment strongly augmented Poly(I:C) induction of IFN- mRNA (Fig. 4.6B).   
Primary rat astrocytes were next used as a more physiologically relevant model 
system to further investigate the regulatory effects of AEA on IFN-β mRNA.  Similar to 
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results observed in BMDM cells, treatment with AEA reduced LPS (Fig. 4.6C), but 
enhanced Poly(I:C)-induced activation (Fig. 4.6D) of IFN- mRNA. 
In conclusion, AEA appears to largely mimic the regulatory effects of 
R(+)WIN55,212-2 on TLR signalling pathways. 
 
4.2.5 R(+)WIN55,212-2 inhibits TLR3 ligand activation of NFκB and IRF7 in a 
cannabinoid receptor independent manner.   
 
Recent studies of cannabinoid-mediated effects in various systems, including the 
immune system, have produced an increasing body of evidence suggesting 
R(+)WIN55,212-2 and other cannabinoid exerting their immunomodulatory effects in a 
CB receptor independent manner (Curran et al., 2005, Mestre et al., 2009, Kaplan et al., 
2003, Sancho et al., 2003).  As a result of the above studies, it was of interest now to 
assess the involvement of the CB receptors in mediating the inhibitory effects of 
R(+)WIN55,212-2 on NFκB and IRF7 activation.  This was explored by assessing the 
ability of the CB1 and CB2 receptor antagonists, SR141716A and SR144528, 
respectively, to modulate the regulatory effects of R(+)WIN55,212-2 in HEK293 TLR3 
cells.  The doses used for the CB antagonists were 1μM and this was governed by their 
previously described affinities and inhibitory potential at the CB receptors (White and 
Hiley, 1998). 
HEK293 TLR3 cells were pre-treated with the respective CB receptor antagonist 
(1µM) for 1 hour, prior to treatment with R(+)WIN55,212-2 (20µM) for 1 hour and 
Poly(I:C) treatment for a further 6 hours.  Cells were subsequently assayed for the 
induction of a NFκB-regulated luciferase gene.  SR141716A failed to influence either 
the Poly(I:C)-induced activation of NFκB, or the inhibitory effects of R(+)WIN55,212-
2 on the induction process (Fig. 4.7A).  Similar results were also obtained upon 
examination with the CB2 receptor antagonist, SR144528 (Fig. 4.7B).   
SR141716A (Fig. 4.7C) or SR144528 (Fig. 4.7D) treatment also had no 
influence on the Poly(I:C)-induced activation of IRF7, or the inhibitory effects of 
R(+)WIN55,212-2 on the induction process.  Overall, these results indicate the lack of 
involvement of the CB receptors in mediating the inhibitory effects of R(+)WIN55,212-
2 on the IRF7 and NFκB pathways.  
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4.2.6 R(+)WIN55,212-2 and Anandamide inhibit TLR induction of TNF-α in a CB 
receptor independent manner. 
 
To investigate whether the CB receptor antagonists, SR141716A and SR144528, 
were capable of blocking the inhibitory effect of R(+)WIN55,212-2 on TLR ligand 
activation of TNF-α expression, U373-CD14 astrocytoma cells were pre-treated for 1 
hour with 1µM of SR141716A or SR144528 prior to treatment with 20µM of 
R(+)WIN55,212-2 for 1 hour followed by TLR ligand activation for 24 hours.  U373-
CD14 astrocytoma supernatants were subsequently assayed for TNF-α production.  
Both antagonists failed to block the inhibitory effect of R(+)WIN55,212-2 on TNF-α 
expression by LPS (Fig. 4.8A and Fig. 4.8B) and Poly(I:C) (Fig. 4.8C and Fig. 4.8D). 
AEA can also signal through the CB receptors (Felder et al., 1995), however 
research has also demonstrated AEA exerting its regulatory effects independent of both 
CB receptors (Sancho et al., 2003).  Similar to R(+)WIN55,212-2, SR141716A failed to 
block the inhibitory effect of AEA on TNF-α expression induced by LPS (Fig. 4.9A) 
and Poly(I:C) (Fig. 4.9C) treatment.  A comparable result was also observed with 
SR144528 treatment in LPS (Fig. 4.9B) and Poly(I:C) (Fig. 4.9D) stimulated cells and 
is consistent with a recent report (Cencioni et al., 2010).  The above results again 
suggest a CB receptor independent mechanism for the endocannabinoid. 
 
4.2.7 R(+)WIN55,212-2 augments TLR3 ligand activation of IRF3 in a cannabinoid 
receptor independent manner.   
 
We have previously shown that R(+)WIN55,212-2 augments Poly(I:C)-induced 
activation of IRF3.  As a result, the role of the CB receptors in this process was next 
examined.  HEK293 TLR3 cells were pre-treated with the specific antagonist (1µM) for 
1 hour, prior to treatment with R(+)WIN55,212-2 (20µM) for 1 hour and Poly(I:C) 
treatment for a further 6 hours.  The cells were subsequently assayed for IRF3 
activation.  Both SR141716A and SR144528 failed to affect R(+)WIN55,212-2 induced 
potentiation of IRF3 activation by Poly(I:C) (Fig. 4.10A and Fig. 4.10B) respectively.  
These results additionally indicate the clear lack of involvement of the CB receptors in 
mediating the regulatory effects of R(+)WIN55,212-2 on various transcription factors 
employed by the TLR3 signalling pathway.   
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4.2.8 R(+)WIN55,212-2 augments TLR3 ligand activation of IFN-β mRNA in a 
cannabinoid receptor independent manner.   
 
 As previously observed, R(+)WIN55,212-2 augments Poly(I:C) activation of 
IFN-β mRNA following TLR3 ligand activation.  The CBs receptors were now probed 
as potential targets in mediating this increased activation.  BMDM cells were treated 
with the specific CB receptor antagonists (1µM) for 1 hour, prior to treatment with 
R(+)WIN55,212-2 (20µM) for 1 hour and Poly(I:C) treatment for a further 16 hours.  
The CB1 and CB2 selective receptor antagonists, SR141716A and SR144528 
respectively, both failed to regulate the effects of R(+)WIN55,212-2 on Poly(I:C)-
induced expression of IFN-β mRNA (Fig. 411A and Fig. 4.11B).  Overall, these 
findings indicate that the regulatory effects of R(+)WIN55,212-2 on the TLR3-IRF3-
IFN-β axis are mediated independently of the CB1 and CB2 receptors.   
 
4.2.9 The regulatory effects of R(+)WIN55,212-2 on TLR3 ligand activation of 
IRF3, IRF7 and IFN-β mRNA are independent of Gi protein signalling. 
 
Both CB receptors primarily signal through Gi proteins.  To further confirm the 
lack of involvement of the CB receptors in the observed effects of R(+)WIN55,212-2, 
the dependence of the latter on Gi-protein signalling was explored.  Cannabinoid 
receptors when coupled to a heterotrimeric Gi-protein can be selectively inactivated by 
pre-treatment with pertussis toxin (PTX).  As a result, it was of interest to negate any 
possible contribution of Gi-proteins to the observed regulatory effects of 
R(+)WIN55,212-2 on TLR3-induced activation of IRF7, IRF3 and IFN-β mRNA. 
HEK293-TLR3 cells were challenged with PTX (50 ng/ml) for 1 hour prior to 
treatment with R(+)WIN55,212-2 (20µM) for 1 hour and further stimulated with 
Poly(I:C) for 6 hours.  PTX failed to modulate the regulatory effects of 
R(+)WIN55,212-2 on Poly(I:C)-mediated induction of IRF3 (Fig 4.12A), and IRF7 (Fig 
4.12B), thus further arguing against a role for the CB receptors in mediating the 
regulatory effects of R(+)WIN55,212-2.   
The sensitivity of PTX treatment on R(+)WIN55,212-2 regulatory effects of 
IFN-β mRNA was also assessed in BMDM cells treated with LPS (Fig. 4.13A) and 
Poly(I:C) (Fig. 4.13B)  The inability of PTX to modulate the regulatory effects of 
R(+)WIN55,212-2 on LPS/Poly(I:C)-mediated induction of IFN-β mRNA expression 
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indicates no involvement of the classical CB receptors and also their coupling to Gi 
proteins. 
 
4.2.10 The regulatory effects of R(+)WIN55,212-2 on TLR ligand activation of 
TNF-α expression are independent of Gi protein signalling. 
 
The role of the CB receptors in mediating the inhibitory effects of 
R(+)WIN55,212-2 on pro-inflammatory TNF expression was next assessed.  U373-
CD14 astrocytoma cells were challenged with PTX (50 ng/ml) for 1 hour, prior to 
treatment with R(+)WIN55,212-2 (20µM) for 1 hour and further stimulated with LPS or 
Poly(I:C) for 24 hours.  The cells were assayed for TNF-α expression in response to 
LPS (Fig. 4.14A) and Poly(I:C) (Fig. 4.14B) treatment.  In both assays, 
R(+)WIN55,212-2 inhibitory effects on TNF-α expression were insensitive to PTX 
treatment which is consistent with a previous report (Facchinetti et al., 2003).   
The above findings prompted an analysis of the expression levels of the two CB 
receptors in various cell models.  It has previously been demonstrated that 1321N1 
astrocytoma cells do not express the CB1 or CB2 receptors (Curran et al., 2005).  As a 
result, it was of particular interest to assess CB receptor expression in U373-CD14 
astrocytoma cells owning to the TLR expression similarity between the cell models.  
The expression of the CB receptors was also examined in BMDM cells.  CB receptor 
expression was approached using RT-PCR to specifically amplify regions of the CB1 
and CB2 receptor cDNAs.  As it had previously been shown that B cells express high 
levels of CB receptors (Galiegue, 1995), the Burkitt lymphoma B (BJAB) cell line was 
utilised as a positive control both for the primers and the RT-PCR procedure.  RT-PCR 
analysis resulted in the generation of products with the predicted sizes of 500 bp (CB1) 
and 400 bp (CB2) from U373-CD14 astrocytoma cDNA (Fig. 4.15A) demonstrating the 
presence of the CB receptors in this cell line.  Interestingly, subjecting cDNA from 
BMDM cells to RT-PCR analysis also resulted in the expression of such products (Fig. 
4.15B).  To confirm the viability of the cell’s RNA as a source for RT-PCR analysis, 
primers specific for the housekeeping human and mouse GAPDH gene were used to 
amplify an approx 450 bp product (not shown).  Overall, this illustrates the presence of 
the CB1 and CB2 receptors in the U373-CD14 astrocytoma and BMDM cells and is 
consistent with previous data demonstrating the expression of the CB receptors in 
U373-CD14 astrocytoma cells (Hart et al., 2004).  Despite the presence of both CB 
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receptors in both tested cell models, it is clearly evident that the current studied CBs 
regulatory effects are not mediated via the CB receptors.  Subjecting cDNA from 
HEK293 cells to RT-PCR analysis resulted in the failure to generate any CB receptor 
products, indicating the absence of known CB receptors in this cell line (data not 
shown).  This consistent with CB receptor studies having to transfect each CB receptor 
into HEK293 cells (Vásquez et al., 2003, Lauckner et al., 2005).  In addition, the 
absence of the CB receptors in HEK293 cells further argues against a role for the CB 
receptors in mediating the regulatory effects of R(+)WIN55,212-2 and AEA. 
 
4.2.11 Fenofibrate inhibits NFκB and IRF7 activation by TLR ligands. 
 
Due to the ability of R(+)WIN55,212-2 and AEA to interact with PPARα 
(O'Sullivan and Kendall, 2009, Sun et al., 2007, Mestre et al., 2009), its respective 
agonist, fenofibrate, was probed for its ability to mimic the regulatory effects of the 
cannabinoids. 
Pre-treatment of HEK293 TLR4 or TLR3 cells with various concentrations of 
fenofibrate caused a dose-dependent inhibition of LPS- (Fig. 4.16A) and Poly(I:C)-
induced (Fig. 4.16B) activation of NFκB.  A comparable, yet more potent profile was 
also observed in U373-CD14 astrocytoma cells (Fig 4.16C and Fig. 4.16D), indicating 
that this effect is not cell type-specific.  
In IRF7 luciferase assays, fenofibrate strongly and dose dependently inhibited 
both LPS- (Fig. 4.17A) and Poly (I:C)-induced (Fig. 4.17B) activation of the 
transcription factor.  Similar results were also observed in U373-CD14 astrocytoma 
cells (Fig. 4.17C and Fig. 4.17D), where higher concentrations were more effective. 
 
4.2.12 Fenofibrate inhibits TNF-α expression by TLR ligands.   
 
The regulatory effect of fenofibrate on TLR-induced expression of the 
proinflammatory protein TNF-α was next assessed.  Stimulation of BMDM cells with 
LPS and Poly(I:C) for 24 hours induced significant TNF-α expression and fenofibrate 
treatment inhibited expression in both cases in a dose dependent manner (Fig. 4.18A 
and Fig. 4.18B).  The inhibitory effects of fenofibrate on TNF-α expression were also 
consistent in U373-CD14 astrocytoma cells following LPS (Fig. 4.18C) and Poly(I:C) 
(Fig. 4.18D) treatment. 
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4.2.13 Fenofibrate differentially regulates IRF3 activation by TLR ligands. 
 
The regulatory effects of fenofibrate on the activation of the IRF3 pathway were 
next assessed.  As illustrated in Fig. 4.19A, exposure of HEK293 TLR4 cells to LPS 
enhanced IRF3 luciferase activity, and this was abrogated by fenofibrate treatment 
which is consistent with a recent study (Koch et al., 2010).  Treatment of HEK293 
TLR3 cells with Poly(I:C) enhanced IRF3 luciferase activity and similar to 
R(+)WIN55,212-2, pre-treatment with fenofibrate also potentiated the response (Fig. 
4.19B).  Similar results were also evident in U373-CD14 astrocytoma cells (Fig. 4.19C) 
following Poly(I:C) treatment.   
 
4.2.14 Fenofibrate differentially regulates activation of the IFN-β promoter and 
IFN-β mRNA by TLR ligands. 
 
The regulatory effects of fenofibrate on activation of the IFN-β promoter were 
next examined.  Pre-treatment with fenofibrate enhanced Poly(I:C)-induced activation 
of the IFN- promoter in HEK293 TLR3 cells (Fig. 4.20A) and this was apparent at low 
concentrations of fenofibrate.  Pre-exposure of U373-CD14 astrocytoma cells to 
fenofibrate also notably augmented Poly(I:C)-induced activation of the IFN-β promoter 
(Fig.. 4.20B).  However this was evident at higher concentrations of the drug.  
The regulatory actions of fenofibrate on IFN-β mRNA expression were then 
explored.  Treatment of BMDM cells with Poly(I:C) caused robust activation of IFN-β 
mRNA and this activation was further amplified by pre-treatment with fenofibrate (Fig. 
4.21B).  However, in contrast, pre-treatment with fenofibrate reduced LPS induction of 
IFN- mRNA (Fig. 4.21A).  These results are also reproduced in primary rat astrocytes 
where pre-treatment with fenofibrate repressed LPS-induced (Fig. 4.21C) but 
augmented Poly(I:C)-induced expression of IFN-β mRNA (Fig. 4.21D). 
These results further emphasise the differential role of fenofibrate on TLR3 and 
TLR4 signalling pathways.  Comparable to R(+)WIN55,212-2, fenofibrate also acts as a 
positive regulator of Poly(I:C)-induced activation of IRF3 and its associated IFN-β 
mRNA expression.   
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4.2.15 The PPARα antagonist, GW6471 induces selective effects on the regulatory 
actions of R(+)WIN55,212-2 and Anandamide. 
 
The regulatory effects of the PPARα agonist fenofibrate are very similar to the 
regulatory effects of cannabinoids on TLR signalling.  This hinted at a potential role for 
PPARα in mediating the effects of cannabinoids and this was directly addressed by use 
of a PPARα antagonist.  
The ability of the PPARα antagonist; GW6471 to alter the inhibitory effects of 
R(+)WIN55,212-2 and AEA on NFκB and IRF7 was initially examined.  HEK293 
TLR3 cells were pre-treated with GW6471 (1µM) for 1 hour, prior to treatment with 
R(+)WIN55,212-2 or AEA (20µM) for 1 hour and Poly(I:C) treatment for a further 6 
hours.  In both cannabinoid treatment groups, GW6471 failed to influence either the 
Poly(I:C)-induced activation of NFκB, or the strong inhibitory effects of each drug on 
the transcriptional activity of NFκB (Fig. 4.22A and Fig. 4.22B).  In parallel, GW6471 
treatment also failed to regulate the strong inhibitory effects of R(+)WIN55,212-2 on 
Poly(I:C)-induced activation of IRF7 (Fig. 4.23A).  The results presented here clearly 
indicate that the inhibitory effects of R(+)WIN55,212-2 and AEA on NFκB or IRF7 
activity are insensitive to antagonism by GW6471.  Despite this, the upregulation of 
IRF3 induced by R(+)WIN55,212-2 in response to Poly(I:C) treatment was slightly 
reversed by the addition of GW6471 (Fig. 4.23B). 
The involvement of PPARα in regulating the positive effects of 
R(+)WIN55,212-2 and AEA on Poly(I:C)-induced activation of the IFN-β promoter was 
next examined. The PPARα antagonist reversed the regulatory effects of 
R(+)WIN55,212-2 on Poly(I:C)-induced activation of the IFN-β promoter (Fig. 4.24A).  
However it failed to affect the regulatory actions of AEA on the same response (Fig. 
4.24B).  This was further corroborated in BMDM cells where GW6471 blocked the 
regulatory effects of R(+)WIN55,212-2 on Poly(I:C) mediated induction of IFN-β 
mRNA (Fig. 4.25B).  However, the PPARα antagonist failed to affect the inhibitory 
effects of R(+)WIN55,212-2 on LPS mediated induction of IFN-β mRNA (Fig. 4.25A).   
To investigate whether GW6471 was capable of blocking the inhibitory effect of 
R(+)WIN55,212-2 on TLR-induced activation of TNF-α, U373-CD14 astrocytoma cells 
and primary mouse astrocytes were employed.  Both cell types were pre-treated for 1 
hour with 1µM of GW6471 prior to treatment with 20µM of R(+)WIN55,212-2 for 1 
hour followed by LPS or Poly(I:C) treatment for 24 hours.  In U373-CD14 astrocytoma 
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cells, GW6471 failed to block the inhibitory effect of R(+)WIN55,212-2 on TNF-α 
production induced by LPS (Fig. 4.26A) and Poly(I:C) (Fig. 4.26B) treatment.  This 
observation was also apparent in primary mouse astrocytes following LPS (Fig. 4.26C) 
and Poly(I:C) (Fig. 4.26D) treatment.   
 
4.2.16 The PPARγ antagonist, GW9662 induces selective effects on the regulatory 
actions of R(+)WIN55,212-2. 
 
Although much evidence is attributed to R(+)WIN55,212-2 regulatory effects 
via PPARα, a current study (Mestre et al., 2009) has elaborated on findings by our 
laboratory (Curran et al., 2005).  Mestre and colleagues described the ability of 
R(+)WIN55,212-2 to suppress ICAM-1 and VCAM-1 in the brain endothelium of 
TMEV-IDD mice.  This effect was again independent of the CB receptors but 
dependent on PPARγ, as its selective antagonist; GW9662, blocked R(+)WIN55,212-2 
inhibitory effects on adhesion molecule expression.   
Due to the selective role of PPARα in mediating the regulatory effects of the 
studied cannabinoid compounds and taking into consideration the above observations, it 
was now of interest to assess PPARγ as a potential target in the pharmacological profile 
of R(+)WIN55,212-2.   
The ability of GW9662 to alter the regulatory effects of R(+)WIN55,212-2 on 
TLR3 induction of IRF7 and IRF3 activity was initially examined.  Following 
transfection of HEK293 TLR3 cells with the relevant constructs, the cells were pre-
treated with GW9662 (1µM) for 1 hour, prior to treatment with R(+)WIN55,212-2 
(20µM) for 1 hour and Poly(I:C) treatment for a further 6 hours.  GW9662 partially 
blocked R(+)WIN55,212-2 inhibitory effects on Poly(I:C)-induced activation of IRF7 
(Fig. 4.27A).  However the PPARγ antagonist robustly reversed R(+)WIN55,212-2 
augmentation of Poly(I:C)-induced activation of IRF3 (Fig. 4.27B).  Similar results 
were also observed upon examination of IFN-β mRNA expression in BMDM cells 
where the PPARγ antagonist blocked the regulatory effects of R(+)WIN55,212-2 on 
Poly(I:C)-induced activation of IFN-β mRNA (Fig. 4.28B).  However, GW9662 failed 
to affect R(+)WIN55,212-2 inhibitory effects on LPS-induced activation of IFN-β 
mRNA expression (Fig 4.28A). 
The role of PPARγ in mediating the inhibitory effects of R(+)WIN55,212-2 on 
TLR-induced expression of TNF-α was next examined in U373-CD14 astrocytoma cells 
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and primary mouse astrocytes.  Both cell types were pre-treated for 1 hour with 1µM of 
GW9662 prior to treatment with 20µM of R(+)WIN55,212-2 for 1 hour followed by 
LPS or Poly(I:C) treatment for 24 hours.  GW9662 slightly reversed the inhibitory 
effects of R(+)WIN55,212-2 on Poly(I:C) induction of TNF-α expression in U373-
CD14 astrocytoma cells (Fig. 4.29B) where complete reversal was observed in primary 
astrocytes (Fig. 4.29D).  However, the inhibitory effects of R(+)WIN55,212-2 on LPS-
induced activation (Fig. 4.29A and Fig. 4.29C) of TNF-α expression was insensitive to 
GW9662 treatment.   
Given that some of the effects of the cannabinoids appear to be PPAR-mediated, 
the ability of cannabinoids to regulate PPAR expression was next investigated.  BMDM 
cells were treated with R(+)WIN55,212-2 or AEA (20µM) at various time points.  It 
was found that R(+)WIN55,212-2 treatment resulted in an increase of approximately 7-
fold in PPARα mRNA expression after 1 hour, with highest upregulation of the receptor 
after 16 hours (Fig. 4.30A).  PPARγ mRNA expression was also significantly induced 
by R(+)WIN55,212-2 (Fig. 4.30C).  Furthermore AEA treatment also resulted in an 
increased expression of both PPARα and PPARγ mRNAs after 1 hour (Fig. 4.30B and 
Fig. 4.30D), however, in comparison to R(+)WIN55,212-2, AEA failed to retain this 
significant activation as increased time points resulted in downregulation of the PPARs, 
more notably in PPARγ mRNA expression.  This suggests that cannabinoid may exert 
some of their responses by controlling the expression levels of PPARs.   
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4.3 Discussion 
 
The initial part of this chapter focused on the regulatory effects of the 
endocannabinoid, AEA, and it was of interest to assess if its regulatory mechanism was 
similar to R(+)WIN55,212-2.  AEA was found to be a strong suppressor of TLR4 
induced activation of IRF3, NFκB and IRF7.  AEA was also a potent regulator of TLR3 
ligand activation of IRF7, but not of NFκB or IRF3.  Similar to R(+)WIN55,212-2, 
AEA also augmented TLR3 activation of IRF3 albeit significantly less than the 
synthetic cannabinoid.  In respect to transcription factor activation, the TLR4 signalling 
pathway appears to be a more potent target for the regulatory effects of AEA.  This 
translated into effects on downstream gene expression with AEA inhibiting TLR-
induction of TNF-α protein expression whilst enhancing TLR-induced activation of the 
IFN-β promoter and IFN-β mRNA expression   
In an effort to characterise the pharmacological characteristics of 
R(+)WIN55,212-2 and AEA, two independent approaches indicate that the regulatory 
effects of the cannabinoid compounds on various transcription factors and their related 
cytokines, are largely mediated by a mechanism independent of the CB1 and CB2 
receptors.  Firstly, selective antagonists for these receptors mostly failed to influence the 
regulatory action of the cannabinoids.  Secondly, the failure of PTX to interfere with 
R(+)WIN55,212-2 and AEA activity, effectively excludes any contribution of Gi-
proteins to the observed effects.  Indeed, Sagan and colleagues report on AEA and 
R(+)WIN55,212-2 inhibiting cAMP formation through GPCRs distinct from the CB 
receptors (Sagan et al., 1999), which further supports our theory on the pharmacological 
effects of the studied cannabinoids. 
Recent reports on the ability of R(+)WIN55,212-2 and AEA to target PPARs 
lead us to explore the importance of this receptor in mediating the regulatory effects of 
the cannabinoids.  The PPARα agonist; fenofibrate, was initially studied to examine if 
its regulatory role was similar to cannabinoids.  Comparable to R(+)WIN55,212-2 and 
AEA, fenofibrate also inhibited several of the studied transcription factors and TNF-α 
expression.  More importantly, fenofibrate augmented TLR3-induced activation of IRF3 
and IFN-β, thus further supporting an anti-inflammatory role for this fibrate.   
Owing to the regulatory similarities between cannabinoids and fenofibrate, the 
involvement of PPARα in mediating the regulatory effects of R(+)WIN55,212-2 and 
AEA was probed.  The large LBD of PPARα allows for the interaction with a wide 
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variety of fatty acid-derived molecules (Wang et al., 2004).  Despite this, cannabinoids 
are highly lipophilic agents and their ability to overcome the hydrophilic diffusional 
barrier of the cell membrane to access intracellular and nuclear receptors remains 
largely unknown.   
The PPARα antagonist, GW6471, failed to induce any significant effect on the 
inhibitory actions of cannabinoids in the TLR4 signalling pathway.  While agonists of 
PPARα e.g. fenofibrate can strongly suppress the activation of the TLR4 signalling 
pathway (Xu et al., 2007), it appears that PPARα is not the target in mediating the 
regulatory effects of R(+)WIN55,212-2 on TLR4 activation of various transcription 
factors and responsive genes.  This observation is partially consistent with recent 
preliminary work (S Grassin Delyle, 2010).  In addition, similar to our data, AEA has 
also been reported to be insensitive to antagonism by GW6471 (Alhamoruni et al., 
2010).  Furthermore, AEA failed to retain significant activation of PPARα mRNA over 
a longer time period.   
R(+)WIN55,212-2 has also been reported to bind to and increase the 
transcriptional activity of PPARα (Sun et al., 2007).  Likewise, the data presented here 
provides evidence for the ability of R(+)WIN55,212-2 to activate PPARα mRNA.  This 
may contribute to PPARα ligand activation with endogenous targets e.g. 
hydroxydecanoic acid and certain long chain fatty acids (Ziouzenkova and Plutzky, 
2004).  However, while PPARα may not directly facilitate the inhibition of 
R(+)WIN55,212-2 on pro-inflammatory pathways, our preliminary data suggest that 
PPARα may be a potential target site for the regulatory effects of R(+)WIN55,212-2 on 
the TLR3-IRF3-IFN-β signalling axis.  Further studies are necessary to unequivocally 
demonstrate this.  It should be emphasised that not all of the effects of R(+)WIN55,212-
2 on the IFN-β promoter are mediated by PPARα. Indeed the former can augment 
TLR3-induced activation of IRF3 in a PPAR-independent manner whilst in contrast 
fenofibrate inhibits activation of IRF3 in response to polyI:C. Thus whilst 
R(+)WIN55,212-2 employs PPARα to promote activation of AP-1 and the PRDIV 
domain of the IFN-β promoter, it can also utilise a PPARα-independent mechanism that 
overrides any negative regulatory effects of PPARα on IRF3 and the PRDI-III regions 
of the promoter. 
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Much research has provided evidence on AEA targeting PPARγ, including its 
ability to increase transcriptional activation of and bind directly to PPARγ (Bouaboula 
et al., 2005, Gasperi et al., 2007) and inhibit IL-2 in a partial PPARγ dependent 
mechanism (Rockwell and Kaminski, 2004).  The data presented here additionally 
describes AEA increasing PPARγ mRNA; however, similar to its effects on PPARα 
mRNA, AEA decreased activation of PPARγ mRNA over a longer time period.  Despite 
ample literature on AEA interacting with PPARγ, it is still not clear whether PPARγ 
activation is due to direct interaction with AEA or secondary metabolism generating a 
PPARγ active ligand.   
R(+)WIN55,212-2 has also been reported to increase the transcriptional activity 
of PPARγ (O'Sullivan et al., 2009).  Our data suggests that R(+)WIN55,212-2 is a 
potent inducer of PPARγ mRNA.  Furthermore the combination of GW9662 and 
Poly(I:C) treatment slightly blocked R(+)WIN55,212-2 inhibitory effects on IRF7 
activation but completely reversed R(+)WIN55,212-2 augmentation of IRF3 activity 
and IFN-β mRNA expression.   
Much data indicate that cannabinoids, both synthetic and plant-derived, manifest 
at least some effects via PPARs. Such effects include palmitoylethanolamide (PEA)-
induced blunting of β-amyloid (Aβ)-induced inflammation (Scuderi et al., 2011), 
R(+)methanandamide-induced apoptosis (Eichele et al., 2009), cannabidiol- and 
tetrahydrocannabinol-induced vasorelaxation (O'Sullivan et al., 2006; O'Sullivan et al., 
2009), N-Oleoylethanolamine-induced protection following middle cerebral artery 
occlusion (Sun et al., 2007) and ajulemic acid-induced fibroblast differentiation and IL-
8 promoter activity inhibition (Liu et al., 2003). In addition, data presented herein 
demonstrate such PPAR-dependency for the synthetic cannabinoid R(+)WIN55,212-2. 
R(+)WIN55,212-2 belongs to the family of aminoalkylindoles that possess 
cannabimimetic properties despite being structurally dissimilar to plant-derived 
cannabinoids (Pacheco et al., 1991).  Although R(+)WIN55,212-2 displays high affinity 
for both CB1 and CB2 cannabinoid receptors, with moderate selectivity for CB2 
(Howlett, 2002), our laboratory (Curran et al., 2005; Downer et al., 2011) and others 
(Marchalant et al., 2007, Facchinetti et al., 2003, Germain et al., 2002, Nilsson et al., 
2006, Sánchez et al., 2006) have demonstrated cannabinoid receptor-independent effects 
of this aminoalkylindole. Indeed our findings are consistent with PPAR-dependent 
effects of R(+)WIN55,212-2 on cell viability (Giuliano et al., 2009) and adhesion 
molecule expression (Mestre et al.,2009).  It is noteworthy that Mestre and colleagues 
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(2009) demonstrated that R(+)WIN55,212-2 regulates endothelial expression of 
VCAM-1 adhesion molecule independent of CB1 and CB2 receptors, but involvement 
of PPAR receptors was identified, further demonstrating a non cannabinoid-dependent 
effect for this aminoalkylindole.  The selectivity of R(+)WIN55,212-2 in targeting 
PPARα independently of CB1 or CB2 is further supported by data indicating that 
ligands (pyrazol fatty acid amides) incorporating cannabinoid and PPARα features, may 
lack cannabinoid activity (hypothermia, locomotor activity) but behave as potent 
activators of PPARs (Alvarado et al., 2008).  
Since their initial characterisation, PPARs have attracted an increasing amount 
of experimental attention particularly in their role in inflammation.  The mechanistic 
involvement of the PPARs in the innate and adaptive immune systems is a relatively 
new research area.  Despite this, recent observations of the potent anti-inflammatory 
activities of PPARα- and PPARγ-specific ligands in various disease models have been 
reported (Lovett-Racke et al., 2004, Xu et al., 2007).   
In conclusion, it appears that PPARγ, rather than PPARα, is a more potent 
endogenous target in mediating the anti-inflammatory effects of R(+)WIN55,212-2.  
This is particularly evident in relation to the TLR3 signalling pathway.  The overall 
ability of R(+)WIN55,212-2 to augment the Poly(I:C)-induced transcriptional activity 
of IRF3, activation of IFN-β mRNA and the potential of PPARγ to mediate this 
mechanism, is a novel finding.  Furthermore, it appears that the molecular target 
governing R(+)WIN55,212-2 anti-inflammatory effects is distinct from TLR4 signalling 
and is certainly independent of PPARγ.   
This observation, not only broadens the potential use of cannabinoids as 
therapeutic agents, but also supports PPARγ as the likely target.  Whilst PPARγ may act 
as a mediator in manifesting neuroprotective effects of some cannabinoids, it would also 
be of great value to identify the components of the TLR3 signalling pathway that are 
principally targeted in mediating these effects.  This constitutes the major objective of 
the following chapter.  
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Figure 4.1 Anandamide inhibits LPS, Poly(I:C) and IL-1β-induced activation of
NFκB in HEK293 TLR3/TLR4 and 1321N1 astrocytoma cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) and 1321N1
astrocytoma cells (C) were co-transfected with a NFκB-regulated firefly luciferase
reporter (80 ng), phRL-TK (constitutively expressed Renilla luciferase) (40 ng), and
pcDNA3.1 (120 ng). Cells were allowed to recover overnight and then pre-treated
with or without various concentrations of Anandamide for 1 h prior to stimulation in
the presence or absence of LPS (100ng/ml), Poly(I:C) (25μg/ml) or IL-1β (10ng/ml)
for a further 6 h. Cell extracts were generated and assayed for firefly and Renilla (for
normalizing transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-
treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with ligand treated
cells. One way ANOVA effect of treatment (A) F value (14, 30) = 33.23. P < 0.001
(B) F value (15, 32) = 21.43. P < 0.001 (C) F value (13, 28) = 13.36. P < 0.001.
Results are mean +/- S.E.M. of three independent experiments.
HEK293 TLR4 HEK293 TLR3
1321N1
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Figure 4.2 Anandamide inhibits LPS and Poly(I:C)-induced activation of IRF7 in
HEK293 TLR3/TLR4 cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) were co-transfected with
the trans-activator plasmid pFA-IRF-7 (25ng), pFR-Luc (60ng), phRL-TK
(constitutively expressed Renilla luciferase) (40ng) and pcDNA3.1 (145ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of Anandamide for 1 h prior to stimulation in the presence or absence
of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. ***P < 0.001 compared with vehicle-treated cells. +P < 0.05, ++P < 0.01
and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (13, 28) = 37.73. P < 0.001 (B) F
value (13, 28) = 20.79. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.3 Anandamide inhibits LPS and Poly(I:C) induction of TNF-α
expression in U373-CD14 astrocytoma cells.
U373-CD14 astrocytoma cells were pre-treated with or without various concentrations
of Anandamide for 1 h prior to stimulation in the presence or absence of LPS
(100ng/ml) (A) or Poly(I:C) (25μg/ml) (B) for a further 24 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. **P< 0.01 and
***P < 0.001 compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P <
0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (13, 24) = 8.605. P < 0.001 (B) F
value (13, 24) = 21.08. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
Figure 4.4 Anandamide differentially regulates LPS and Poly(I:C)-induced
activation of IRF3 in HEK293 TLR3/TLR4 cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) were were co-transfected
with the trans-activator plasmid pFA-IRF-3 (30ng) pFR-Luc (60ng), phRL-TK
(constitutively expressed renilla luciferase) (40ng) and pcDNA3.1 (140ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of Anandamide for 1 h prior to stimulation in the presence or absence
of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. *P < 0.05 and ***P < 0.001 compared with vehicle-treated cells. ++P <
0.01 and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (13, 24) = 22.74. P < 0.001 (B) F
value (13, 28) = 11.26. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.5 Anandamide regulatory effects on Poly(I:C)-induced activation of the
IFN-β promoter and activation of PRDII on the IFN-β promoter in HEK 293
TLR3 cells.
HEK293 cells stably transfected with TLR3 were co-transfected with IFN-β luciferase
reporter plasmid (80ng) (A) or the luciferase reporter construct; PRD-II-Luc (80ng)
(B), phRL-TK (constitutively expressed renilla luciferase) (40ng) and pcDNA3.1 (120
ng). Cells were allowed to recover overnight and then pre-treated with or without
various concentrations of Anandamide for 1 h prior to stimulation in the presence or
absence of Poly(I:C) (25μg/ml) for a further 6 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05, ++P < 0.01 and +++P < 0.001 compared with Poly(I:C)-treated cells. One
way ANOVA effect of treatment (A) F value (19, 40) = 117.1. P < 0.001 (B) F value
(13, 28) = 20.94. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
Figure 4.6 Anandamide differentially regulates LPS and Poly(I:C)-induced
activation of IFN-β mRNA in BMDM cells and primary rat astrocytes.
BMDM cells (A+B) and primary astrocyte cultures prepared from neonatal rat brains
(C+D) were pre-treated with or without various concentrations of Anandamide for 1 h
prior to stimulation in the presence or absence of LPS (100ng/ml) or Poly(I:C)
(25μg/ml) for a further 16 h. RNA extracts were generated and converted into cDNA.
Samples were subsequently assayed by quantitative real-time PCR for levels of IFN-β
mRNA. Gene expression was calculated relative to the endogenous control and
analysis was performed using the 2-ΔΔCT method. *P < 0.5 and ***P < 0.001
compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells. One way ANOVA effect of treatment
(A) F value (13, 25) = 10.29. P < 0.001 (B) F value (13, 28) = 15.37. P < 0.001 (C) F
value (13, 28) = 10.68. P < 0.001 (D) F value (13, 28) = 24.99. P < 0.001. Results are
mean +/- S.E.M. of three independent experiments.
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Figure 4.7 R(+)WIN55,212-2 inhibits Poly(I:C)-induced activation of NFκB and IRF7
in HEK293 TLR3 cells in a cannabinoid receptor independent manner.
HEK293 cells stably transfected with TLR3 were co-transfected with a NFκB-regulated
firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed Renilla luciferase)
(40 ng), and pcDNA3.1 (120 ng) (A+B). In an separate assay, HEK293 cells stably
transfected with TLR3 were co-transfected with the trans-activator plasmid pFA-IRF-7
(25ng), pFR-Luc (60ng), phRL-TK (constitutively expressed Renilla luciferase) (40ng)
and pcDNA3.1 (145ng) (C+D). Cells were allowed to recover overnight then challenged
for 1 h with SR141716A (1µM) or SR144528 (1µM) prior to treatment with or without
R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the presence or absence of
Poly(I:C) (25µg/ml) for a further 6 h. Cell extracts were generated and assayed for firefly
and Renilla (for normalizing transfection efficiency) luciferase. ***P < 0.001 compared
with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with
Poly(I:C)-treated cells. #P < 0.05 and ###P < 0.001 compared with cells treated with
R(+)WIN55,212-2 in the presence of Poly(I:C). One way ANOVA effect of treatment (A)
F value (10, 19) = 7.946. P < 0.001 (B) F value (10, 22) = 11.39. P < 0.001 (C) F value
(10, 22) = 17.75. P < 0.001 (D) F value (10, 22) = 18.05. P < 0.001. Results are mean +/-
S.E.M. of three independent experiments.
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Figure 4.8 R(+)WIN55,212-2 inhibits LPS and Poly(I:C) induction of TNF-α
expression in U373-CD14 astrocytoma cells in a cannabinoid receptor
independent manner.
U373-CD14 astrocytoma cells were challenged for 1 h with SR141716A (1µM)
(A+C) or SR144528 (1µM) (B+D) prior to treatment with or without R(+)WIN55,212-
2 (20µM) for 1 h and further stimulated in the presence or absence of LPS (100ng/ml)
or Poly(I:C) (25μg/ml) for a further 24 h. Supernatants were assayed for TNF-α levels
by sandwich ELISA. ***P < 0.001 compared with vehicle-treated cells. +P < 0.05
and ++P < 0.01 compared with LPS or Poly(I:C)-treated cells. #P < 0.05 compared
with cells treated with R(+)WIN55,212-2 in the presence of LPS. One way ANOVA
effect of treatment (A) F value (10, 22) = 11.74. P < 0.001 (B) F value (10, 22) =
9.392. P < 0.001 (C) F value (10, 22) = 12.01. P < 0.001 (D) F value (10, 22) = 14.21.
P < 0.001. Results are mean +/- S.E.M. of three independent experiments.
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Figure 4.9 Anandamide inhibits LPS and Poly(I:C) induction of TNF-α
expression in U373-CD14 astrocytoma cells in a cannabinoid receptor
independent manner.
U373-CD14 astrocytoma cells were challenged for 1 h with SR141716A (1µM)
(A+C) or SR144528 (1µM) (B+D) prior to treatment with or without Anandamide
(20µM) for 1 h and further stimulated in the presence or absence of LPS (100ng/ml) or
Poly(I:C) (25μg/ml) for a further 24 h. Supernatants were assayed for TNF-α levels by
sandwich ELISA. *P < 0.05 and ***P < 0.001 compared with vehicle-treated cells.
++P < 0.01 and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 7.866. P < 0.001 (B) F
value (10, 22) = 12.77. P < 0.001 (C) F value (10, 22) = 10.93. P < 0.001 (D) F value
(10, 22) = 16.60. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.10 R(+)WIN55,212-2 augments Poly(I:C)-induced activation of IRF3 in
HEK293 TLR3 cells in a cannabinoid receptor independent manner.
HEK293 cells stably transfected with TLR3 were were co-transfected with the trans-
activator plasmid pFA-IRF-3 (30ng) pFR-Luc (60ng), phRL-TK (constitutively
expressed renilla luciferase) (40ng) and pcDNA3.1 (140ng). Cells were allowed to
recover overnight then challenged for 1 h with SR141716A (1µM) (A) or SR144528
(1µM) (B) prior to treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and
further stimulated in the presence or absence of Poly(I:C) (25µg/ml) for a further 6 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells.
++P < 0.01 compared with Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 40.10. P < 0.001 (B) F
value (10, 22) = 33.29. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.11 R(+)WIN55,212-2 augments Poly(I:C)-induced activation of IFN-β
mRNA in BMDM cells in a cannabinoid receptor independent manner.
BMDM cells were challenged for 1 h with SR141716A (1µM) (A) or SR144528
(1µM) (B) prior to treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and
further stimulated in the presence or absence of Poly(I:C) (25µg/ml) for a further 16 h.
RNA extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. **P < 0.01 compared with vehicle-treated cells. ++P < 0.01
compared with Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 20.60. P < 0.001 (B) F
value (10, 22) = 16.87. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.12 Effects of R(+)WIN55,212-2 on Poly(I:C)-induced activation of IRF3
and IRF7 are independent of Gi protein signalling.
HEK293 cells stably transfected with TLR3 were were co-transfected with the trans-
activator plasmid pFA-IRF-3 (30ng) pFR-Luc (60ng), phRL-TK (constitutively
expressed renilla luciferase) (40ng) and pcDNA3.1 (140ng) (A). In an separate assay,
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF-7 (25ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed Renilla luciferase) (40ng) and pcDNA3.1 (145ng) (B). Cells were allowed
to recover overnight then challenged for 1 h with pertussis toxin (50ng/ml) prior to
treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in
the presence or absence of Poly(I:C) (25µg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. ***P < 0.001 compared with vehicle-treated cells. ++P < 0.01 and +++P <
0.001 compared with Poly(I:C)-treated cells. One way ANOVA effect of treatment
(A) F value (10, 22) = 34.42. P < 0.001 (B) F value (10, 22) = 20.97. P < 0.001.
Results are mean +/- S.E.M. of three independent experiments.
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Figure 4.13 Effects of R(+)WIN55,212-2 on LPS and Poly(I:C)-induced activation
of IFN-β mRNA in BMDM cells are independent of Gi protein signalling.
BMDM cells were pre-treated for 1 h with pertussis toxin (50ng/ml) prior to treatment
with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the
presence or absence of LPS(100ng/ml) (A) or Poly(I:C) (25µg/ml) (B) for a further 16
h. RNA extracts were generated and converted into cDNA. Samples were
subsequently assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene
expression was calculated relative to the endogenous control and analysis was
performed using the 2-ΔΔCT method. *P < 0.05 compared with vehicle-treated cells.
+P < 0.05 and ++P < 0.01 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 9.194. P < 0.001 (B) F
value (10, 22) = 11.82. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.14 Effects of R(+)WIN55,212-2 on LPS and Poly(I:C)-induced activation
of TNF-α expression in U373-CD14 astrocytoma cells are independent of Gi
protein signalling.
U373-CD14 astrocytoma cells were pre-treated for 1 h with pertussis toxin (50ng/ml)
prior to treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and further
stimulated in the presence or absence of LPS (100ng/ml) (A) or Poly(I:C) (25µg/ml)
(B) for a further 24 h. Supernatants were assayed for TNF-α levels by sandwich
ELISA. ***P < 0.001 compared with vehicle-treated cells. +P < 0.05 and ++P < 0.01
compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 9.916. P < 0.001 (B) F
value (10, 22) = 20.21. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.15 Expression of CB1 and CB2 receptors in U373-CD14 astrocytoma
and BMDM cells.
Total cellular RNA was prepared from U373-CD14 astrocytoma (A) and BMDM (B)
cells and subjected to first strand cDNA synthesis using Superscript II reverse
transcriptase and random oligonucleotide primers. PCR amplification was preformed
to selectively amplify regions of CB1 and CB2 cDNA. This resulted in the generation
of products with the predicted size of 500bp (CB1) and 400bp (CB2).
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Figure 4.16 Fenofibrate inhibits LPS and Poly(I:C)-induced activation of NFκB in
HEK293 TLR3/TLR4 and U373-CD14 astrocytoma cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) and U373-CD14
astrocytoma cells (C+D) were co-transfected with a NFκB-regulated firefly luciferase
reporter (80 ng), phRL-TK (constitutively expressed Renilla luciferase) (40 ng), and
pcDNA3.1 (120 ng). Cells were allowed to recover overnight and then pre-treated with or
without various concentrations of Fenofibrate for 1 h prior to stimulation in the presence or
absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with vehicle-treated cells.
++P < 0.01 and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells. One way
ANOVA effect of treatment (A) F value (13, 28) = 10.97. P < 0.001 (B) F value (13, 28) =
33.96. P < 0.001 (C) F value (13, 28) = 39.61. P < 0.001 (D) F value (13, 28) = 77.08. P <
0.001. Results are mean +/- S.E.M. of three independent experiments.
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Figure 4.17 Fenofibrate inhibits LPS and Poly(I:C)-induced activation of IRF7
in HEK293 TLR3/TLR4 and U373-CD14 astrocytoma cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) and U373-CD14
astrocytoma cells (C+D) were co-transfected with the trans-activator plasmid pFA-
IRF-7 (25ng), pFR-Luc (60ng), phRL-TK (constitutively expressed Renilla
luciferase) (40ng) and pcDNA3.1 (145ng). Cells were allowed to recover overnight
and then pre-treated with or without various concentrations of Fenofibrate for 1 h prior
to stimulation in the presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for
a further 6 h. Cell extracts were generated and assayed for firefly and Renilla (for
normalizing transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-
treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with LPS or
Poly(I:C)-treated cells. One way ANOVA effect of treatment (A) F value (13, 28) =
12.00. P < 0.001 (B) F value (13, 28) = 33.96. P < 0.001 (C) F value (13, 28) = 11.36.
P < 0.001 (D) F value (13, 28) = 40.35. P < 0.001. Results are mean +/- S.E.M. of
three independent experiments.
HEK293 TLR4 HEK293 TLR3
U373-CD14 U373-CD14
A B
C D
Figure 4.18 Fenofibrate inhibits LPS and Poly(I:C) induction of TNF-α
expression in BMDM and U373-CD14 astrocytoma cells.
BMDM (A+B) and U373-CD14 astrocytoma (C+D) cells were pre-treated with or
without various concentrations of Fenofibrate for 1 h prior to stimulation in the
presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 24 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. *P< 0.05 and ***P
< 0.001 compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (19, 34) = 20.09. P < 0.001 (B) F
value (19, 34) = 18.30. P < 0.001 (C) F value (13, 28) = 67.40. P < 0.001 (D) F value
(13, 28) = 77.39. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.19 Fenofibrate regulatory effects on LPS and Poly(I:C)-induced
activation of IRF3 in HEK293 TLR3/TLR4 and U373-CD14 astrocytoma cells.
HEK293 cells stably transfected with TLR4 (A) or TLR3 (B) and U373-CD14
astrocytoma cells (C) were co-transfected with the trans-activator plasmid pFA-IRF-3
(30ng), pFR-Luc (60ng), phRL-TK (constitutively expressed renilla luciferase) (40ng)
and pcDNA3.1 (140ng). Cells were allowed to recover overnight and then pre-treated
with or without various concentrations of Fenofibrate for 1 h prior to stimulation in the
presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 6 h. Cell
extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05 and +++P < 0.001 compared with LPS or Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (13, 24) = 10.36. P < 0.001 (B) F
value (13, 24) = 9.527. P < 0.001 (C) F value (13, 28) = 8.635. P < 0.001. Results are
mean +/- S.E.M. of three independent experiments.
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Figure 4.20 Fenofibrate augments Poly(I:C)-induced activation of the IFN-β
promoter in HEK293 TLR3 and U373-CD14 astrocytoma cells.
HEK293 cells stably transfected with TLR3 (A) and U373-CD14 astrocytoma (B)
cells were co-transfected with IFN-β luciferase reporter plasmid (80ng), phRL-TK
(constitutively expressed renilla luciferase) (40ng) and pcDNA3.1 (120 ng). Cells
were allowed to recover overnight and then pre-treated with or without various
concentrations of Fenofibrate for 1 h prior to stimulation in the presence or absence of
Poly(I:C) (25μg/ml) for a further 6 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05, ++P < 0.01 and +++P < 0.001 compared with Poly(I:C)-treated cells. One
way ANOVA effect of treatment (A) F value (19, 40) = 13.36. P < 0.001 (B) F value
(19, 40) = 70.52. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.21 Fenofibrate differentially regulates LPS and Poly(I:C)-induced
activation of IFN-β mRNA in BMDM cells and primary rat astrocytes.
BMDM cells (A+B) and primary astrocyte cultures prepared from neonatal rat brains
(C+D) were pre-treated with or without various concentrations of Fenofibrate for 1 h
prior to stimulation in the presence or absence of LPS (100ng/ml) or Poly(I:C)
(25μg/ml) for a further 16 h. RNA extracts were generated and converted into cDNA.
Samples were subsequently assayed by quantitative real-time PCR for levels of IFN-β
mRNA. Gene expression was calculated relative to the endogenous control and
analysis was performed using the 2-ΔΔCT method. *P < 0.5 and ***P < 0.001
compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells. One way ANOVA effect of treatment
(A) F value (13, 24) = 9.864. P < 0.001 (B) F value (13, 27) = 13.30. P < 0.001 (C) F
value (13, 28) = 35.95. P < 0.001 (D) F value (13, 28) = 22.37. P < 0.001. Results are
mean +/- S.E.M. of three independent experiments.
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Figure 4.22 Effects of PPARα antagonism on the regulatory effects of
cannabinoids on the Poly(I:C)-induced activation of NFκB in HEK293 TLR3
cells.
HEK293 cells stably transfected with TLR3 were co-transfected with a NFκB-
regulated firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed
Renilla luciferase) (40 ng), and pcDNA3.1 (120 ng). Cells were allowed to recover
overnight then challenged for 1 h with GW6471 (1µM) prior to treatment with or
without R(+)WIN55,212-2 (20µM) (A) or Anandamide (20μM) (B) for 1 h and further
stimulated in the presence or absence of Poly(I:C) (25µg/ml) for a further 6 h. Cell
extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. **P < 0.05 and ***P < 0.001 compared with
vehicle-treated cells. +++P < 0.001 compared with Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 12.64. P < 0.001 (B) F
value (10, 22) = 36.18 P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.23 Effects of PPARα antagonism on the regulatory effects of
R(+)WIN55,212-2 on the Poly(I:C)-induced activation of IRF7 and IRF3 in
HEK293 TLR3 cells.
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF-7 (25ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed Renilla luciferase) (40ng) and pcDNA3.1 (145ng) (A). In a separate assay
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF-3 (30ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed renilla luciferase) (40ng) and pcDNA3.1 (140ng) (B). Cells were allowed
to recover overnight then challenged for 1 h with GW6471 (1µM) prior to treatment
with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the
presence or absence of Poly(I:C) (25µg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. ***P < 0.001 compared with vehicle-treated cells. ++P < 0.01 compared
with Poly(I:C)-treated cells. ##P < 0.01 compared with cells treated with
R(+)WIN55,212-2 in the presence of Poly(I:C). One way ANOVA effect of treatment
(A) F value (10, 19) = 20.84. P < 0.001 (B) F value (10, 19) = 26.77 P < 0.001.
Results are mean +/- S.E.M. of three independent experiments.
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Figure 4.24 Effects of PPARα antagonism on the regulatory effects of
cannabinoids on the Poly(I:C)-induced activation of the IFN-β promoter in
HEK293 TLR3 cells.
HEK293 cells stably transfected with TLR3 cells were co-transfected with IFN-β
luciferase reporter plasmid (80ng), phRL-TK (constitutively expressed renilla
luciferase) (40ng) and pcDNA3.1 (120 ng). Cells were allowed to recover overnight
then challenged for 1 h with GW6471 (1µM) prior to treatment with or without
R(+)WIN55,212-2 (20µM) (A) or Anandamide (20μM) (B) for 1 h and further
stimulated in the presence or absence of Poly(I:C) (25µg/ml) for a further 6 h. Cell
extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. **P < 0.01 and ***P < 0.001 compared with
vehicle-treated cells. +++P < 0.001 compared with Poly(I:C)-treated cells.
One way ANOVA effect of treatment (A) F value (10, 19) = 73.17. P < 0.001 (B) F
value (10, 19) = 10.45 P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.25 Effects of PPARα antagonism on the regulatory effects of
R(+)WIN55,212-2 on IFN-β mRNA expression in BMDM cells.
BMDM cells were pre-treated for 1 h with GW6471 (1µM) prior to treatment with or
without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the presence or
absence of LPS (100ng/ml) (A) or Poly(I:C) (25µg/ml) (B) for a further 16 h. RNA
extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. *P < 0.05 compared with vehicle-treated cells. ++P < 0.01
compared with Poly(I:C)-treated cells. ##P < 0.01 compared with cells treated with
R(+)WIN55,212-2 in the presence of Poly(I:C).
One way ANOVA effect of treatment (A) F value (10, 19) = 5.465. P < 0.001 (B) F
value (10, 19) = 13.41 P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
A B
C D
Figure 4.26 Effects of PPARα antagonism on the regulatory effects of
R(+)WIN55,212-2 on TNF-α expression in U373-CD14 astrocytoma cells and
primary mouse astrocytes.
U373-CD14 astrocytoma cells (A+B) and primary astrocyte cultures prepared from
neonatal murine brains (C+D) were pre-treated for 1 h with GW6471 (1µM) prior to
treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in
the presence or absence of LPS (100ng/ml) or Poly(I:C) (25µg/ml) for a further 24 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. ***P < 0.001
compared with vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001
compared with LPS or Poly(I:C)-treated cells. One way ANOVA effect of treatment
(A) F value (10, 22) = 16.99. P < 0.001 (B) F value (10, 22) = 21.74. P < 0.001 (C) F
value (10, 44) = 28.70. P < 0.001 (D) F value (10, 44) = 34.09. P < 0.001. Results are
mean +/- S.E.M. of three independent experiments (five independent experiments for
primary mouse).
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Figure 4.27 Effects of PPARγ antagonism on the regulatory effects of
R(+)WIN55,212-2 on the Poly(I:C)-induced activation of IRF7 and IRF3 in
HEK293 TLR3 cells.
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF-7 (25ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed Renilla luciferase) (40ng) and pcDNA3.1 (145ng) (A). In a separate assay
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF-3 (30ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed renilla luciferase) (40ng) and pcDNA3.1 (140ng) (B). Cells were allowed
to recover overnight then challenged for 1 h with GW9662 (1µM) prior to treatment
with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the
presence or absence of Poly(I:C) (25µg/ml) for a further 6 h. Cell extracts were
generated and assayed for firefly and Renilla (for normalizing transfection efficiency)
luciferase. **P < 0.01 compared with vehicle-treated cells. +P < 0.05 and +++P <
0.001 compared with Poly(I:C)-treated cells. ###P < 0.01 compared with cells treated
with R(+)WIN55,212-2 in the presence of Poly(I:C). One way ANOVA effect of
treatment (A) F value (10, 22) = 13.38. P < 0.001 (B) F value (10, 22) = 20.96 P <
0.001. Results are mean +/- S.E.M. of three independent experiments.
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Figure 4.28 Effects of PPARγ antagonism on the regulatory effects of
R(+)WIN55,212-2 on IFN-β mRNA expression in BMDM cells.
BMDM cells were pre-treated for 1 h with GW9662 (1µM) prior to treatment with or
without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the presence or
absence of LPS (100ng/ml) (A) or Poly(I:C) (25µg/ml) (B) for a further 16 h. RNA
extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. *P < 0.05 compared with vehicle-treated cells. +P < 0.05
compared with Poly(I:C)-treated cells. ##P < 0.01 compared with cells treated with
R(+)WIN55,212-2 in the presence of Poly(I:C).
One way ANOVA effect of treatment (A) F value (10, 19) = 5.465. P < 0.001 (B) F
value (10, 22) = 17.04 P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
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Figure 4.29 Effects of PPARγ antagonism on the regulatory effects of
R(+)WIN55,212-2 on TNF-α expression in U373-CD14 astrocytoma cells and
primary mouse astrocytes.
U373-CD14 astrocytoma cells (A+B) and primary astrocyte cultures prepared from
neonatal murine brains (C+D) were pre-treated for 1 h with GW9662 (1µM) prior to
treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in the
presence or absence of LPS (100ng/ml) or Poly(I:C) (25µg/ml) for a further 24 h.
Supernatants were assayed for TNF-α levels by sandwich ELISA. *P < 0.05 and ***P <
0.001 compared with vehicle-treated cells. ++P < 0.01 and +++P < 0.001 compared with
LPS or Poly(I:C)-treated cells. #P < 0.05 compared with cells treated with
R(+)WIN55,212-2 in the presence of Poly(I:C). One way ANOVA effect of treatment (A)
F value (10, 22) = 16.73. P < 0.001 (B) F value (10, 19) = 8.876. P < 0.001 (C) F value
(10, 44) = 25.65. P < 0.001 (D) F value (10, 44) = 31.32. P < 0.001. Results are mean +/-
S.E.M. of three independent experiments (five independent experiments for primary
mouse).
U373-CD14 U373-CD14
Primary Mouse Primary Mouse
A B
C
Figure 4.30 R(+)WIN55,212-2 and Anandamide regulatory effects on PPARα
mRNA and PPARγ mRNA in BMDM cells.
BMDM cells were treated at various time points with or without R(+)WIN55,212-2
(20µM) or Anandamide (20μM). RNA extracts were generated and converted into
cDNA. Samples were subsequently assayed by quantitative real-time PCR for levels
of PPARα (A+B) and PPARγ (C+D) mRNA. Gene expression was calculated relative
to the endogenous control and analysis was performed using the 2-ΔΔCT method.
Results are mean +/- S.E.M. of three independent experiments .
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Chapter 5 
 
 
 
Defining the molecular target for the action of 
WIN55,212-2 on TLR3 signalling 
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5.1 Introduction 
 
TLR4 is widely recognised for its ability to induce the transcription of many 
pro-inflammatory targets, while TLR3 activation is a strong inducer of anti-viral genes.  
Upon ligand activation of TLR3, a TRIF-dependent/MyD88-independent signalling 
response occurs to regulate IRF3 and late phase NFB activity.  TRIF interacts with 
TLR3 through its TIR domain while its N terminal domain forms a complex with 
TBK1/IKKε (Fitzgerald et al., 2003).   
When first characterised, it was thought that the major role of TBK1 and IKKε 
was to activate NFκB (Tojima et al., 2000).  Later studies demonstrated that when 
murine double TBK1/IKKε knockout cells were treated with various inflammatory 
stimuli, there was no effect on NFκB-dependent gene transcription (Hemmi et al., 
2004).  Instead, it was found that TBK1/IKKε play an essential role in regulating the 
production of type I interferons by phosphorylating IRF3 on its C-terminal regulatory 
domain (Fitzgerald et al., 2003).  Despite these results, numerous reports continue to 
publish and propose roles for TBK1/IKKε in phosphorylating and regulating nuclear 
accumulation of the NFκB subunits; p65 and c-Rel (Harris et al., 2006, Buss et al., 
2004a, Mattioli et al., 2006).   
To date, TBK1 and IKKε appear to be the main kinases involved in the 
catalysing phosphorylation of IRF3.  Gene targeting and knockout studies have revealed 
that each kinase may behave in an independent manner with respect to IRF3 activation 
(Hemmi et al., 2004, McWhirter et al., 2004).  For example, cells deficient in TBK1 
exhibit severe impairment of IRF3 activation, nuclear translocation and subsequent 
induction of IFN-β and regulated on activation normal T cell expressed and secreted 
(RANTES) in response to Poly(I:C) or LPS stimulation.  Despite this, some residual 
gene expression was still apparent, presumably due to the action of IKKε.  On the other 
hand, IKKε deficient cells displayed normal expression of IRF3 target genes in response 
to dsRNA, suggesting that TBK1 can fully compensate for the lack of IKKε.  Therefore, 
it is proposed that both TBK1 and, albeit to a lesser extent, IKKε, are necessary for the 
activation of IRF3 and the induction of IFN-inducible genes. 
IRF3 contains two phosphorylation sites within its C terminal domain which 
plays crucially important roles in regulating the activation of IRF3.  Site 1 includes 
Ser385 and Ser386 residues while site 2 includes the residues Ser396, Ser398, Ser402, 
Thr404 and Ser405 (Tamura et al., 2008).  The activation of IRF3 appears to be a 
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sequential phosphorylation process where various groups have reported on the 
phosphoacceptor site(s) targeted by TBK1/IKKε.  Ser396 appears to be a key residue in 
IRF3 activation that is initially phosphorylated (Lin et al., 1998) and is required for 
IRF3 dimerisation (Servant et al., 2003).  However as phosphoacceptor sites in site 1 are 
the most accessible amino acids, others have demonstrated that Ser386 could be the 
initial and critical target for TBK1/IKKε mediated phosphorylation (Mori, Yoneyama et 
al. 2004) and IRF3 dimerisation (Takahasi et al., 2010).  A mutation of Ser386 to an 
alanine residue abolishes the ability of IRF3 to dimerise, a function that is critical in the 
nuclear translocation of IRF3 (Mori et al., 2004).  Furthermore, in vitro assays using 
either recombinant or immunoprecipitated kinases from overexpressing cells and 
truncated recombinant IRF3, suggest that Ser402 is also targeted by TBK1/IKKε 
(Sharma et al., 2003, tenOever et al., 2004).  As a result, the precise sites targeted by 
TBK1/IKKε remain to be characterised. 
A recent study has reported on the ability of c-Jun-NH2-terminal kinase (JNK) to 
phosphorylate IRF3 in its N terminal domain (Zhang et al., 2009).  Consequently, 
TAK1 (a common activator of NFκB, p38 and JNK pathways) can stimulate 
phosphorylated IRF3 via JNK without interfering with the C terminus of IRF3.  IRF3 
can also be phosphorylated within its N terminus in response to stress inducers 
including anisomycin, sorbitol, and DNA-damaging agents such as doxorubicin 
(Servant et al., 2001).  LPS has also been shown to induce N-terminal phosphorylation 
of IRF3 (Solis et al., 2007). 
Under basal conditions IRF3 remains in the cytoplasm but following 
TBK1/IKKε-mediated phosphorylation, IRF3 dimerises and translocates to the nucleus.  
Upon nuclear localisation and preceding DNA binding, IRF3 associates with the co-
activator CBP/p300 on its hydrophobic surface (Kumar et al., 2000, Lin et al., 1998).  
The direct interaction of CBP/p300 with DNA is indispensable for the DNA binding 
activity of phosphorylated IRF3 (Suhara et al., 2002).  Upon association with  
CBP/p300, IRF3 binds to the PRDI/III elements of the IFN-β promoter (Thanos and 
Maniatis, 1995) or the PRD-like element of the IFNα4 promoter.  IFNβ and IFNα4 
subsequently signal via IFNAR and the JAK/STAT pathway to activate the ISGF3 
transcriptional regulator which induces IRF7 expression (Fig 1.3).  In a similar manner 
to IRF3, phosphorylated IRF7 translocates to the nucleus and binds to PRD on the IFN-
α promoter.   
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The activation of IRF3 is not exclusive to TLR signalling events.  RIG-I and 
MDA5 (Fig 1.2) are two cytoplasmic PRRs that recognise dsRNA independently of 
TLR3 and function in the activation of IRF3.  RIG-I and MDA5 both contain a C 
terminal DExD/H box RNA helicase domain, a central ATPase domain and two N-
terminal caspase-recruitment domain (CARD)-like domains (Yoneyama et al., 2004).  
Following ligand binding, both proteins undergo a conformational shift facilitated by 
their ATPase domain.  This allows for recruitment of the downstream adaptor protein, 
IFN-β promoter stimulator (IPS1) via their CARD domains (Potter et al., 2008).  IPS1 is 
localised to mitochondria where it initiates diverse signalling pathways that culminate in 
the activation of IRF3 and NFκB.  IPS1 interacts with TRAF3 via its C-terminal domain 
(Saha et al., 2006).  TRAF3 subsequently forms a multiprotein signalling complex with 
TBK1/IKKε to induce IRF3 phosphorylation and nuclear translocation.   
The compound, BX-795, was originally developed as a small molecular 
inhibitor of 3-phosphoinositidedependent protein kinase 1 (PDK1) (Feldman et al., 
2005).  However it has recently been demonstrated that BX-795 can inhibit TBK1 and 
IKKε at low nanomolar concentrations (Bain et al., 2007) and is now been recognised as 
a potent and relatively competitive inhibitor of TBK1/IKKε (Clark et al., 2009).  
Indeed, BX-795 has previously been reported to be unsuccessful in blocking the 
transcriptional activity of NFκB by TLR ligands and TNF-α stimulation (Clark et al., 
2009).  Furthermore, BX-795 does not inhibit IKKβ (Bain et al., 2007) or IKKα (Clark 
et al., 2009), critical kinases involved in the nuclear translocation of NFκB.  In relation 
to IRF3 regulation by TBK1/IKKε, treatment of macrophages with BX-795 was shown 
to block the phosphorylation, nuclear translocation and transcriptional activity of IRF3 
and also IFN-β production induced by TLR3 and TLR4 stimulation (Clark et al., 2009).   
In the previous chapter it was intriguing to note that cannabinoids and 
fenofibrate augmented TLR3 signalling.  Given that the TLR3 pathway employs the 
TRIF/TBK1/IKKε/IRF3 axis, we next aimed to identify the molecular targets for the 
pharmacological agents in this pathway.  This also offered the potential to further 
understand the molecular basis to the therapeutic effects of cannabinoids and fenofibrate 
with relevance to M.S.  
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5.2 Results 
 
5.2.1 R(+)WIN55,212-2 targets TRIF-meditated signalling. 
 
In the preceding chapters, it was observed that R(+)WIN55,212-2 augments 
Poly(I:C)-induced activation of IRF3.  In order to pinpoint the molecular targets that 
mediate this effect, the sensitivity of TRIF-mediated signalling to the pharmacological 
agent was initially explored.   
 HEK293 TLR3 cells were transfected with the trans-activator plasmid pFA-
IRF3 (where IRF3 is fused downstream of the yeast Gal4 DNA binding domain) and 
with or without a construct encoding TRIF.  Following transfection, in separate assays, 
cells were treated with or without various concentrations of R(+)WIN55,212-2 or S(-
)WIN55,212-2 for 7 hours.  Overexpression of TRIF promoted strong induction of 
IRF3-regulated luciferase expression (Fig. 5.1A) and this was dose-dependently 
augmented by R(+)WIN55,212-2 (Fig. 5.1A).  This effect was again stereoselective 
since S(-)WIN55,212-2 failed to affect the ability of TRIF to activate IRF3 (Fig.5.1B). 
These findings suggested that R(+)WIN55,212-2 can directly target TRIF-mediated 
signalling.  
 
5.2.2  Regulatory effects of R(+)WIN55,212-2 on TLR induction of IFN-β mRNA in 
TRIF-deficient cells 
 
TRIF-deficient BMDM (TRIF KO) cells were next employed to evaluate the 
importance of TRIF in manifesting the positive effects of R(+)WIN55,212-2 on IFN-β 
mRNA expression.  The responsiveness to Poly(I:C) and LPS was greatly reduced in 
TRIF KO cells with only modest induction of IFN-β mRNA following ligand treatment 
(Fig. 5.2A and Fig. 5.2C).  Interestingly, R(+)WIN55,212-2 failed to modulate this 
effect in response to Poly(I:C) treatment (Fig. 5.2C), thus further suggesting that 
R(+)WIN55,212-2 targets a TRIF-mediated pathway.  
In LPS treated cells, pre-exposure of the cells to R(+)WIN55,212-2 (Fig 5.2A) 
inhibited LPS-induced activation of IFN-β mRNA expression which is consistent with 
its effect in wild type BMDM cells.  S(-)WIN55,212-2 failed to influence IFN-β mRNA 
expression by LPS (Fig. 5.2B) or Poly(I:C) (Fig. 5.2D) which again verifies specificity 
for the WIN55,212-2 compound. 
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5.2.3  Use of the TBK1/IKKε inhibitor, BX-795, to explore TBK1/IKKε as possible 
targets for R(+)WIN55,212-2. 
 
As TRIF is an upstream regulator of TBK1 and IKKε (Fitzgerald et al., 2003), 
the importance of these kinases in manifesting the regulatory effects of 
R(+)WIN55,212-2 were next examined by using the potent and selective TBK1/IKKε 
inhibitor; BX-795.  Given the previous controversy with respect to regulation of the 
NFκB pathway by BX-795 (Clark et al., 2009), it was necessary to investigate the 
sensitivity of NFκB activation to BX-795 in our experimental systems.  This was 
evaluated by treating HEK293 TLR3 cells with BX-795 (1µM) for 1 hour followed by 
treatment with R(+)WIN55,212-2 or S(-)WIN55,212-2 (20µM) for 1 hour and 
subsequent Poly(I:C) treatment for 6 hours.  In both assays, treatment with BX-795 
failed to affect the ability of Poly(I:C) to regulate NFκB-regulated luciferase expression.  
As previously observed, R(+)WIN55,212-2 inhibited Poly(I:C)-induced activation of 
NFκB whereas S(-)WIN55,212-2 was ineffective. The inhibitory effects of 
R(+)WIN55,212-2 on NFκB were partially reversed but not totally removed by BX-795 
treatment (Fig. 5.3A).  As expected, S(-)WIN55,212-2 was insensitive to BX-795 
treatment (Fig. 5.3B).   
In order to further explore the effects of BX-795 on R(+)WIN55,212-2 and the 
NFκB pathway, their regulatory potential on the expression of the NFκB-responsive 
gene, TNF-α, was explored. This was examined in two model systems; U373-CD14 
astrocytoma cells and primary mouse astrocytes.  Both cells types were treated with for 
BX-795 (1µM) for 1 hour, prior to treatment with R(+)WIN55,212-2 (20µM) for 1 hour 
and Poly(I:C) treatment for 24 hours.  R(+)WIN55,212-2 inhibited Poly(I:C) induced 
expression of TNF-α in both cell types (Fig. 5.4A and Fig 5.4B) with almost complete 
abolition of TNF-α expression in primary mouse astrocytes (Fig 5.4B).  Pre-treatment of 
both cells types with BX-795 failed to affect the regulatory effects of R(+)WIN55,212-2 
on TNF-α expression suggesting that the inhibitory activity of R(+)WIN55,212-2 on 
pro-inflammatory gene expression is independent of TBK1/IKKε.    
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5.2.4 Regulatory effects of R(+)WIN55,212-2 on TLR3 induced activation of IRF3, 
the IFN-β promoter and IFN-β mRNA is dependent on the TLR3-TRIF-
TBK1/IKKε signalling pathway. 
 
Given that TBK1/IKKε are upstream kinases of IRF3, the role of these kinases 
as potential targets for R(+)WIN55,212-2 was next examined.  BX-795 was employed 
for this purpose.  Cells were treated with BX-795 (1µM) for 1 hour followed by 
treatment with R(+)WIN55,212-2 (20µM) for 1 hour and Poly(I:C) stimulation for 6 
hours.  As expected, BX-795 showed strong inhibitory effects on Poly(I:C)-induced 
activation of IRF3 (Fig. 5.5A) and the IFN-β promoter (Fig. 5.5B).  Some residual 
activity was apparent in both cases but in the presence of BX-795 neither the activation 
of IRF3 (Fig. 5.5A) or the IFN-β promoter (Fig. 5.5B) was augmented by. 
R(+)WIN55,212-2.  This suggests that the latter requires functional TBK1/IKKε in 
order to enhance the IRF3 pathway.   
The transcriptional regulation of IFN-β mRNA was also assessed in BMDM 
cells.  Similar to the above data, BX-795 strongly inhibited Poly(I:C)-induced 
expression of IFN-β mRNA and the residual expression in the presence of BX-795 was 
not potentiated by R(+)WIN55,212-2 (Fig. 5.6A).  This again confirms the need for the 
catalytic activity of TBK1 and IKKε in order for R(+)WIN55,212-2 to manifest its  anti-
inflammatory effects. . 
 
5.2.5 R(+)WIN55,212-2 enhances phosphorylation of IRF3 by TLR3 ligand 
activation.  
 
Due to the ability of R(+)WIN55,212-2 to augment Poly(I:C)-induced activation  
of IRF3 in a TBK1/IKKε dependent manner, it was next examined whether 
R(+)WIN55,212-2 could regulate the phosphorylation status of IRF3.  BMDM cells 
were treated with R(+)WIN55,212-2 (20µM) for 1 hour followed by Poly(I:C) treatment 
at various time points (30, 60, 120 and 180 minutes).  To establish if R(+)WIN55,212-2 
could increase the C-terminal phosphorylation of IRF3, the lysates were immunoblotted 
for Ser396, a critical residue in IRF3 phosphorylation.  Increased phosphorylation of 
Ser396, albeit to modest levels, was detected after Poly(I:C) treatment time of 60 
minutes and this response was augmented by R(+)WIN55,212-2 pre-treatment (Fig. 
5.7A).  BMDM cells were also treated with S(-)WIN55,212-2 and Poly(I:C) in a similar 
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manner.  As shown in (Fig. 5.7B), pre-treatment with S(+)WIN55,212-2 had no effect 
on the Poly(I:C)-induced phosphorylation of Ser396 which again confirms the 
specificity of the regulatory effects of R(+)WIN55,212-2.   
 
5.2.6 R(+)WIN55,212-2 enhances nuclear localisation of IRF3.  
 
Due the ability of R(+)WIN55,212-2 to enhance the Poly(I:C)-induced 
phosphorylation of IRF3 and as phosphorylation of IRF3 is a pre-requisite to nuclear 
translocation of the transcription factor, the regulatory effects of R(+)WIN55,212-2 on 
subcellular localisation of IRF3 was assessed in primary mouse astrocytes and HEK293 
TLR3 cells, by use of confocal microscopy.   
Primary murine astrocytes were pre-treated with R(+)WIN55,212-2 or             
S(-)WIN55,212-2 (20 µM) for 1 hour prior to Poly(I:C) exposure for an additional hour.  
As shown in (Fig. 5.8A), IRF3 localises predominantly to the cytoplasm.  However, 
stimulation of cells with Poly(I:C) leads to the nuclear translocation of IRF3.  
Intriguingly, R(+)WIN55,212-2 promotes the nuclear localisation of IRF3 both in the 
presence and absence of Poly(I:C) (Fig. 5.8A) whilst S(-)WIN55,212-2 is without effect 
(Fig. 5.8B). 
To further confirm these findings, HEK293 TLR3 cells were transfected with an 
expression construct encoding GFP-tagged IRF3 (800 ng).  Control slides were 
transfected with EGFP construct (800 ng).  Cells were allowed to recover overnight and 
pre-treated with R(+)WIN55,212-2 (20 µM) for 1 hour prior to Poly(I:C) exposure for 
an additional hour.  The ability of R(+)WIN55,212-2 to promote the nuclear 
translocation of IRF3 was also confirmed in HEK293 cells by monitoring the 
translocation of IRF3-GFP fusion protein (Fig. 5.9A).  The positive effects of 
R(+)WIN55,212-2 on enhancing the nuclear localisation of IRF3 provides a novel 
mechanistic basis to the enhancement of the TLR3-TRIF-TBK1/IKKε-IRF3-IFN- 
pathway. 
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5.3 Discussion 
 
The aim of this chapter was to identify molecular targets that may underpin the 
regulatory effects of R(+)WIN55,212-2 on the TLR3 pathway.  As previously 
explained, TRIF is a critical adaptor molecule employed in the TLR3 signalling 
pathway.  In overexpression studies, it was found that R(+)WIN55,212-2 augmented 
TRIF-induced activation of IRF3.  TRIF knockout studies also revealed the importance 
of this adaptor molecule in mediating the positive regulatory effects of the synthetic 
cannabinoid.  Interestingly Poly(I:C) showed some residual activity in TRIF knockout 
cells.  It is not immediately obvious since one would expect total abolition of TLR3 
signalling in the absence of TRIF.  A plausible explanation may lie in the fact that 
Poly(I:C) can also trigger cytosolic receptors such as RIG-I or MDA5 and this may 
account for the residual activity.  However in order to trigger the RIG-I pathway, 
Poly(I:C) would have to gain access to the cytosol.  Generally in experimental model 
systems this is achieved by use of liposomal-based transfection reagents e.g. 
lipofectamine.  In the present study, lipofectamine was not used at the time of addition 
of Poly(I:C).  However, some residual lipopfectamine may have remained in the cell 
culture from the transfection protocol on the preceding day and this may facilitate entry 
of Poly(I:C) into the cytosol and its subsequent triggering of the RIG-I pathway.  
Irrespective of the exact mechanism underlying the ability of Poly(I:C) to signal in 
TRIF-deficient cells, R(+)WIN55,212-2 fails to augment activation of IRF3 or the 
induction of IFN-β in the absence of TRIF.  These results strongly suggest that 
R(+)WIN55,212-2 targets a TRIF-mediated signalling pathway.  
The use of the TBK1/IKKε inhibitor; BX-795 strongly suppressed the activation 
of IRF3 and the IFN-β promoter in response to TLR3 ligand stimulation whilst having 
no effect on the activation of NFκB.  It was interesting to note this lack of effect of BX-
795 on NFκB, since previous studies have implicated a role for TBK1/IKKε in 
promoting the  phosphorylation and nuclear accumulation of p65 (Buss et al., 2004b) 
and in facilitating the nuclear accumulation of c-Rel (Harris et al., 2006). However 
unlike the present study, the latter studies did not employ Poly(I:C) as a stimulus.  
Furthermore we also show that the Poly(I:C)-induced expression of the NFκB-
responsive gene, TNF-α is insensitive to BX-795.  This again confirms the absence of a 
role for TBK1/IKKε in regulation of the NFκB pathway, at least with respect to TLR3 
signalling.  It is also worth noting that the selectivity of BX-795 for the IRF3 pathway is 
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consistent with a previous report using TBK1/IKKε murine knockout models that 
highlighted important roles for these kinases in the IRF3-IFN-β pathway and not the 
NFκB pathway (Hemmi et al., 2004).   
Interestingly, BX-795 failed to totally abolish the ability of Poly(I:C) to activate 
IRF3 and induce IFN-β suggesting that some of its signalling may be mediated 
independently of TBK1/IKKε.  This may be due to the recently described role for JNK 
in phosphorylating IRF3 in its N terminal domain (Zhang et al., 2009) and lead to a 
situation where IRF3 is activated without requiring the C terminal phosphorylation of 
IRF3.  Such N terminal phosphorylation of IRF3 is also apparent in response to stress 
inducers (Servant et al., 2001).  Thus the residual activity of Poly(I:C) in the presence of 
BX-795 may be attributable to JNK signalling but whatever the molecular basis, it is 
clear that R(+)WIN55,212-2 fails to regulate activation of IRF3 and induction of IFN-β 
in the absence of a functional TBK1/IKKε complex.  
Given the positive effects of R(+)WIN55,212-2 on the IRF3 pathway appear to 
be dependent on TBK1/IKKε and the latter are the immediate upstream kinases of IRF3, 
the regulatory effects of the synthetic cannabinoid on the phosphorylation status of 
IRF3 was explored.  Intriguingly R(+)WIN55,212-2 enhances Poly(I:C)-induced 
phosphorylation of IRF3 and this is consistent with its augmentation of Poly(I:C)-
induced activation of IRF3 and induction of IFN-β.  However, a difference arises when 
the regulatory effects of R(+)WIN55,212-2 on the subcellular localisation of IRF3 was 
explored.  Intriguingly, even in the absence of Poly(I:C), R(+)WIN55,212-2 appears to 
facilitate the nuclear accumulation of IRF3.  This was surprising given that 
R(+)WIN55,212-2 failed to affect the basal phosphorylation of IRF3 in the absence of 
Poly(I:C) and such phosphorylation is required for nuclear translocation.  However it 
should be noted that in detecting phosphorylation of IRF3, a phosphospecific antibody 
that specifically detects phosphorylation of Ser396 was employed.  This does not 
exclude the possibility that R(+)WIN55,212-2 may regulate the phosphorylation of 
other sites that may also facilitate nuclear accumulation of IRF3.  Indeed, as already 
described above, JNK is known to phosphorylate IRF3 on its N terminus thus leading to 
its activation.  
Whilst the increased nuclear localisation of IRF3 in response to 
R(+)WIN55,212-2 may be due to increasing its nuclear translocation another possibility 
exists that IRF3 may undergo a basal cycle of cytoplasmic-nuclear-cytoplasmic 
shuttling.  This is particularly common for other transcription factors such as NFκB.  In 
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such a scenario, R(+)WIN55,212-2 may sequester IRF3 in the nucleus as part of this 
shuttling process.  It is interesting to speculate from the previous chapter that given the 
possible role of PPARs in mediating the regulatory effects of R(+)WIN55,212-2, the 
latter may induce expression of PPARs that can then interact with IRF3 and retain it in 
the nucleus.  This hypothesis is deserving of future exploration.  
Figure 5.1 R(+)WIN55,212-2 targets TRIF mediated signalling in HEK293 TLR3
cells.
HEK293 cells stably transfected with TLR3 were co-transfected with the trans-
activator plasmid pFA-IRF3 (30ng), pFR-Luc (60ng), phRL-TK (constitutively
expressed renilla luciferase) (40ng), a construct encoding TRIF (40ng) and pcDNA3.1
(100ng). Cells were allowed to recover overnight and then treated with or without
various concentrations of R(+)WIN55,212-2 (A) or S(-)WIN55,212-2 (B) for 7 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. **P < 0.01 and ***P < 0.001 compared with
vehicle-treated cells. +P < 0.05, ++P < 0.01 and +++P < 0.001 compared with TRIF-
transfected treated cells.
One way ANOVA effect of treatment (A) F value (13, 28) = 31.32. P < 0.001 (B) F
value (13, 28) = 9.120. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
A
B
Figure 5.2 R(+)WIN55,212-2 regulatory effects on LPS and Poly(I:C)-induced
activation of IFN-β mRNA in TRIF deficient BMDM cells.
TRIF deficient BMDM cells were pre-treated with or without various concentrations
of R(+)WIN55,212-2 (A+C) or S(-)WIN55,212-2 (B+D) for 1 h prior to stimulation in
the presence or absence of LPS (100ng/ml) or Poly(I:C) (25μg/ml) for a further 16 h.
RNA extracts were generated and converted into cDNA. Samples were subsequently
assayed by quantitative real-time PCR for levels of IFN-β mRNA. Gene expression
was calculated relative to the endogenous control and analysis was performed using
the 2-ΔΔCT method. **P < 0.01 and ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05 compared with LPS-treated cells. One way ANOVA effect of treatment (A)
F value (13, 24) = 11.58. P < 0.001 (B) F value (13, 24) = 18.20. P < 0.001 (C) F value
(13, 24) = 10.25. P < 0.001 (D) F value (13, 28) = 12.76. P < 0.001. Results are mean
+/- S.E.M. of three independent experiments.
A
D
B
C
AB
Figure 5.3 R(+)WIN55,212-2 inhibitory effect on Poly(I:C)-induced activation of
NFκB in HEK293 TLR3 cells in the TBK1/IKKε signalling pathway.
HEK293 cells stably transfected with TLR3 were co-transfected with a NFκB-
regulated firefly luciferase reporter (80 ng), phRL-TK (constitutively expressed
Renilla luciferase) (40 ng), and pcDNA3.1 (120 ng). Cells were allowed to recover
overnight then challenged for 1 h with BX-795 (1µM) prior to treatment with or
without R(+)WIN55,212-2 (20µM) (A) or S(-)WIN55,212-2 (20μM) (B) for 1 h and
further stimulated in the presence or absence of Poly(I:C) (25µg/ml) for a further 6 h.
Cell extracts were generated and assayed for firefly and Renilla (for normalizing
transfection efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells.
+P < 0.05 compared with Poly(I:C)-treated cells. #P < 0.05 compared with cells
treated with R(+)WIN55,212-2 in the presence of Poly(I:C).
One way ANOVA effect of treatment (A) F value (10, 22) = 12.09. P < 0.001 (B) F
value (10, 22) = 19.06. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments.
AB
Figure 5.4 R+)WIN55,212-2 inhibitory effect on Poly(I:C)-induced activation of
TNF-α expression in U373-CD14 astrocytoma cells and primary mouse astrocytes
is independent of the TBK1/IKKε signalling pathway.
U373-CD14 astrocytoma cells (A) and primary astrocyte cultures prepared from
neonatal murine brains (B) were challenged for 1 h with BX-795 (1µM) prior to
treatment with or without R(+)WIN55,212-2 (20µM) for 1 h and further stimulated in
the presence or absence of Poly(I:C) (25μg/ml) for a further 24 h. Supernatants were
assayed for TNF-α levels by sandwich ELISA. ***P < 0.001 compared with vehicle-
treated cells. +P < 0.05 and +++P < 0.001 compared with Poly(I:C)-treated cells. One
way ANOVA effect of treatment (A) F value (10, 22) = 27.78. P < 0.001 (B) F value
(10, 41) = 27.79. P < 0.001. Results are mean +/- S.E.M. of three independent
experiments (five independent experiments for primary mouse astrocytes).
U373-CD14
Primary Mouse
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Figure 5.5 R+)WIN55,212-2 regulatory effects on Poly(I:C)-induced activation of
IRF3 and the IFN-β promoter in HEK293 TLR3 cells is dependent on the
TBK1/IKKε signalling pathway.
HEK293 cells stably transfected with TLR3 were were co-transfected with the trans-
activator plasmid pFA-IRF3 (30ng) pFR-Luc (60ng), phRL-TK (constitutively expressed
renilla luciferase) (40ng) and pcDNA3.1 (140ng). In a separate assay, HEK293 cells
stably transfected with TLR3 were co-transfected with IFN-β luciferase reporter plasmid
(80ng), phRL-TK (constitutively expressed renilla luciferase) (40ng) and pcDNA3.1 (120
ng). Cells were allowed to recover overnight and then challenged for 1 h with BX-795
(1µM) prior to treatment with or without R(+)WIN55,212-2 (20µM) (A+B) for 1 h and
further stimulated in the presence or absence of Poly(I:C) (25μg/ml) for a further 6 h. Cell
extracts were generated and assayed for firefly and Renilla (for normalizing transfection
efficiency) luciferase. ***P < 0.001 compared with vehicle-treated cells. ++P < 0.01 and
+++P < 0.001 compared with Poly(I:C)-treated cells. ###P < 0.001 compared with cells
treated with R(+)WIN55,212-2 in the presence of Poly(I:C). One way ANOVA effect of
treatment (A) F value (10, 22) = 18.60. P < 0.001 (B) F value (10, 22) = 71.14. P < 0.001.
Results are mean +/- S.E.M. of three independent experiments.
AFigure 5.6 R+)WIN55,212-2 regulatory effects on Poly(I:C)-induced activation of
IFN-β mRNA in BMDM cells is dependent on the TBK1/IKKε signalling
pathway.
BMDM cells were pre-treated for 1 h with BX-795 (1µM) prior to treatment with or
without R(+)WIN55,212-2 (20µM) (A) for 1 h and further stimulated in the presence
or absence of Poly(I:C) (25µg/ml) for a further 16 h. RNA extracts were generated
and converted into cDNA. Samples were subsequently assayed by quantitative real-
time PCR for levels of IFN-β mRNA. Gene expression was calculated relative to the
endogenous control and analysis was performed using the 2-ΔΔCT method. *P < 0.05
compared with vehicle-treated cells. +++P < 0.001 compared with Poly(I:C)-treated
cells.
One way ANOVA effect of treatment (A) F value (10, 22) = 12.90. P < 0.001. Results
are mean +/- S.E.M. of three independent experiments.
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Figure 5.7 R(+)WIN55,212-2 enhances Poly(I:C) phosphorylation of IRF3 in
BMDM cells.
BMDM cells were pre-treated with or without R(+)WIN55,212-2 (20µM) (A) or
S(-)WIN55,212-2 (B) for 1 h and further stimulated in the presence or absence of
Poly(I:C) (25µg/ml) for a further 1 h. Cells were harvested in SDS-PAGE sample
buffer and subjected to western blotting using antibodies recognizing IRF3, IRF3
phosphorylated at Ser396 and β-Actin. All immunoblots were subjected to
densitometric analysis with levels of phospho-IRF3 normalized to total levels of IRF3
(A+B lower panels). Results are mean +/- S.E.M. of three independent experiments.
Figure 5.8 R(+)WIN55,212-2 promotes IRF3 translocation to the nucleus in primary
mouse astrocytes.
Primary astrocyte cultures prepared from neonatal murine brains were pre-treated with
R(+)WIN55,212-2 (20 µM) (A) or S(-)WIN55,212-2 (20 µM) (B) for 1 h prior to Poly(I:C)
(25 µg/ml) exposure for 1 h. Cells were fixed, mounted in anti fade medium with DAPI
and visualised using confocal microscopy. Confocal images were captured using a UV
Zeiss 510 Meta System laser scanning microscope equipped with the appropriate filter sets.
Data analysis was performed using the LSM 5 browser imaging software. Images are
representative of three independent experiments. Scale bars are 20 µm.
BA
Figure 5.9 R(+)WIN55,212-2 promotes IRF3 translocation to the nucleus in HEK293
TLR3 cells
HEK293 TLR3 cells were transfected with an expression construct encoding GFP-tagged
IRF3 (800 ng). Control slides were transfected with EGFP construct (800 ng). Cells were
allowed to recover overnight and pre-treated with R(+)WIN55,212-2 (20 µM) for 1 h prior
to Poly(I:C) (25 µg/ml) exposure for 1 h.
Cells were fixed in 4% PFA, incubated with DAPI (1.5 µg/ml) in PBS for 30 min, washed,
and mounted. All samples were viewed using an Olympus FluoView FV1000 confocal
laser scanning microscope equipped with the appropriate filter sets. Acquired images were
analysed using the Olympus FV-10 ASW imaging software. Negative control experiments
were performed by replacing the primary antibody with isotype controls and using equal
gain settings during acquisition and analysis.
A
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6.1 Concluding Remarks 
 
Over the past decade, considerable progress has been made in improving our 
understanding of the mammalian immune system and in particular the role of TLR 
signalling pathways.  The function of various transcription factors in the regulation of TLR 
signalling and in the development of T and B cell subsets, has demonstrated the complex 
link between the innate and adaptive immune response.  However, dysregulation of a 
variety of transcription factors can bestow autoimmunity in certain individuals and can be a 
triggering factor in the pathogenesis of autoimmune diseases such M.S.   
It is widely accepted that M.S. in an autoimmune disease involving autoreactive 
CD4
+
 T lymphocytes, B lymphocytes, plasma lymphocytes, extensive macrophage/glial 
activation which act cooperatively in the destructive process of demyleination.   
Currently there are few effective treatments for the symptoms of M.S.  Most of the 
current drugs only benefit a minority of people and frequently have adverse side effects.  In 
the absence of such effective treatments, M.S. patients are willing to seek alternative 
therapies such as those which come in the form of cannabis.  Anecdotal and scientific 
evidence both report on M.S. patients to self-medicate with and perceive benefit from the 
consumption of cannabis (Consroe et al., 1997).   
Cannabis has been used medicinally for thousands of years to alleviate a wide 
variety of conditions including pain, dysentery, sleep disturbance, nausea and vomiting (Di 
Marzo et al., 1998, Russo, 1998).  Cannabinoids affect almost every system in the human 
body including the cardiovascular, respiratory, immune, reproductive and nervous systems 
due to the presence of the high expression of cannabinoid receptors.  Up until 1971, doctors 
in the U.K. were able to prescribe oral tinctures of cannabis to patients.  However, this was 
outlawed by the issue of the Misuse of Drugs Act.  This act completely prohibited cannabis 
use unless under exceptional circumstances, such as strictly monitored scientific research.  
The advent of synthetic and endogenous cannabinoid compounds, coupled with the 
development of animal models of disease, enabled the biology of cannabinoids to blossom 
and shed light on the anecdotal reports on the medicinal value of cannabis. 
The largest randomised controlled trial studying the effects of cannabis on M.S. was 
carried out in 2003 (Zajicek et al., 2003).  The “Cannabinoids for Treatment of Spasticity 
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and other Symptoms Related to Multiple Sclerosis” (CAMS) study involved 667 patients 
with stable M.S. and muscle spasticity, and compared the oral synthetic δ-9-THC 
molecules, Marinol and Cannador, to placebo.  The primary outcome measure, using the 
Ashworth scale, displayed no statistically significant improvements in spasticity and no 
effect on tremor.  Despite this, patients self-reported improvements in pain, muscle spasms, 
spasticity and sleep disturbance.  The follow-up CAMS study in 2005 was more 
encouraging.  This involved 630 patients where two thirds of patients involved in the 
original study opted to continue treatment over a 12 month period (Zajicek et al., 2005).  
Objective improvements in spasticity, as measured by the Ashworth Scale and general 
disability indices were reported, as well as amelioration in pain and tremor.  Following on 
from the CAMS study, a new study, “Cannabinoid Use in Progressive Inflammatory brain 
Disease” CUPID began in 2006 and is expected to be completed in 2012.  The main 
differences in this trial are the randomised recruitment of M.S. patients with either primary 
or secondary progressive M.S. who will receive the cannabinoid treatments over a longer 
time period.    
The oromucosal spray, Sativex (a combination of δ-9-THC and cannabidiol), 
developed by GW Pharmaceuticals under licence of the British Home Office is approved 
for the treatment of spasticity associated with M.S.  In 2005, Canadian authorities approved 
the marketing of Sativex, while in 2010, Sativex was licensed as a prescription only 
medicine in the U.K. (Kmietowicz, 2010).  Several studies (Collin et al., 2007, Wade et al., 
2004) have tested the therapeutic effects of Sativex on spasticity in M.S. patients but no 
major improvement in spasticity was observed as measured by the Ashworth scale.  This 
may be due to cannabidiol having no demonstrable activity in experimental spasticity 
(Baker et al., 2000) and its ability to act as a cannabinoid receptor antagonist (Thomas et 
al., 2007).  Although Sativex may have better pharmacokinetics than ingested agents, it is 
not as favourable as smoked cannabis.  This is because it is administered oromucosally and 
therefore enters the bloodstream directly.  Furthermore, much greater dose-titrations are 
possible.  However, the side effects associated with smoked cannabis are more significant 
than those obtained from the spray form.  Common side effects include anxiety, panic, 
paranoia, acute psychosis and hallucinations where users also experience a brief euphoria 
state (JOHNS, 2001).   
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Despite the use of the Ashworth Scale in the above clinical trials, several studies 
(Shakespeare et al., 2003, Fleuren et al., 2010) have reported on its lack of reliability and 
sensitivity to measure the significant functional change in spasticity.  As a result, there is a 
clear need to find alternatives. 
Since the initial discovery of various endocannabinoids and development of 
synthetic cannabinoids, numerous studies have reported on their protective 
neuroinflammatory role in both autoimmune (EAE) and viral (TMEV) models of M.S. 
(Croxford and Miller, 2003, Jean-Gilles et al., 2009, Mestre et al., 2009).  Furthermore, 
various groups have also determined the significant involvement of both the CB1 and CB2 
receptors (Pryce et al., 2003, Sanchez et al., 2006, Palazuelos et al., 2008) and the role of 
TLRs (Prinz et al., 2006, Visser et al., 2005) in EAE and M.S. pathology.  However, 
despite the vast amount of published information, limited research has described the 
regulatory effects of cannabinoids on TLR signalling events with respect to M.S.  As a 
result, this forms the basis for the work described in this thesis.   
Both the canonical and non-canonical NFκB pathways are involved in the 
pathogenesis of autoimmune diseases and play crucial roles in the development, 
maturation, and homeostasis of T and B lymphocytes (Hayden et al., 2006).  NFκB 
subunits including p50, p65 and c-Rel have all been found in the nuclei of infiltrating 
macrophages in active M.S. plaques (Bonetti et al., 1999) where p65 expression is also 
increased in the nuclei of certain oligodendrocytes.  In addition, studies investigating the 
role of NFκB in EAE demonstrate that p65 and p50, but not c-Rel, RelB or p52, are the 
prototypic inducible subunits in the CNS during EAE (Hilliard et al., 1999, Pahan and 
Schmid, 2000).  However, these findings require some caution, as EAE is normally induced 
via active immunization with CNS tissue or myelin antigens in complete Freund’s adjuvant 
which is a potent activator of the canonical NFκB pathway.   
Much controversy also surrounds the use of EAE as an animal model of M.S. 
particularly due to the inability of the EAE model to adequately reflect the pathology of 
M.S. (t Hart et al., 2011, O'Brien et al., 2010) i.e. immunopathogenic mechanisms inducing 
CNS inflammation in EAE models favours CD4+/MHC class II restricted T cells driven 
autoimmune mechanisms, whereas CD8+/MHC class I T cells are prevalent in M.S. 
lesions.  Furthermore, there are obvious dissimilarities between innate and adaptive 
116 
 
immune functions in humans and rodents (Mestas and Hughes, 2004, Gibbons and Spencer, 
2011).  It is worth nothing that while some therapies have proven positive in EAE but failed 
to succeed in clinical trials e.g. TNF-α neutralizing agents (Sriram and Steiner, 2005, 
Fromont et al., 2009), others have successfully translated into clinical practice in humans 
including many of the currently known M.S. treatments for example, glatiramer acetate 
(Teitelbaum et al., 1971) mitoxantrone (Lublin et al., 1987) and natalizumab (Yednock et 
al., 1992).  In addition, EAE studies have demonstrated various disease modifying drugs 
which can lead to protection against EAE by inhibiting NFκB activation.  For example, 
Beta-interferon has been proposed to function by shifting the immune response in M.S. 
from a pro-inflammatory Th1 to anti-inflammatory Th2 type, an effect that is mediated by 
NFκB inhibition (Martín-Saavedra et al., 2007, Hamamcioglu and Reder, 2007).  As a 
result, agents that inhibit NFκB are attractive therapeutic options for M.S. patients and 
further clarifies why NFκB was the initial target reported in this thesis in assessing the 
possible therapeutic role of R(+)WIN55,212-2 in M.S. 
Although it was initially assumed that the anti-inflammatory effects exhibited by the 
cannabinoid compounds were mediated by their ability to inhibit NFκB, regardless of the 
triggering stimulus, further work revealed that IRF3 is also a target.  The knowledge that 
MyD88 deficiency is protective in EAE (Prinz et al., 2006), while TRIF deficiency 
exacerbates the disease (Guo et al., 2008) and since IRF3 is regulated by the latter, 
provided a suitable platform for investigating the regulatory effects of the cannabinoid 
compounds on IRF3 activation.  R(+)WIN55,212-2 treatment was found to enhance IRF3 
phosphorylation and nuclear translocation, and positively impact on it and IFN- 
expression in response to TLR3 signalling.  In addition, the TLR3 signalling events leading 
to NFB and IRF3 activation is differentially sensitive to R(+)WIN55,212-2 and suggests 
that the latter target a component of the IRF3 pathway that is not in common to the NFB 
pathway.  This target may well be TRIF but it is more likely that the target is TBK1/IKKε 
due to the loss of the observed effects of each drug on IRF3 and IFN-β, when these kinases 
are blocked.  As a result, it is now proposed, that R(+)WIN55,212-2, by directly regulating 
the TLR3-TRIF-TBK1/IKKε signalling axis, controls the expression pattern of IRF3 and 
IFN-.  Furthermore, despite the opposing effects of R(+)WIN55,212-2 on the NFB and 
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IRF3 signalling pathways, it is interesting to note that R(+)WIN55,212-2 targets both 
transcription factors at the nuclear level.   
The present study also highlighted the importance of IFN- production as a key 
mechanism underlying the protective effects of R(+)WIN55,212-2 in EAE and M.S.  It is 
proposed that such protective effects are due to combined neuroprotection and a dampening 
of inflammation that is specific to disease models  
The regulatory effects, particularly of R(+)WIN55,212-2 cannot be explained by 
mere virtue of its lipophilic characteristics since its enantiomeric form is ineffective.  
Furthermore, the often observed dose-response nature of regulatory effects of 
R(+)WIN55,212-2 induced downregulation of various transcription factors by TLR ligand 
stimulation additionally argues for a receptor mediated effect.  However the primary 
receptor target that mediates the effects of both cannabinoids on the IFN- pathway 
remains undefined.  AEA, like R(+)WIN55,212-2 binds to both the CB1 and CB2 
receptors.  Despite this, the use of selective CB1/2 receptor antagonists, in addition the Gi 
protein inhibitor, PTX, failed to influence the regulatory effects of both cannabinoids on 
various transcription factors and their responsive genes.  While, the inhibitory effects of 
AEA may be due to the presence of FAAH, a previous study has demonstrated that FAAH 
is not involved in AEA inhibition of TNF-α induced activation of NFκB (Sancho et al., 
2003).  Indeed, both CB1- (Curran et al., 2005b, Facchinetti et al., 2003, Germain et al., 
2002, Nilsson et al., 2006, Marchalant et al., 2007, Sanchez et al., 2006) and CB2- (Curran 
et al., 2005b, Facchinetti et al., 2003, Smith et al., 2000, Nilsson et al., 2006, Sancho et al., 
2003) independent effects of R(+)WIN55,212-2 and AEA have been reported.  The ability 
of the PPARα agonist, fenofibrate, to mimic certain regulatory effects of the cannabinoids 
along with the above information, resulted in PPARα been subsequently assessed as 
potential target in the pharmacological profile of R(+)WIN55,212-2 and AEA.  However, 
further studies implicated that PPARγ may be a more relevant endogenous target in 
mediating the anti-inflammatory effects of R(+)WIN55,212-2, particularly in response to 
the TLR3 signalling pathway.  While it now appears that TBK1/IKKε may be pivotal 
kinases in mediating R(+)WIN55,212-2 anti-inflammatory effects, further studies would 
need to assess if PPARγ also targets TBK1/IKKε or alternatively if PPARs may have 
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exclusively a nuclear role and act to physically interact with IRF3 and promote its nuclear 
retention and so facilitate its transactivation potential. 
Approximately 30% of treatments currently on the market are reported to interact 
with GPCR (Wise et al., 2002).  This statistic alone emphasises the importance of 
cannabinoid receptors and their associated ligands in the treatment of various conditions.  
Furthermore, as GPCRs constitute the most widely targeted proteins to modify 
physiological functions and pathological processes, the development of pharmacological 
agents that selectively target such receptors opens the prospect for entirely new therapeutic 
venues.  In terms of targeting drugs for clinical studies, the psychotropic effects exerted by 
activation of CB1 in particular, coupled with law enforcement, have somewhat diminished 
the enthusiasm for promoting the medicinal value of cannabis.  Conversely, selectively 
targeting the CB2 receptor system appears to be neuroprotective in M.S., where disease 
symptoms and underling pathology are controlled (Baker et al., 2000).  However, as 
described in this work, the cannabinoid regulatory effects are not mediated by their 
interaction with GPCRs and as previously reported; δ-9-THC has also been demonstrated to 
interact with novel receptors distinct from the cannabinoid receptors (O'Sullivan and 
Kendall, 2009, Sun et al., 2007).  The existence of novel cannabinoid receptors and the 
discovery of cannabinoids interacting with PPARs have generated a new wave of interest in 
the area of neuroimmunology.  This discovery may well lead to pharmacological 
interventions that are devoid of the psychotropic and euphoric effects attributed to the 
activation of cannabinoid receptors. 
As presented here, both R(+)WIN55,212-2 and AEA display numerous anti-
inflammatory effects and offer a novel therapeutic approach in the treatment of M.S.  
However, before proceeding to clinical trials, additional research on the psychotropic and 
euphoric effects of these cannabinoid compounds will need to be examined.  Anecdotal 
evidence has reported on both the psychotropic and euphoric effects obtained from 
R(+)WIN55,212-2 consumption.  This is probably due to R(+)WIN55,212-2 activating the 
CB receptors.  Furthermore, in terms of legal substitutes for cannabis, it has recently been 
reported that analyses of Spice (brand name of, and generic slang, for a herbal mixture sold 
in head shops) show that it contains synthetic cannabinoids such as JWH-018 and HU-210 
(Schifano et al., 2009) which produce the psychotropic and euphoric effects associated with 
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consuming this legal drug.  Another factor in terms of clinical trial drug suitability is the 
toxicity of the substance.  Our laboratory previously demonstrated that R(+)WIN55,212-2 
did not cause any detrimental effects on cellular viability (Curran et al., 2005a). 
In order to extend the findings described in this work, it would be of particular 
interest to assess R(+)WIN55,212-2 and AEA ability to promote PPARα and PPARγ 
transactivation and expression.  As each cannabinoids regulatory effects are independent of 
the cannabinoid receptors, to further extend this work, one should assess that the CB1 and 
CB2 antagonists and pertussis toxin are active in the experimental systems.  Transcriptional 
activation of the IFN-β gene is tightly regulated and transcriptionally controlled by a 
limited number of transcription factors.  We have already investigated R(+)WIN55,212-2 
and AEA regulatory effects on the positive regulated domains recognised and regulated by 
NFκB and by IRF3/IRF7.  Transcriptional activation of the IFN-β gene is also regulated by 
the transcription factor AP-1.  Therefore, to extend the above findings, cannabinoid 
regulatory effects on the AP-1-binding enhancer element of the IFN-β promoter should be 
considered.  In relation to M.S. work, the numbers of patient subjects should be increased.  
Furthermore, it would be of interest to perform this experiment using S(-)WIN55,212-2.  
In conclusion, this work describes the anti-inflammatory effects of the synthetic 
cannabinoid; R(+)WIN55,212-2.  This work suggests that the innate arm of the immune 
response is a novel target for the anti-inflammatory actions where a novel dual molecular 
mechanism of action is described.  R(+)WIN55,212-2 can exert direct anti-inflammatory 
properties by downregulating the TLR induced activation of NFB and induction of its pro-
inflammatory targets.  In parallel, by enhancing the activation of IRF3 and subsequent 
induction of its anti-inflammatory target; IFN-, R(+)WIN55,212-2 can boost an 
endogenous protective system.  Such effects of R(+)WIN55,212-2, in particular its capacity 
to induce endogenous expression of IFN-, offers a potentially attractive alternative to the 
currently marketed Beta-interferon therapies.  Overall, these findings encourage clinical 
trials to assess if the therapeutic application of R(+)WIN55,212-2 in M.S. can extend 
beyond symptomatic relief. 
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